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Abstract
Crescentic glomerulonephritis (CRGN) is a significant cause of renal failure in humans and often
has an autoimmune aetiology. The Wistar-Kyoto (WKY) rat has a marked susceptibility to
CRGN, whilst the Lewis (Lew) rat is resistant, making this a useful model system to study
molecular mechanisms underlying the disease. Previous work has demonstrated the importance
of macrophages in CRGN and defined some of the genetic determinants underlying CRGN sus-
ceptibility. Given emerging data linking epigenetic modifications to both macrophage activation
and autoimmune diseases, I hypothesized that variation in DNA methylation in macrophages
could contribute to susceptibility to glomerulonephritis in the WKY rat.
This thesis investigated this hypothesis using both experimental and bioinformatic approaches.
Experimental methods including locus-specific sequencing of diﬀerentially expressed genes and
unbiased whole genome sequencing allowed investigation of variability in DNA methylation be-
tween the two rat strains. Further analyses of methylation in the pathogenesis of CRGN was
achieved by both in vivo experiments in WKY rats and in vitro work on cultured macrophages
using an inhibitor of DNA methylation. Bioinformatic analysis of sequencing and transcrip-
tional data allowed examination of the aﬀect of DNA methylation on gene expression in rat
macrophages, and histone and transcription factor binding site data were used to explore the
interaction of methylation and distant gene regulatory sequences.
Whole genome shotgun bisulfite sequencing revealed that WKY bone marrow-derived macrophages
were generally less methylated than Lew, and more than 13,000 CpG dinucleotides were robustly
diﬀerentially methylated between the two strains. Multiplexed PCR sequencing was used to ver-
ify whole genome methylation signatures. At the genome-wide level, the relationship between
methylation and expression was complex but my analyses suggested that diﬀerentially methy-
lated CpGs might be enriched at distant gene regulatory elements.
These data oﬀer evidence of an association between DNA methylation and susceptibility to
CRGN and therefore impart a basis for understanding the distinct genes, pathways and gene
regulatory elements that could underlie this association.
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CGI CpG island
ChIP Chromatin immunoprecipitation
CpG Cytosine guanine dinucleotide
CRGN Crescentic Glomerulonephritis
DAC 5-aza-2’-deoxycytidine
DC Dendritic cell
DNMT DNA methyltransferase
DTH Delayed type hypersensitivity
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EAG Experimental autoimmune glomerulonephritis
ELISA Enzyme-linked immunosorbent assay
ES Embryonic stem cell
ESRF End stage renal failure
FDR False discovery rate
FSGS Focal segmental glomerulosclerosis
GATK Genome analysis toolkit
GBM Glomerular basement membrane
GN Glomerulonephritis
GO Gene ontology
GWAS Genome-wide association study
H Core histone
HCP High CpG content promoters
HDAC Histone deacetylase
HIF Hypoxia inducible factors
HPLC High performance liquid chromatography
HSC Haematopoietic stem cells
IFNα Interferon-α/Type I interferon
IFNγ Interferon-γ/Type II interferon
IL Interleukin
IP Intra-peritoneal
IRF IFN-regulatory factor
JMJD jumonji C domain containing protein
K Lysine
KLF Kru¨ppel-like factor
LCP Low CpG content promoters
Lew Lewis (LEW/Crl) rat strain
LMR Low methylated region
LPS Lipopolysaccharide
MBD Methyl-CpG-binding domain
MCP-1 Monocyte chemoattractant protein-1
MeCP2 Methyl-CpG-binding protein 2
MHC Major histocompatability complex
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MPO Myeloperoxidase
NGS Next generation sequencing
NO Nitric oxide
NP Neuronal Progenitor cells
NTN Nephrotoxic nephritis
NTS Nephrotoxic serum
PAMP Pathogen-associated molecular patterns
PBS Phosphate buﬀered saline
PCR Polymerase chain reaction
PR3 Proteinase 3
PRG Primary response gene
PRR Pattern recognition receptor
QTL Quantitative trait locus
ROS Reactive oxygen species
SLE Systemic lupus erythematosus
SNP Single nucleotide polymorphism
SP Specificity protein
SRG Secondary response gene
Syk Spleen tyrosine kinase
TDG Thymine-DNA glycolase
TET Ten-eleven translocation
TF Transcription factor
TFBS Transcription factor binding site
TLR Toll-like receptor
TNF-α Tumour necrosis factor-α
TSS Transcription start site
WGA Whole genome amplification
WGBS Whole genome shotgun bisulfite sequencing
WKY Wistar-Kyoto (WKY/NCrl) rat strain
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1.1 Glomerulonephritis
Glomerulonephritis (GN) is a common cause of kidney disease in the UK. Clinical presentation
can range from asymptomatic urinary abnormalities to severe acute kidney injury. This latter
presentation often correlates with a characteristic histological pattern of crescentic GN (CRGN)
and is associated with poor patient outcomes. Studies suggest significant rates of end-stage
renal failure (ESRF) and death in patients with CRGN (Jayne et al., 2007). Even where best
treatment is rapidly initiated, current therapeutic regimens have been associated with high rates
of adverse events (Stone et al., 2010). Taken together, these points continue to make CRGN a
clinically important field of study.
Glomerular crescents are typified by the disruption of the glomerular capillary wall (Figure 1.1
black arrows) with a resultant infiltration of macrophages, T-cells and plasma proteins into
Bowman’s space (Figure 1.1 red arrows) (Tarzi et al., 2011). At this stage, crescents are termed
cellular and may be amenable to treatment (Figure 1.1 blue arrow). Cellular crescents may
then either undergo restitution or organise into fibrous crescents, which are a marker of chronic
and irreversible kidney damage (Figure 1.1 green arrow) (Tarzi et al., 2011).
Glomerular crescents may have one of a diverse range of inflammatory or auto-immune causes.
Further study of crescents seen in diﬀerent causative diseases has led to a classification of CRGN
into three types according to the existence and distribution of immune complexes (Tarzi et al.,
2011).
14
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Figure 1.1: Glomerular crescents are formed by accumulation of cells in Bowman’s
space following glomerular basement membrane rupture
Black arrows: glomerular capillary wall. Red arrows: Bowman’s space. Blue arrow: cellular
crescent. Green arrow: fibrous crescent. Purple arrow: mesangium
Images from Feehally, Floege & Johnson (2007), Comprehensive Clinical Nephrology 3rd Ed
The first of these three types is termed pauci-immune due to the relative lack of immune
complex deposits and is the most common form of CRGN representing up to 80% of cases.
Pauci-immune GN is most commonly caused by one of the antineutrophil cytoplasm antibody
(ANCA)-associated vasculitides (AAV). A group of diseases in which there is usually a detectable
ANCA in the serum, either reactive to proteinase 3 (PR3), a constituent of neutrophil granules,
or to myeloperoxidase (MPO), seen within monocyte lysosomes (Tarzi et al., 2011). The AAV
have an increasing incidence with age and aﬀect ∼20 patients per million population in Europe
(Kamesh et al., 2002). Perhaps unsurprisingly for this heterogenous group of diseases, the
pathogenesis of AAV is complex. Distinct mechanisms including a pro-inflammatory neutrophil
phenotype, B-cell dysregulation and alterations in T-cell subsets and the alternative complement
pathway have all been implicated in development of AAV (Savage, 2011).
The second type of CRGN identifiable according to the pattern of immune complexes shows
linear deposition of IgG on the capillary wall and is almost exclusively the result of the anti
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glomerular basement membrane (GBM) disease. This rare disease aﬀects ∼0.5 patients per
million population in Europe and is often accompanied (50-60%) of cases by life-threatening
pulmonary haemorrhage (Tarzi et al., 2011). Anti-GBM disease results from the formation
of antibodies to the non-collagen domain of α3 type IV collagen, a normally sequestered epi-
tope found in both the lung and the renal GBM, thus accounting for the clinical presentation
(Pedchenko et al., 2010).
The third category of CRGN is immune complex CRGN. This is accompanied by granular im-
mune complex deposition and is the most heterogenous group, being associated with a number of
diverse conditions including renal lesions seen in systemic lupus erythematosus (SLE), termed
lupus nephritis; IgA nephropathy and Henoch-Schonlein purpura; postinfectious GN and cy-
roglobulinaemia (Tarzi et al., 2011). Whilst all these diseases can show crescent formation, this
particular feature is not necessarily a hallmark of any disease.
Although significant progress has been made into elucidating the pathogenesis of CRGN, treat-
ment of the diseases underlying crescent formation may be associated with sub-optimal out-
comes and high adverse event rates. Whilst initial treatment regimes based around high dose
steroids and the alkylating agent cyclophosphamide have been successful in ensuring that the
majority of CRGN causing diseases are no longer universally fatal (Harper and Savage, 2005),
these regimens have been shown to result in a large amount of adverse events which begin to
accumulate soon after starting treatment (Little et al., 2010). In addition, except for anti-GBM
disease which rarely relapses, many of the diseases causing CRGN, especially the AAV and lupus
nephritis, commonly relapse, thus necessitating further escalation in treatment and increasing
the likelihood of progression to ESRF and adverse events related to treatment.
These factors have led to the ongoing search for therapies which may have better eﬃcacy and
fewer side eﬀects. To this aim, therapies against B-cells, T-cells and relevant signal transduction
mechanisms in these conditions have been explored (reviewed in Pallan et al. (2009)). For
example, the anti-CD20 chimeric monoclonal antibody against B cells, rituximab, now has
widespread use in AAV (Specks et al., 2013) and SLE.
As can be seen in Figure 1.1 and as will be outlined in subsequent sections of this chapter, the
macrophage is clearly an important immune cell population that is involved in crescent formation
but not targeted in any specific way by current therapies, thus making it an attractive avenue
for investigation in CRGN.
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1.2 Macrophages in renal disease
Vertebrates use two distinct arms of the immune system to respond to challenge or invasion; the
innate and adaptive systems. The adaptive system utilises B- and T-cells to generate antigen
responses de novo, thus ensuring that they are highly specific and tailored towards discrete
infections or insults (Iwasaki and Medzhitov, 2010; Medzhitov and Horng, 2009). Alternatively,
the innate immune system is largely non-specific and uses cells including macrophages, dendritic
cells and neutrophils to detect conserved features of pathogenic microbes, often referred to as
pathogen-associated molecular patterns or PAMPs. Detection of PAMPs is often by means
of genetically encoded receptors termed pattern recognition receptors (PRRs) (Medzhitov and
Horng, 2009). Such detection commonly results in the complex response referred to as inflam-
mation.
One of the key eﬀector cells of the innate immune system is the macrophage. Macrophages
are formed following the diﬀerentiation of monocytes in tissues and have a diverse range of
basic functions including phagocytosis and antigen presentation. Monocytes are mobile cells
and can therefore migrate into tissues as part of the inflammatory response where they may
diﬀerentiate into macrophages. The products of activated macrophages, including the classic
proinflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin (IL)-1, and IL-6, fur-
ther maintain inflammation (Wells et al., 2005). Whilst this response is essential for organ
protection, unregulated inflammation is implicated in a wide variety of human diseases.
As shown by Figure 1.1, infiltration of macrophages into glomeruli is an accepted concept in
kidney disease. A landmark study in 1985 used human biopsy specimens from patients with a
variety of diseases causing pauci-immune and immune complex CRGN to show that monocytes
and macrophages were enriched in crescentic lesions as opposed to other forms of glomerular
disease not classically associated with crescents (Ferrario et al., 1985).
More recent work suggests that macrophages infiltrating glomeruli are derived from a subset of
inflammatory monocytes in both humans and rodents (Rees, 2010). Infiltrating monocytes can
then diﬀerentiate into either macrophages or dendritic cells (DCs). DCs are antigen presenting
cells which closely interact with the adaptive immune system. The proportions of infiltrating
monocytes forming DCs or macrophages appears to be a function of the experimental model
and remains an active research question (Rees, 2010).
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Once present in glomeruli, one of the key issues is then if macrophages are the cells responsible
for glomerular injury, if they exacerbate existing injury or are simply bystanders to ongoing
processes.
Evidence for a direct role of macrophages in the injury process has come from three strands.
Firstly, numerous studies in both experimental animals and humans have established the poten-
tial cytotoxicity of macrophages isolated from glomeruli (reviewed in Wang and Harris (2011)).
For example, reactive oxygen species, which are one of the main mediators of glomerular dam-
age, and nitric oxide (NO), which has both direct eﬀector functions such as cytotoxicity and
immuno-regulatory functions, have both been found in glomerular macrophages. Addition-
ally, the pro-inflammatory cytokines, TNF-α and IL-1β, have been shown to be produced by
glomerular macrophages, further suggesting that glomerular macrophages have the potential for
mediating injury.
The second strand of evidence is that depletion of glomerular macrophages across a number of
distinct models of GN leads to a reduction of relevant phenotypes such as proteinuria, a sig-
nificant marker of glomerular damage, and structural glomerular abnormalities on microscopy.
A number of diﬀerent strategies have been used to diminish macrophages. Perhaps most rele-
vant to CRGN are studies that have shown that experimental anti-GBM disease in rabbits can
be ameliorated by use of a sheep anti-rabbit macrophage serum that both depleted circulating
monocytes and glomerular macrophage accumulation (Holdsworth et al., 1981). Rabbits treated
in this way showed a large reduction in proteinuria and only minor histologic abnormalities fol-
lowing treatment with serum (Holdsworth et al., 1981). A diﬀerent approach reduced glomerular
macrophages in a rat model of anti-GBM disease. In this case, the depletion was achieved by
use of a neutralising antibody (Ab) to rat Monocyte chemoattractant protein-1 (MCP-1, also
known as chemokine (C-C motif) ligand 2 or CCL2), which is important in the recruitment and
activation of a number of diﬀerent leukocyte cell types during inflammation. Rats treated with
anti-MCP-1 Ab showed a significant reduction in both macrophage infiltration and proteinuria
(Tang et al., 1996).
The final strand of evidence is from experiments that make use of the adoptive transfer of
macrophages. This theme is important because ablative techniques, outlined in the paragraph
above, are likely to have oﬀ-target eﬀects on cells and tissues distinct from macrophages. One
such adoptive transfer experiment both suppressed the normal course of a rat model of anti-GBM
disease and ablated bone marrow with cyclophosphamide, before transferring macrophages in
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to experimental animals. This transfer led to persistent accumulation of macrophages within
glomeruli, evolution of proteinuria and histologic abnormalities (Ikezumi et al., 2003). Another
transfer experiment used the mouse model of adriamycin nephrosis. This is a model of a non-
CRGN human kidney disease known as focal segmental glomerulosclerosis (FSGS), which is
characterised by heavy proteinuria. Although not directly relevant to CRGN, this model is
interesting because it used two distinct populations of macrophages; those that were “resting”
and those that had been “activated” by exposure to lipopolysaccharide (LPS; see Section 1.3 for
more information on macrophages and LPS), which is the prototypical PAMP. Even relatively
small transfusions of activated macrophages exacerbated renal injury in adriamycin nephrosis,
whilst transfusion of up to 500x more resting macrophages did not worsen renal injury. Further-
more, using macrophages tagged with red fluorescent membrane label, the authors were able to
show that the activated, but not the resting macrophages homed to the inflamed kidneys (Wang
et al., 2008).
1.3 Macrophage activation and polarisation
The work of Wang et al. (2008), described above, hints at how the role of macrophages in
renal disease and CRGN may be more complex than simply depending upon their presence or
absence. The concept of macrophage activation was first introduced in the 1970s and remains
a much-discussed research topic to this day (Rees, 2010). Initially a single form of macrophage
activation was known, where the cytokine, type II interferon, or IFNγ, primed macrophages for
more eﬀective killing of intracellular pathogens regardless of the infecting bacteria. Following
initial observations in T-cells which showed that IFNγ and the cytokine IL-4 polarised T-cells
into widely diﬀering subtypes, it was then shown that IL-4 had a similar eﬀect on macrophages
resulting in a phenotype of decreased phagocytosis and intracellular killing of pathogens. After
these initial findings, multiple other cytokines were found to activate macrophages resulting in
the formation of a broad classification of macrophage activation by Mantovani et al. (2004).
This classification is broadly summarised in Figure 1.2. M1a (otherwise known as “classically
activated”) macrophages show increased phagocytosis of pathogens and stimulate delayed hy-
persensitivity (DTH) reactions via eﬀects on antigen presentation and increased expression of
class II major histocompatability complex (MHC) molecules. They also secrete a number of pro-
inflammatory cytokines such as IL-1β, TNFα, IL-6 and IL12, and chemokines. M1b (“innate
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Figure 1.2: Macrophages are activated by diverse stimuli and display diﬀering
downstream phenotypes
The category name of each class is in black within the circle. The main activating stimulus for
each category is in red & the major phenotypic consequences of the categories are shown in the
box adjacent to the segments. DTH: delayed type hypersensitivity, for other definitions see text
This figure is a composite of figures from Rees, 2010 & Mantovani et al., 2004
activated”) macrophages are similar in their properties to M1a macrophages, exhibiting signif-
icant expression of IL-1β, TNFα and IL-6. However, their main stimulus is LPS not IFNγ and
they do not secrete IL-12 which augments production of IFNγ and promotes DTH responses.
LPS is a major ligand of a certain group of PRRs (Section 1.2) known as Toll-like receptors
(TLRs). TLRs are expressed on the cell surface of numerous cell types but predominantly in
immune cells including macrophages. Sustained study of LPS stimulation of TLRs has led to
this pathway becoming the best characterised inducer of acute inflammation (Medzhitov, 2001;
Medzhitov and Horng, 2009).
As outlined above, the responses of M2 macrophages are generally anti-inflammatory. M2a
activation is induced by IL-4 or IL-13 and results in a phenotype that is mainly opposed to
that of M1a macrophages for example by increased production of IL-10. M2a macrophages also
stimulate responses associated with the Th2 subset of helper (CD4) T-cells. M2b activated
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macrophages are anti-inflammatory and similar to M2a, promote Th2 responses. Polarisation
into M2b macrophages results after exposure to LPS or following detection of IgG immune
complexes via receptors which are present on the cell surface of macrophages and recognise the
fragment, crystallisable (Fc) region of IgG, known as Fcγ receptors (FcγR). The M2c class is
mainly polarised by IL-10 but also by steroids and is profoundly anti-inflammatory.
The above description of the classification of macrophage activation is far from exhaustive.
This complexity, when taken together with the idea that in vivo, macrophages will experience
a vast number of distinct stimuli with the ability to activate numerous diﬀerent cell surface
receptors, makes the utility of macrophage classification outside of the broadest terms ques-
tionable. However, an understanding of the complexity of macrophage activation is necessary
when considering the evolution of a disease in which macrophages have a significant role, such
as CRGN.
1.4 The nephrotoxic nephritis model
Animal models have proved powerful in elucidating the aetiology of a number of human diseases.
One such model of CRGN uses the Wistar-Kyoto (WKY) and Lewis (Lew) inbred rat strains
which share an identical MHC haplotype (RT-1l). In this model, the WKY rat demonstrates a
significant and robust susceptibility to CRGN when inoculated with nephrotoxic serum (NTS)
whilst the Lew strain is resistant to disease, suggesting that non-MHC genes contribute to
disease susceptibility (Tam et al., 1999). NTS is raised in rabbit against rat glomerular basement
membrane antiserum (rabbit anti-rat GBM antiserum). The renal histology which follows NTS
injection is very similar to that seen in humans and is highly reproducible, making NTN a
valuable animal model of human GN (Tam et al., 1999).
The model was initially characterised by Kawasaki et al. (1992), who showed that the WKY
rat developed features of severe CRGN at doses of NTS that were 20 times smaller than those
required to induce disease in the Lew and other control rat strains.
Further study of the phenotype of the NTN model by Tam et al. (1999) revealed that proteinuria
and non-visible haematuria were detected four days following NTN innoculation and that serum
creatinine showed a progressive increase in diseased rats from 18 days after disease induction.
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Analysis of glomerular leukocyte infiltration in WKY and Lew rats showed that the major type
of white cell within the glomeruli following NTS injection was the monocyte and/or macrophage.
These cells were present from 2.5 hours after NTS injection and greatest infiltration was seen
between days four and eight, with severe CRGN seen in all WKY rats by day 11 (Tam et al.,
1999). WKY glomeruli also showed increasing fibrin deposition and necrosis from day four
onward. After four to six weeks, 94% of glomeruli showed glomerulosclerosis; a fibrotic scarring
of the glomeruli resulting in irreversible loss of function. In contrast to alternative NTN models,
such as the accelerated mouse NTN model (Tarzi et al., 2002) and an anti-GBM disease model
in Sprague-Dawley rats (Kluth et al., 2001), phenotypes were robustly reproducible.
This clear progression of disease from macrophage infiltration and fibrinoid necrosis to scar-
ring and renal failure makes NTN an excellent experimental model of human CRGN histology.
However, the use of a nephrotoxic serum to induce glomerular injury means that disease is medi-
ated by heterologous planted antigens and therefore, NTN cannot model autoimmune processes
which underlie most human causes of CRGN. In addition, the single disease inducing dose of
NTS may mean that the NTN model is particularly relevant to anti-GBM disease, which is
classically seen as a non-relapsing disease (Tarzi et al., 2011).
The rapid accumulation of macrophages in glomeruli means that NTN is a powerful tool for
studying innate immunity. Notwithstanding this, adaptive immune responses and therefore,
T cells, clearly have a role in CRGN formation. The mouse model of NTN that involves pre-
immunisation with sheep IgG followed by injection with polyclonal sheep anti-mouse glomerular
basement membrane Ab (Tarzi et al., 2002), has highlighted a role for a number of adaptive
eﬀector cells in NTN (summarised in Tipping and Holdsworth (2006)). Of particular interest is
that the co-occurrence of glomerular fibrin deposition with an influx of both macrophages and
T cells, suggests an importance for a delayed-type hypersensitivity response. Such a response
is dependent upon macrophage-secreted IL-12 to stimulate production of Th1 CD4+ T cells.
Therefore, deficiency or blockade of Th1 cytokines ameliorates disease whilst administration of
IL-12 exacerbates disease (Tipping and Holdsworth, 2006).
In summary, the initial descriptions of the rat NTN model were marked by a resemblance to
human GN and high reproducibility. Moreover:
1. The macrophage dependence of the rat model makes NTN a very useful tool for investi-
gating CRGN pathogenesis and testing new treatment approaches (Tam et al., 1999)
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2. The unique susceptibility of the WKY rat to NTN in contrast with other rat strains
suggests the model is useful for studying genetic and epigenetic contributions to disease
pathogenesis
These two factors will now be considered in turn.
1.4.1 Evaluation of prospective treatment approaches to CRGN using the
NTN model
Since its initial description, NTN has been used in a number of studies using pharmacological
agents. These studies have sought both to act as pre-clinical analyses of drugs which may
later enter clinical trials in humans (Khan et al., 2005) and to elucidate in vivo properties of
macrophages in a disease phenotype.
Drugs blocking TNF-α have enjoyed considerable success in the treatment of inflammatory
diseases including rheumatoid arthritis, ankylosing spondylitis and inflammatory bowel disease
(Feldmann and Maini, 2001). As can be seen from Figure 1.2, production of TNF-α is a feature
of pro-inflammatory M1 macrophage phenotypes. As a result, Anti-TNF-αmonoclonal antibody
therapy was trialled in the NTN model (Khan et al., 2005). This study showed that anti-TNF-α
therapy was eﬀective in reducing clinical and histological phenotypes even when treatment was
commenced at day 14, the time of maximal disease (See Section 1.4). However, a multi-centre
randomised, placebo-controlled trial using an anti-TNF-α monoclonal antibody in a form of
AAV did not demonstrate eﬀective remission induction and did show more treatment-related
complications (Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group, 2005).
Prior to these studies, anti-TNF-α monoclonal antibodies had been in clinical use for rheuma-
toid arthritis for some time. Similarly, the eﬀect of other pre-exisiting drugs on NTN has been
studied. The lipid-lowering statin class of drugs are amongst the most widely prescribed in
the world. In addition to their lipid-lowering eﬀect statins exhibit anti-inflammatory properties
(Antonopoulos et al., 2012), and decrease total glomerular macrophage infiltration (Campese
and Park, 2007). A recent study using the NTN model was able to show that statin treatment
decreased histological and clinical phenotypes of NTN and that this was associated with an
apparent preponderance of M2 macrophages (Fujita et al., 2010). Similar to statins, pharma-
cological blockers of the angiotensin II type 1 receptor (ARBs) are in widespread clinical use.
They are used for treatment of hypertension or heart failure, and their use has been shown
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to ameliorate macrophage accumulation in glomeruli (Mii et al., 2009). A similar study to
that using statins showed that high dose ARB treatment reduced macrophage infiltration, de-
creased crescentic glomerular lesions and appeared to bring about a phenotypic switch to M2
macrophages (Aki et al., 2010).
These studies suggest that inducing a dominance of the anti-inflammatory M2 phenotype
macrophages may be a successful strategy in treating NTN. Use of intra-peritoneal (IP) in-
jection of the cytokine IL-4, the major polarising ligand of M2a macrophages (Figure 1.2), in
the model revealed that this treatment was associated with a significant eﬀect on proteinuria
and glomerular macrophage infiltration (Cook et al., 1999). Similarly, high dose IP use of an-
other broadly anti-inflammatory cytokine, IL-11, reduced proteinuria and necrotic GN in the
NTN model (Lai et al., 2001).
Finally, downstream signal transduction pathways have also been targeted by pharmacological
perturbation in NTN. Perhaps the most successful of these has been inhibition of spleen tyrosine
kinase (Syk). This molecule is involved in mediating inflammatory events following FcγR acti-
vation and FcγRs have been associated in both macrophage activation (Figure 1.2) and in GN
(Aitman et al., 2006). Similar to other treatments, use of a Syk inhibitor, R788 (fostamatinib
disodium), has been shown to reduce renal damage and promote a less inflammatory glomerular
milieu (Smith et al., 2010). However, in addition, when treatment with R788 was started at
day seven, when crescents are widespread (Section 1.4), established disease was reversed.
Taken together, these studies suggest that pharmacological experiments using the NTN model
have been important in illustrating how a broad reduction in macrophage inflammatory phe-
notypes has been successful in reducing renal injury. This may be the result of an increased
polarisation of macrophages towards the M2 side of the spectrum (Aki et al., 2010; Fujita et al.,
2010). However, these approaches are largely dependent on pre-existing hypotheses regarding
which molecules should be perturbed, based on known signalling pathways in NTN pathogenesis.
1.4.2 Genetic analysis of the NTN model
The unique susceptibility of the WKY rat strain to NTN compared with the Lew, the usual
control strain, and other distinct rat strains including Brown Norway, the reference strain (Gibbs
et al., 2004), made study of the genetics of NTN extremely attractive. To this end, a cross of
WKY and Lew animals produced an F1 generation that showed an intermediate phenotype to
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WKY and Lew for proteinuria, crescent formation and macrophage infiltration into glomeruli
(Aitman et al., 2006). Phenotypes of F2 generation animals represented the range of the parental
strains, thus suggesting that proteinuria, crescent formation and macrophage infiltration are
continuous/quantitative traits, which might be amenable to mapping of underlying quantitative
trait loci (QTLs).
QTL analysis allows the combined use of phenotypic and genotypic data to define regions that
are linked to genes that underlie the traits in question (Flint et al., 2005). The study of Aitman
et al. (2006) used microsatelite markers to assess genetic variability in the F2 cross and a
genome-wide QTL analysis revealed two major and five minor QTLs, denoted Crgn1-7, for the
phenotypes in question. Crgn1, the first major QTL, mapped to chromosome 13 and explained
21.8% of the genetic variance in crescent formation, 16.7% of the variance in proteinuria and
12.9% of the variance in macrophage infiltration (Aitman et al., 2006). Further investigation of
the Crgn1 region of linkage identified copy number variation of the Fcgr3 gene as underlying
this QTL. The Lew strain has a duplication in exon 5 of Fcgr3 where one copy is shorter by
226bp. This short exon is deleted in the WKY (Aitman et al., 2006). Deletion of this copy is
associated with increased macrophage activation in both the WKY and additional rat strains
with loss of the short copied exon (Aitman et al., 2006). Furthermore, the short exon showed
a single nucleotide deletion at position 129 (∆G129). This mutation causes a frameshift which
results in transcription of a novel product denoted Fcgr3-rs (Aitman et al., 2006). Fcgr3-rs
has a cytoplasmic domain that is six amino acids longer than that of Fcgr3, and appears to
be a decoy receptor which, whilst able to bind Fc, is unable to activate downstream signalling
pathways (Page et al., 2012).
The second major QTL found by Aitman et al. (2006), Crgn2, mapped to chromosome 16
and explained 16.8% of crescent formation variance and 17.7% of the genetic variance in pro-
teinuria. The molecular basis for Crgn2 was established using distinct experimental methods
to those used for Crgn1. The first of these methods involved formation of two congenic rat
strains; WKY.LCrgn2 and LEW.WCrgn2. The first of these strains consists of a WKY genetic
background with the Lew Crgn2 region replaced or introgressed within this background. The
second strain is the reverse, with a Lew background containing the WKY Crgn2 region. Con-
genic strains are established through the selective mating of inbred strains and in this case F1
rats from an initial WKY and Lew cross were then crossed with either of the WKY or LEW
parental strain depending upon which genetic background was required (Behmoaras et al., 2008).
When NTN was induced in these congenic strains, significant decreases in glomerular crescents
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and macrophage infiltration were seen in WKY.LCrgn2 compared to WKY, and increases in
proteinuria were seen in LEW.WCrgn2 compared to Lew. Moreover, bone marrow-derived
macrophages (BMDMs) from WKY.LCrgn2 rats showed a less inflammatory phenotype than
those from the WKY strain (Behmoaras et al., 2008).
These two results implicated the 22.6cM Crgn2 interval both in NTN susceptibility and macrophage
activation. As a result, analysis was then focused on molecular candidates which could underlie
these observations. Microarray expression profiling of both baseline and nephritic glomeruli from
WKY and Lew rats, showed that the activator protein-1 (AP-1) transcription factor gene Jund,
was diﬀerentially expressed in both nephritic and normal glomeruli between strains (Behmoaras
et al., 2008). Furthermore, Jund is located within the congenic interval and the promoter shows
a C/T polymorphism between WKY and Lew which appeared to underlie the observed over
expression of Jund in the WKY rat.
Although the evidence presented above suggests a key contribution of macrophages in determin-
ing the WKY strain’s propensity to NTN, it is worth noting that additional studies in the model
have used transplantation experiments to show that intrinsic renal cells contribute to CRGN
susceptibility (Smith et al., 2007). These experiments showed that transplantation of WKY
bone marrow (BM) to Lew animals resulted in crescent formation above that of Lew animals
transplanted with Lew marrow. Additionally, transfer of Lew to WKY BM resulted in fewer
crescents than that seen with WKY isologous grafts (Smith et al., 2007), thus suggesting con-
tributory factors independent of BM. The study went on to use kidney transplant experiments
to show that engraftment of WKY kidneys into animals from a WKYxLew F1 cross resulted in
worse disease following NTN induction than when a Lew kidney was engrafted (Smith et al.,
2007). The central stalk of each glomerulus is composed of cells known as mesangial cells (See
Figure 1.1 purple arrow). Combination of these kidney transplant results with the fact that cul-
tured mesangial cells from WKY express greater amounts of the pro-inflammatory chemokine
MCP-1 (see Section 1.2) than Lew, suggests that genetic diﬀerences in these intrinsic renal cells
may also contribute to diﬀerential NTN susceptibility.
1.5 The pro-inflammatory phenotype of WKY macrophages
Notwithstanding the evidence for a contribution of intrinsic renal cells outlined directly above,
it is apparent that an important mediator of the increased susceptibility of the WKY to NTN
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may be an enhanced inflammatory macrophage phenotype in this strain. Evidence for this
pro-inflammatory phenotype has been collected from diﬀerent approaches, including functional
assays, enzyme-linked immunosorbent assay (ELISA) and quantitative polymerase chain reac-
tion (PCR) measurements of cytokines and finally, whole genome technologies (Aitman et al.,
2006; Behmoaras et al., 2008; Hull et al., 2013; Maratou et al., 2011).
The importance of the WKY pro-inflammatory macrophage phenotype on glomerular damage
was shown directly by Aitman et al. (2006), who used an antibody-directed cellular cytotoxicity
assay to reveal an increased macrophage-mediated killing of glomerular mesangial cells, an in
vitro correlate of the glomerular necrosis seen in the NTN model (Section 1.4).
Further evidence for the pro-inflammatory phenotype of WKY BMDMs comes from the study in-
vestigating Crgn2 and its molecular correlate JunD (the expressed protein of Jund) (Behmoaras
et al., 2008). Here, following LPS stimulation, BMDMs from WKY animals showed greater ex-
pression of the inducible nitric oxide synthase gene (Nos2 ) by quantitative PCR, and increased
secretion of the cytokines MCP-1 and IL-10 (Behmoaras et al., 2008). Functional assays of
Fc receptor-mediated macrophage activation showed that this was increased in WKY BMDMs,
with greater phagocytosis demonstrated both by direct visualisation of opsonised polystyrene
beads and greater detection of post-phagocytosis oxidisation (Behmoaras et al., 2008).
JunD is a transcription factor and therefore binds specific DNA sequences, often with a down-
stream eﬀect on transcription of DNA. As a result, further study of the role of JunD in
macrophage activation has been performed using two whole genome technologies (Hull et al.,
2013):
1. Microarray gene expression analysis following short interfering RNA (siRNA) knockdown
of Jund
2. Chromatin immunoprecipitation (ChIP) with massively parallel sequencing (-Seq) to iden-
tify genomic targets of JunD
The analysis from item 1 above revealed that genes which showed the greatest expression changes
associated with siRNA knockdown of Jund were associated with IL-1β synthesis (Hull et al.,
2013). The analysis from item 2, identified JunD binding targets with links to oxidative stress
pathways (Hull et al., 2013). Thus, it is possible that JunD over expression in WKY BMDMs
mediates transcriptional programs driving oxidative stress and IL-1β synthesis contributing to
the pro-inflammatory phenotype of these cells.
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Previous to the study of Hull et al. (2013) described above, Maratou et al. (2011) had used
microarray analysis in WKY and Lew macrophages, in the absence of RNA interference tech-
niques, both to identify genes that may predispose the WKY to inflammation and also to seek
positional candidates for the minor QTLs Crgn3-7 (Maratou et al., 2011). This study identi-
fied 800 transcripts that were diﬀerentially expressed between WKY and Lew BMDMs in the
basal state. 61 genes mapped to the QTLs Crgn3-7 in basal macrophages. The remaining 739
diﬀerentially expressed transcripts included genes with profound diﬀerential expression between
the strains and biological relevance such as Arg1, arginase, which has been widely implicated in
macrophage activation in the context of GN (Waddington and Cattell, 2000), and Mmp7, ma-
trix metalloproteinase 7, which has been linked to macrophage infiltration in an inflammatory
model (Haro et al., 2000). However, many of the highly diﬀerentially expressed genes detected
in this analysis had not been previously associated with CRGN or macrophage activity. The
study of Maratou et al. (2011) illustrated the strengths of an unbiased genome-wide diﬀeren-
tial expression analysis and provides further information relating to previous work, for example
yielding candidate genes for Crgn3-7. Additionally this paper implicates biologically relevant
candidate genes, such as Arg1 and Mmp7, and finally can highlight novel candidate genes that
may be involved in CRGN.
1.6 Epigenetic modifications
Epigenetic mechanisms can be responsible for complex phenotypic variation determined by dif-
ferences in regulation of gene expression that are independent of the underlying DNA sequence.
A number of epigenetic modifications and mechanisms are recognised including methylation and
hydroxymethylation of DNA, post-translational modification of histones, and gene silencing by
both short and long non-coding RNA (Portela and Esteller, 2010).
1.6.1 DNA methylation
Covalent modification of DNA most commonly results in methylation of cytosine bases in CpG
dinucleotides to form 5-methylcytosine (5mC). Whilst non-CpG methylation is seen in human
cells (Lister et al., 2009), its function is currently unknown (Jones, 2012). Despite the recent
expansion of interest in epigenetic mechanisms, DNA methylation remains the only modification
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for which stable mitotic inheritance in somatic diﬀerentiated cells has been described (Bird,
2002).
Despite the general stability of DNA methylation, a number of enzyme groups can change
CpG methyl groups to form other modifications. For example, the ten-eleven translocation
(TET) methylcytosine dioxygenases, can oxidise 5mC to form distinct molecules including
5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (He
et al., 2011; Ito et al., 2011; Tahiliani et al., 2009). Of these three modifications, 5hmC is the
most common and has been detected in diverse cell types and tissues (Branco et al., 2012). 5hmC
has an important role as an intermediate in the removal of 5mC, especially during developmental
periods in preimplantation embryos when methylation patterns are erased and reprogrammed,
thus generating cells with a broad developmental potential (Hackett et al., 2013).
DNA methylation is catalysed by the DNA methyltransferase (DNMT) family of enzymes. Of
these, DNMT1 preferentially recognises hemimethylated DNA, thus it commonly methylates
the unmethylated strand after DNA synthesis and replication (Jones and Liang, 2009). Alter-
natively, distinct DNMTs, DNMT3a and DNMT3b, are often restricted to chromatin regions
containing methylated DNA and can methylate DNA in the absence of mitosis and cell division
as they are equally able to methylate hemimethylated or unmethylated DNA (Jones and Liang,
2009). There is evidence that it is these members of the DNMT family which mediate the
de novo methylation that follows the erasure of 5mC via 5hmC described above (Cedar and
Bergman, 2012).
DNA methylation can be removed either passively or actively (Jones, 2012). In this context,
passive DNA demethylation refers to when DNA methylation is lost following cell division, a
phenomenon that is seen after treatment with DNA methylation inhibitor drugs such as the
cytidine analogue 5-aza-2’-deoxycytidine (DAC) or its ribose congener, 5-azacytidine (Egger
et al., 2004). Alternatively, active DNA demethylation can occur in the absence of cell division
and is dependent on enzymatic reactions. For example, the TET enzymes referred to above
catalyse the formation of 5caC from 5mC via 5fC (He et al., 2011). This process can then be
followed by excision of the 5caC base by an enzyme known as thymine-DNA glycolase (TDG),
leaving an abasic site into which the base excision repair (BER) pathway inserts an unmethy-
lated cytosine (He et al., 2011). An additional enzyme; activation-induced cytidine deaminase
(AID), promotes hydroxylation of 5mC to 5hmC and has been linked to DNA demethylation
via base excision (Cortellino et al., 2011). AID also has a well characterised role in class-switch
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recombination, the process by which B cells change the class of antibody they produce. A recent
paper has shown no AID-dependent demethylation in B cells (Fritz et al., 2013) thus suggesting
that active demethylation may be achieved by diﬀerent mechanisms according to cell type. As
epigenetic modifications are associated with an increasing number of diseases, knowledge of the
diverse enzyme systems involved in DNA methylation is important if this modification is to
become a target for therapy.
1.6.2 Histone modifications
The nucleosome is the functional unit of chromatin and is composed of an octamer of four core
histones (H3, H4, H2A, H2B) around which 147 base pairs of DNA are wound (Kouzarides,
2007). Histone tails can undergo various post-transcriptional modifications including methyla-
tion, acetylation, phosphorylation and ubiquitylation. Some of these modifications, for example
acetylation and ubiquitylation, are largely restricted to the single amino acid residue lysine (K),
whilst other modifications, such as methylation, can aﬀect diverse residues (Kouzarides, 2007).
The functional consequences of these modifications may be either local, such as single gene
transcription, or genome wide. For example, histone modifications have been implicated in
the sorting of chromatin into heterochromatin, which is inaccessible for transcription, and eu-
chromatin, which is accessible. The “silent” heterochromatin state shows a general depletion
of histone acetylation and a high level of methylation at the H3 lysine 9 residue (H3K9), the
H3 lysine 27 (H3K27) residue and the H4 lysine 20 (H3K20) residue (Kouzarides, 2007). Con-
versely, euchromatin is typically marked by high levels of histone acetylation and significant
trimethylation at H3 lysine 4 (H3K4), H3 lysine 36 (H3K36) and H3 lysine 79 (Portela and
Esteller, 2010). It is worth noting that some regions of the genome exhibit both activating and
repressive modifications and are known as bivalent domains (Kouzarides, 2007).
At a level more relevant to gene transcription, it has been shown that promoter regions of active
genes are highlighted by a reduction in H3 Lysine 4 monomethylation (H3K4me1) and a peak
of H3 Lysine 4 trimethylation (H3K4me3) (Heintzman et al., 2007). Alternatively, enhancer
regions, which regulate the activation of genes from distant positions that can be upstream,
downstream or within a target or neighbouring gene, show an opposed histone methylation
signature with peaks of H3K4me1 and depletion of H3K4me3 (Heintzman et al., 2007). Such
findings are useful in that they implicate histone modifications as a useful means of annotating
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both promoters and distant gene regulatory sequences. In addition, given that histone modi-
fications are strongly conserved across species from yeast to human (Heintzman et al., 2007),
these datasets may have use in cross-species comparison work.
1.7 Functions of DNA methylation
DNA methylation in cells is largely bimodal with DNA cytosine bases showing either full methy-
lation or no methylation. Approximately 70-80% of CpG dinucleotides in the human genome
are methylated (Bock, 2012). CpG dinucleotides can form clusters of >200 bases known as
CpG islands (CGIs). These islands have a GC content of at least 50%, and the observed/-
expected CpG ratio is greater than 60%. Approximately 60% of human gene promoters are
associated with CGIs (Bock, 2012), whilst the rest of the genome shows a relative depletion of
CpG dinucleotides (Jones, 2012), thus suggesting that the function of CpG methylation may
be dependent on its co-occurrence with CGIs. CGIs are largely unmethylated and the majority
of unmethylated regions that make up the bimodal DNA methylation pattern are CGIs (Cedar
and Bergman, 2012).
It is widely accepted that DNA methylation of CGIs has a silencing eﬀect on the expression
of genes, with methylation of CGIs at the transcription start site (TSS) often associated with
long-term transcriptional silencing, for example in genes located on the inactive X chromosome
(Jones, 2012). Transcriptional silencing through DNA methylation is thought to be mediated
by recruitment of methyl-CpG-binding domain (MBD) proteins such as methyl-CpG-binding
protein 2 (MeCP2). MeCP2 recruits histone deacetylases with the resulting low acetylation
leading to gene expression silencing (Esteller, 2007). MBDs are also able to recruit histone
methyltransferases that increase H3K9 methylation, a repressive histone mark (see Section 1.6.2;
Fuks et al. (2003)). Additionally, there is some evidence that CpG methylation may directly
preclude the binding of transcription factors necessary for gene expression (Kuroda et al., 2009),
thus decreasing expression of target genes directly.
The majority of CGIs are unmethylated when they coincide with gene TSSs, suggesting that
expression of genes with CGI-containing promoters have a distinct mechanism of transcriptional
control. Flexibility of gene activity is sensitive to transcription factor binding at these sites
(Gal-Yam et al., 2006) and transcriptionally active TSSs are marked by upstream nucleosome
depletion which provides a permissive environment for binding of transcriptional machinery
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(Yuan et al., 2005). Alternatively, repression of relevant genes with CGI-containing promoters
may be dependent upon binding of polycomb proteins (Jones, 2012).
CpG dinculeotides occurring outside CpG islands have been less characterised (Han et al.,
2011). The methylation status of these CpGs is more variable, and can diﬀer according to
the tissue of study (Jones, 2012). The relationship between promoter methylation and gene
expression may be more complex in these CpG-poor promoters; with some studies suggesting
that CpG-poor promoters can be transcriptionally active whilst hypermethylated (Weber et al.,
2005), whilst other studies evince an inverse relationship between cytosine methylation and
gene expression (Han et al., 2011). In common with CGI-containing promoters, active non-CpG
island containing promoters are associated with histone modifications linked with active genes
such as histone acetylation and H3K4me3 (Section 1.6.2; Han et al. (2011)). However, CpG-
poor promoters which are transcriptionally inactive do not show enrichment of inactive histone
marks, possibly implying that these genes may be able to modify their expression patterns more
readily than those with CGI-containing promoters.
DNA methylation is also observed outside promoters and TSSs. Gene bodies often show fewer
CpG dinucleotides than expected by chance and these CpGs may be extensively methylated
(Jones, 2012). Interestingly, gene bodies that show a greater level of CpG methylation appear
to be more actively transcribed in plants (Cokus et al., 2008), humans (Lister et al., 2009) and
pathological specimens (Kulis et al., 2012). This apparent positive correlation is maintained
in hypermethylated gene body CpG dinucleotides occuring in the context of CGIs despite the
fact that these CpGs are enriched for H3K9me3 and bind MeCP2 (Nguyen et al., 2001); two
modifications which are associated with repressed transcription when they are seen at gene TSSs
as described above (Nguyen et al., 2001).
In addition to gene bodies, enhancer regions (see Section 1.6.2 for definition) are of interest with
regard to DNA methylation. Enhancers are commonly CpG-poor (Jones, 2012) and frequently
exhibit intermediate methylation levels of between 10 and 50% (Stadler et al., 2011). There is
some evidence that methylation status of enhancer regions may be functional: a consequence
of glucocorticoid binding of its receptor is the formation of euchromatin de novo at enhancer
regions (John et al., 2008). These regions show demethylation following glucocorticoid treatment
with a resultant increase in enhancer activity (Wiench et al., 2011).
The factors that influence the laying down of DNA methylation patterns are variable dependent
upon the context in which DNA methylation is being considered (Cedar and Bergman, 2012).
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For example, the inherent bimodal pattern of cytosine methylation referred to above is laid
down in cells following the erasure of preimplantation methylation patterns in embryos (Cedar
and Bergman, 2012), and in this context, appears to be a function of the underlying sequence
information of the DNA (Straussman et al., 2009). Alternatively, dynamic tissue specific eﬀects
on methylation can be observed when highly methylated regions are demethylated to form
so called low methylated regions (LMRs) which show 10-50% methylation. Recent evidence
suggests that LMRs are formed by transcription factor binding to highly methylated regions
(Stadler et al., 2011). Conversely, under methylated regions may become de novo methylated in
a tissue specific manner (Straussman et al., 2009). However, whether this is mediated by TFs
is yet to be elucidated.
1.8 Epigenetic modifications and inflammation
The constituent cells of the immune system exhibit significant phenotypic diversity and plasticity
in response to environmental stimuli. For example, na¨ıve CD4 positive T cells can diﬀerentiate
into a number of distinct lineages including T helper 1 (Th1), T helper 2 (Th2) cells and inducible
T regulatory cells (Tregs) (Zhu and Paul, 2008). Additionally, as described in Section 1.3,
macrophages show phenotypic flexibility in M1 and M2 cell subpopulations (Rees, 2010). These
observations have led to the hypothesis that molecular mechanisms and processes underlying
this plasticity may be mediated by epigenetic modifications. Indeed, macrophages continuously
stimulated with IL-4, a significant driver of the putative M2 macrophage phenotype (Figure
1.2), show a decrease of repressive histone marks such as trimethylation of H3K27me3 at the
promoters of M2 marker genes after IL-4 stimulation (Ishii et al., 2009).
Moreover, ChIP-seq mapping of the H3K4me3 histone modification (which is associated with
gene activation) and H3K27me3 in CD4 positive T cells has demonstrated that key cytokines
are associated with only active histone modifications in relevant cells (Wei et al., 2009). For
example, the IFNγ gene, IFNG, was associated with an enrichment of H3K4me3 in Th1 cells,
which are known to be one of the main sources of this cytokine. The IL-4 gene, IL4, was
similarly associated with H3K4me3 peaks in Th2 cells which secrete this cytokine (Wei et al.,
2009).
DNA cytosine methylation also associates with the plasticity of CD4 positive T cells. Cross-
species conserved regions in IFNG which are hypermethylated in na¨ıve CD4 positive cells are
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demethylated during diﬀerentiation into Th1 cells (Schoenborn et al., 2007). Furthermore,
a genome wide analysis of CpG methylation comparing na¨ıve CD4 T cells and Tregs found
that diﬀerentially methylated regions between these two cell types were not enriched in gene
promoters, but did occur within the enhancers of genes specific to T cell lineage diﬀerentiation
(Schmidl et al., 2009). When methylated, all of these regions lost their enhancer activity as
shown by luciferase gene reporter experiments, thus suggesting that enhancer activity is critically
mediated by CpG methylation in T cells (Schmidl et al., 2009).
1.8.1 Epigenetic modifications in macrophages
Macrophages are to be studied in this project because of their relevance to the pathogenesis of
renal disease and CRGN (see Sections 1.2, 1.4.2 & 1.5). These cells show significant plasticity
and are able to direct relevant transcriptional programs involving many genes depending on
environmental stimuli (Medzhitov and Horng, 2009). One classification system of these gene
sets depends on the kinetics of the inducible response following LPS stimulation; with primary
response genes (PRGs) induced within one hour of stimulation and independent of new protein
synthesis, whilst secondary response genes (SRGs), are dependent on new protein synthesis
and chromatin remodelling at their promoters (Hargreaves et al., 2009). Although much of the
control of these distinct gene sets is mediated by transcription factors, there is emerging evidence
that epigenetic modifications have an important role to play in this process (Hargreaves et al.,
2009).
The diﬀerential requirement for chromatin remodelling between PRG and SRG expression has
recently been linked to histone modifications with SRGs showing an LPS dependent increase
in active histone modifications such as H3 acetylation and H3K4me3 (Ramirez-Carrozzi et al.,
2009). Alternatively, the PRGs show constitutively high levels of these histone modifications
(Ramirez-Carrozzi et al., 2009). In addition to histone marks, underlying sequence context also
seems important, with PRGs generally associated with CpG island containing promoters and
SRGs depleted of CpG islands (Ramirez-Carrozzi et al., 2009).
Repressive histone modifications have also been implicated in gene expression in macrophages.
Removal of the repressive H3K27me3 histone mark by jumonji C domain containing protein
3 (JMJD3), a H3K27me3 demethylating enzyme, has been shown to be upregulated by LPS
stimulation, with a resultant eﬀect on transcription of relevant genes (De Santa et al., 2007).
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Despite the apparent importance of CGI sequences in determining primary or secondary re-
sponse activity described above, little direct study of cytosine methylation in mature macrophages
has been published (Suarez-Alvarez et al., 2012). However, myeloid lineage commitment from
heamatopoietic stem cells has been shown to be associated with a reduced DNA methylation
genome-wide when compared to lymphoid commitment (Ji et al., 2010) suggesting an important
role for DNA methylation in lineage commitment. Additionally, expression of IL-1β, a potent
pro-inflammatory cytokine that is largely produced by macrophages and monocytes, is increased
following pharmacological demethylation in an acute myeloid leukaemia cell line suggesting that
IL-1β production may be dependent on DNA methylation in some form (Wessels et al., 2010).
The above studies suggests that investigation of epigenetic modifications could delineate the
ways in which chromatin remodelling and DNA modifications are important in the acquisition
of inflammatory phenotypes in macrophages.
1.9 Epigenetic modifications and disease
As the molecular biological techniques available for the study of epigenetic modifications have
become increasingly powerful the relevance of these modifications to pathology has become bet-
ter appreciated. Aberrant DNA methylation in cancer was first widely appreciated in the 1980s
and the subsequent discovery of global changes in DNA methylation and histone modification
patterns in diverse malignancies has ensured that cancer remains the paradigmatic pathology
of study in epigenetics and disease (reviewed in Baylin and Jones (2011)). Studies in cancer
have defined three main mechanisms through which DNA methylation can be associated with
disease:
1. DNA methylation and gene silencing: This is the most commonly observed asso-
ciation between DNA methylation and disease in cancer, with approximately 5-10% of
promoter CpG islands showing abnormal gains in malignancy in a range of cancer types
(Baylin and Jones, 2011). Genes silenced by DNA methylation may be either major tu-
mour suppressor genes such as CDKN2A (Baylin and Jones, 2011) or may be part of a
wider signalling defect. For example, aberrant function of the WNT signal transductive
pathway is seen in colorectal cancer (Suzuki et al., 2004) with many tumour cells showing
mutations in the APC gene. Work in colorectal cancer has shown that epigenetic silencing
of genes associated with the WNT pathway is seen in early malignant lesions, suggesting
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that DNA methylation changes may serve to complement genetic mutations in tumour
formation (Suzuki et al., 2004).
2. DNA hypomethylation: In addition to regions of hypermethylation, loci showing rel-
ative loss of DNA cytosine methylation are well described in cancer (Baylin and Jones,
2011). Although one might expect these regions of hypomethylation to be associated
with increased expression of associated genes, a recent study has shown that DNA hy-
pomethylation is associated with the formation of repressive chromatin domains and a
resulting transcriptional silencing in breast cancer cells (Hon et al., 2011). The authors
of this study suggest that these epigenetic alterations may inhibit expression of tumour
suppressor genes thus contributing to tumour formation (Hon et al., 2011).
3. Gene mutations of proteins involved in DNA methylation: Since the advent
of next generation sequencing studies, a number of cancer-specific mutations have been
revealed in the cellular machinery responsible for maintaining and modifying epigenetic
modifications (Baylin and Jones, 2011). For example, mutations in the DNMT3a DNA
methyltransferase enzyme (see Section 1.6.1) are now recognised to occur in approximately
20% of all cases of acute myeloid leukaemia (AML) (Ley et al., 2010). These mutations are
independently associated with poor patient outcomes (Ley et al., 2010; Shah and Licht,
2011), but the relationship between these mutations, downstream epigenetic modifications
and pathogenesis of AML remains uncertain (Shah and Licht, 2011).
1.9.1 Epigenetic modifications in autoimmune disease
In humans, CRGN often occurs in the context of autoimmune diseases such as systemic lupus
eryhtematosus (SLE) or ANCA-associated vasculitis (AAV) (see Section 1.1). The aetiology of
autoimmune diseases is postulated to involve both genetic and environmental factors, thus link-
ing properties intrinsic to, and extrinsic from the DNA sequence in determining gene expression
and making epigenetic alterations attractive areas of study (Ballestar, 2011). Recent interest in
the association between autoimmune diseases and epigenetic mechanisms has seen the implica-
tion of these mechanisms in diverse autoimmune diseases including SLE, rheumatoid arthritis,
type 1 diabetes, multiple sclerosis and systemic sclerosis (reviewed in Quintero-Ronderos and
Montoya-Ortiz (2012)).
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1.9.1.1 Systemic Lupus Erythematosus
Procainamide and hydralazine are drugs used in clinical practice which are known both to bind
DNA and cause an SLE-like syndrome. In the late 1980s, Richardson and colleagues used the
observation that CD4 positive T cells treated with DNA methylation inhibitors demonstrated
self-reactivity and produced an SLE-like syndrome in mice, to explore whether the mechanism of
procainamide and hydralazine induced SLE might involve DNA methylation (Cornacchia et al.,
1988). They found that procainamide and hydralazine both inhibited DNA methylation and
induced self-reactivity in cloned T cells (Cornacchia et al., 1988), suggesting that DNA methyla-
tion may have a role in SLE pathogenesis. The same group further implicated DNA methylation
in SLE by demonstrating global hypomethylation in T-cells but not in non-T lymphocytes from
aﬀected patients using high performance liquid chromatography (HPLC) (Richardson et al.,
1990).
Since this study, hypomethylation of promoters associated with genes known to be overex-
pressed in SLE, such as ITGAL, CD40LG and PRF1, has been demonstrated using specific
gene-targeted experimental methodologies (reviewed in Quintero-Ronderos and Montoya-Ortiz
(2012)). More recently, genome-wide data has confirmed the association between DNA methy-
lation and SLE. Firstly, a bead array platform which interrogated 1,505 CpG dinucleotides
dispersed over 807 gene promoters, demonstrated that 49 genes from immune-related functional
categories had diﬀerentially methylated promoters in leukocytes from monozygotic twins dis-
cordant for SLE (Javierre et al., 2010). Secondly, a very recent study assayed >460,000 CpG
dinucleotides spread across 95% of known coding genes in human CD4 positive T cells, B cells
and monocytes, and found a profound hypomethylation of genes regulated by type I interferon
(interferons which bind to the IFNα receptor) (Absher et al., 2013).
In addition to DNA methylation, epigenetic modifications in non-coding portions of the genome
have been linked to SLE using integration of diverse genome-wide data sets. Genome-wide asso-
ciation studies (GWAS) are used to examine whether common genetic variants, most commonly
single nucleotide polymorphisms (SNPs) associate with certain traits, most often diseases (Mc-
Carthy et al., 2008). GWAS techniques have proved extremely popular in seeking to associate
genetic variation with disease predisposition and have been performed for SLE (Han et al.,
2009). Since the early days of GWAS, it has been observed that approximately 90% of SNPs
associated with diseases are found in non-coding regions of DNA (McCarthy et al., 2008).
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Recent mapping of nine distinct chromatin marks (see Section 1.6.2), allowed six broad classes
of chromatin states to be distinguished in nine human cell types (Ernst et al., 2011). Integration
of these chromatin states in a lymphoblastoid cell line with GWAS data for SLE found that
SLE-associated SNPs were significantly more likely to coincide with enhancer regions of the
genome found by mapping the nine chromatin marks (Ernst et al., 2011). As a result, genetic
variation in enhancers may provide a mechanism for disease predisposition related to non-coding
DNA.
1.9.1.2 ANCA-associated vasculitis
The AAV are an important cause of CRGN (see Section 1.1) and have been associated with
epigenetic modifications. A CpG island in the MPO gene, which is aberrantly expressed in
neutrophils in a subset of patients with AAV, is unmethylated in patients. Furthermore, the
repressive histone mark, H3K27me3 was decreased in AAV patients at both the MPO locus
and in the other main disease gene, PR3 (Ciavatta et al., 2010). This study also demonstrated
higher relative mRNA levels of jumonji C domain containing protein 3 (JMJD3 ), the H3K27me3
demethylase, in patients, suggesting that removal of this transcriptionally repressive mark can
lead to aberrant expression of the disease autoantigens, MPO and PR3, and hinting at an
epigenetic mechanism for disease pathogenesis.
1.9.2 Epigenetic therapy in disease
Increasing recognition that aberrant epigenetic modifications contribute to a range of diseases
has led to an increased interest in therapeutic targeting of these modifications. DNA methyl-
transferase inhibitors such as the pyrimidine analogue 5-aza-2’-deoxycytidine (decitabine, DAC)
have formed a significant part of this interest. DAC is incorporated into DNA during de novo
DNA synthesis and has demonstrated clinical eﬀects in treatment of haematological diseases
such as myelodysplastic syndromes and acute myeloid leukaemia (Lee et al., 2013; Scandura
et al., 2011). However, current epigenetic therapies carry significant toxic sequelae such as
bone marrow suppression, pyrexia and nausea, restricting clinical use of these compounds to
malignant diseases (Bonifer and Bowen, 2010).
Outside of malignant diseases, the use of epigenetic modifying therapies remains experimental.
DNA methylation inhibitors are associated with significant side eﬀects (outlined above) and
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exert non-specific eﬀects across the genome. To date, no autoimmune diseases of relevance to
CRGN have been suﬃciently studied to implicate DNA hypermethylation and therefore suggest
that blanket DNA methylation inhibition may be a useful therapeutic strategy (Chapman-Rothe
and Brown, 2011). Alternatively, drugs interfering with histone modifications (Section 1.6.2),
namely histone deacetylase inhibitors (HDACi; for example vorinostat), have been more widely
studied in autoimmune diseases (Chapman-Rothe and Brown, 2011). Results with this class
of drug in rheumatoid arthritis have proved encouraging (Chapman-Rothe and Brown, 2011)
suggesting that epigenetic treatment of autoimmune disease may prove an important path in
the future.
1.10 Techniques for analysis of DNA methylation
In order to investigate genome-wide DNA cytosine methylation in the NTN model and bone
marrow-derived macrophages, it is necessary to choose a reliable and tractable technique. The
fact that DNA methylation information is erased during the PCR process has made it necessary
to use methylation dependent pre-treatments to conserve and assay data regarding the presence
of methyl groups in DNA (Laird, 2010). Initially, these pre-treatments were used at selected
loci but have recently been adapted for use on the whole-genome scale (Johnson et al., 2012;
Laird, 2010; Lister et al., 2009).
1.10.1 Methods available for detection of DNA methylation
The pre-treatments can be divided into three main areas: digestion with restriction endonuclease
enzymes, aﬃnity enrichment for methylated regions using antibodies specific for methylated
cytosine bases and sodium bisulfite conversion.
1.10.1.1 Restriction enzyme digestion
This pre-treatment takes advantage of the fact that the cutting ability of a number of restric-
tion enzymes is inhibited by cytosine methylation when it occurs in the CpG context (Laird,
2010). The most commonly used of these enzymes in DNA methylation studies are HpaII and
its isoschizomer MspI. These enzymes recognise the sequence CCGG and cleave at the point be-
tween the two cytosine bases. Downstream information can be gained from use of these enzymes
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either by array hybridisation; where digested DNA and mock-treated DNA are dye-labelled and
hybridised to two colour arrays to allow DNA methylation information to be extracted from
relative fluorescence intensities (Yan et al., 2009), or digested fragments can be sequenced in
comparison with randomly sheared fragments (Brunner et al., 2009).
1.10.1.2 Aﬃnity enrichment
As alluded to in Sections 1.5 and 1.8, the epigenetic landscape created by diverse histone modi-
fications and transcription factor binding sites (TFBS) can be investigated using chromatin im-
munoprecipitation followed by next-generation sequencing (ChIP-seq). In this technique, DNA
sequencing follows selective enrichment for short DNA reads bound to either the relevantly mod-
ified histones or TFBSs by use of antibodies. Thus, ChIP-seq can be used to produce genome
wide maps of histone modifications and TFBSs in cell populations (for example; Hull et al.
(2013); Wei et al. (2009)).
A similar approach can be taken with DNA methylation, whereby selective enrichment of methy-
lated DNA is achieved by methyl-bindng proteins with aﬃnity for methylated DNA (Laird,
2010). These enrichment techniques were initially used in conjunction with array hybridisation,
using diﬀerent dyes to label the enriched and non-enriched samples (Weber et al., 2007). How-
ever, they are now being more frequently combined with next- generation sequencing approaches
to allow genome-wide assessment of DNA methylation (Down et al., 2008).
1.10.1.3 Sodium bisulfite conversion
Biological study of DNA methylation has been available through the use of sodium bisulfite (BS)
treatment since the 1990s. This treatment deaminates unmethylated cytosine bases and converts
them to uracil, leaving methylated cytosines unchanged. Subsequent PCR amplification of BS
converted DNA replaces uracil with thymine, thus allowing a read out of the methylation status
of individual cytosine bases.
This technique has proved powerful in that it can be combined with Sanger sequencing to
allow a quantitative read out of DNA methylation status of PCR products (Clark et al., 1994).
Additionally, BS-treated DNA has recently been used in conjunction with whole genome shotgun
sequencing to provide single-base resolution DNA methylation analysis of whole genomes and
thus supply comprehensive methylome sequences of eukaryotic and mammalian genomes (Laird,
Chapter 1. Introduction 41
2010; Lister et al., 2009). In addition to direct sequencing methods, array based methods (for
example, the Illumina Infinium platform) which are able to to use dye labelling to distinguish
between methylation states at individual CpG sites are widely available. These arrays have
proved extremely popular in human disease studies (see for example, Javierre et al. (2010)).
1.10.2 Selection of sodium bisulfite conversion and sequencing for use in this
project
Experiments for this study were designed using bisulfite conversion methods for a number of
reasons. Firstly, BS-conversion can be used with both standard Sanger sequencing and massively
parallel or next generation sequencing (NGS) approaches. As described in Section 1.10.1.3, NGS
technologies have been used with BS conversion to sequence complete mammalian genomes at
single base resolution, thus potentially allowing production of a complete methylome sequence
of both WKY and Lew rat strains in this project. Finally, no rat specific arrays are available for
the Illumina Infinium platform mentioned above. BS-Sanger sequencing can be used to examine
methylation at selected loci within the PCR product range, whilst next generation sequencing
will generate whole-genome sequencing data, known in this context as whole genome shotgun
bisulfite sequencing (WGBS). The MRC CSC has access to a well-recognised NGS platform;
the Illumina HiSeq 2000, thus allowing WGBS data production. The basic principles of NGS
using the Illumina platform are shown in Figure 1.3.
WGBS has inherent advantages as a technique for whole-genome scale detection of DNA methy-
lation. Firstly, BS treatment requires denaturation of DNA from double to single-stranded and
therefore, input DNA can be of comparatively low purity and integrity compared to that required
for techniques based on restriction enzymes (Laird, 2010). This is likely to be an advantage in
experiments in which the starting material is derived from primary animal tissues or samples
requiring multiple steps for DNA extraction.
Measurements of DNA methylation produced by WGBS are largely protected from biases intro-
duced by restriction enzyme pre-treatment and aﬃnity enrichment (Laird, 2010). However, the
major sources of bias in this technique is from incomplete BS conversion and diﬀerential PCR
eﬃciency for methylated versus non-methylated versions of the same sequence (Campan et al.,
2009). The first of these can be controlled by use of spiked DNA controls to monitor eﬃciency
of BS conversion, and the MRC CSC genomics facility (where these sequencing experiments
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Cluster Formation!
a! b! c!
Base Calling!
Figure 1.3: The basic principles of NGS on the Illumina platform. DNA samples are
fragmented & common adaptors ligated to fragment ends. Cluster Formation panel shows
production of immobilised PCR colonies; first, fragments adhere to the flow cell via adaptor
mediated binding & are then amplified and made double stranded (a), before denaturation into
single strands (b), which are then completely amplified, (c), to form ∼1,000 copies of single
template libraries. Base calling requires sequencing cycles where 4 modified deoxynucleotide
species bearing 1 of 4 fluorescent labels are used to label the relevant base. Four colour channel
imaging and cleavage of fluorescent labels completes the cycle. Images from Shendure & Ji,
Next-generation DNA sequencing. Nature Biotechnology 26, 1135-1145 (October 2008).
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were performed) has experience in the use of spiked unmethylated cl857 Sam7 lambda DNA to
assess BS conversion and take account of this in subsequent analysis (Johnson et al., 2012).
Data produced by restriction enzyme and aﬃnity enrichment experiments are constrained by
the distribution of enzyme cleavage sites and aﬃnity targets throughout the genome (Dohm
et al., 2008). As a result, WGBS has increased power over restriction enzyme and aﬃnity
enrichment techniques to both detect non-CpG context DNA methylation (Lister et al., 2009)
and also to achieve good sequencing depth of regions with low CpG density. This latter may
allow detection of diﬀerential methylation between areas of low CpG density which would be a
novel area of study.
The points above have ensured that since its inception, WGBS has been used to produce whole
methylomes of Arabidopsis thaliana (Cokus et al., 2008), human embryonic stem cells (Lister
et al., 2009), peripheral blood mononuclear cells (Li et al., 2010) and colon cancer cells (Hansen
et al., 2011). These datasets have led to novel insights that could not have been attained by
other methods used to assay DNA methylation (Miura et al., 2012). As a result, I chose WGBS
to investigate the role of DNA methylation in macrophages in NTN susceptibility.
1.11 Aims of the project
This project will investigate the hypothesis that variation in DNA cytosine methylation can
determine dysregulation of macrophage activity and contribute to the glomerulonephritis sus-
ceptibility of the WKY rat. The overall aim of the study is to identify genome-wide variation in
DNA methylation which may determine susceptibilty to CRGN and therefore represent a new
therapeutic target.
To investigate this aim I will use sequencing methodologies to detect DNA methylation on
the whole genome scale. Further investigations will be possible by integration of sequencing
data with publicly available datasets examining both genome-wide gene expression and other
epigenetic modifications such as histone modifications. Additionally, an in vivo study examining
the clinical eﬀect of inhibition of DNA methylation in WKY rats will be used to further explore
the role of cytosine methylation in CRGN.
The main objectives of this study are:
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1. To investigate if genes that are diﬀerentially expressed in bone marrow-derived macrophages
from WKY and Lew rats show diﬀerential DNA methylation in promoter regions, and if
cytosine methylation changes in response to stimulation with lipopolysaccharide
2. To gain single base resolution sequence of DNA cytosine methylation in WKY and Lew
rat macrophages using WGBS, thus allowing the association of strain diﬀerences in DNA
methylation with susceptibility to CRGN
3. To investigate the relationship between DNA cytosine methylation and gene expression
in a fully diﬀerentiated cell type using publicly available gene expression data in rat
macrophages
4. To investigate the eﬀect of pharmacological perturbation of DNA methylation on an in
vivo rat model of human glomerulonephritis
Objective 1 is investigated using In silico microarray analysis of gene expression data to identify
diﬀerentially expressed genes in WKY and Lew macrophages. Following this analysis, BS-
Sanger sequencing of PCR products from promoters of diﬀerentially expressed genes is used.
The rationale for this is that if diﬀerentially methylated CpGs in the promoters of genes known
to be diﬀerentially expressed in WKY and Lew macrophages are identified, then this would be
suﬃcient proof of concept to justify proceeding to WGBS experiments. In addition, this schema
is reproduced with LPS stimulation, because if any plasticity of DNA methylation is seen in
response to the environmental stimuli of LPS, then this could also be used to guide further
experiments. These results are presented in Chapter 3.
Objective 2 is studied in Chapter 4. Here, I report an in-depth analysis of WGBS data sets
from WKY and Lew bone marrow-derived macrophages (BMDMs). This analysis allows me
to describe both the general patterns of DNA methylation in BMDMs and also to characterise
diﬀerences in methylation profiles between the two strains. Given that the two strains show
diﬀerential susceptibility to CRGN, CpGs that are diﬀerentially methylated in the WGBS data
between the two strains can be associated with CRGN and therefore used as starting points for
further study.
An in silico analysis of the general relationship between CpG methylation and gene expression
in macrophages from the WKY and Lew rat strains is presented in Chapter 5 (Objective 3).
This is achieved by integration of the data gained from the WGBS in Chapter 4 with publicly
available gene expression data generated by the Physiological Genomics & Medicine group at
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the MRC Clinical Sciences Centre. In Chapter 5 I also undertake an investigation of the relation
between gene expression and CpG methylation with regards to diﬀerentially methylated CpG
dinucleotides (dmCpGs) between the WKY and Lew strain. Further examination of a potential
transcriptional role of dmCpGs is achieved both through the use of histone modification data
derived as part of the ENCODE project and by investigating a potential enrichment of dmCpGs
near to transcription factor binding sites.
Finally, objective 4 is examined in Chapter 6. In this chapter, I initially use in vitro experiments
to examine the eﬀect of a DNA methylation inhibitor, DAC, on BMDMs and DNA methylation.
Then, in vivo administration of DAC to WKY rats with NTN is used to assess the eﬀect of
inhibition of DNA methylation on histological and cellular phenotypes relevant to CRGN. BS-
Sanger sequencing is then used to determine the extent of changes in CpG methylation seen
after drug administration in CpG dinucleotides selected either as part of the work for objectives
1 and 2 or because of biological relevance.
Chapter 2
Materials and Methods
2.1 Laboratory Methods
2.1.1 Laboratory animals
Wistar-Kyoto (WKY/NCrl) and Lewis (LEW/Crl) rats were purchased from Charles River
(UK). All procedures were performed in accordance with the United Kingdom Animals (Scien-
tific Procedures) Act. The complete genome sequence of both of these rat strains is publicly
available (Atanur et al., 2013) and therefore known SNPs between these strains and the Brown
Norway reference strain are accessible.
2.1.2 Rat bone marrow-derived macrophage (BMDM) culture
This protocol has been previously described in Behmoaras et al. (2008). Long bones were
isolated from male rats of ages 8-10 weeks and flushed with Hanks buﬀer (Gibco, UK) to extract
bone marrow. Total bone marrow extract was then centrifuged at approximately 500g/4C for 5
minutes and the supernatant discarded. Resultant cell pellets were resuspended in 10ml Hanks
and red cells were then lysed by a 15 minute incubation in a 5% CO2 incubator at 37C. Samples
were then further centrifuged at 500g/4C for 5 minutes and the supernatant discarded prior to
resuspension. This resuspension occurred in culture media of the following recipe: Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco, Invitrogen, Paisley, UK) containing 25mM HEPES
(Sigma, Kent, UK), 25% L929 conditioned medium, 25% decomplemented fetal bovine serum
46
Chapter 2. Materials and Methods 47
(Biosera, UK), penicillin (100U/ml; Invitrogen), streptomycin (100µg/ml; Invitrogen) and L-
glutamine (2mM; Invitrogen). Cells were then plated equally between 4 x 15cm petri dishes
(Nunc, Thermo Scientific, DE, USA) containing a further 30ml of culture media and incubated
for 5 days in 5% CO2 at 37C.
Where BMDMs were treated with lipopolysaccharide; media was aspirated after the five day
culture period and cells where then washed with cold Hanks solution. Fresh media containing
either 100ng/ml LPS (lipopolysaccharides from Salmonella typhosa purified by gel-filtration
chromatography, Sigma-Aldrich) or vehicle was added for the desired period at 37C.
2.1.2.1 Treatment of BMDMs with 5-aza-2’-deoxycytidine (DAC)
5-aza-2’-deoxycytidine (C8H12N4O4: DAC; see Sections 1.9.2 & 6.1.2) was purchased from
Sigma, UK. To assess the eﬀect of diﬀerent concentrations of DAC on DNA methylation in
BMDMs, bone marrow was plated as described in Section 2.1.2, except that 6cm petri dishes
(Nunc) were used. During the 5 day culture period, culture media was changed daily. Where
experimental design (see Section 6.2.2.1) required exposure to DAC this was made up fresh each
day to a concentration of 1mM by dissolving 50mg/ml in 50% acetic acid and then diluting in
distilled water. This was then diluted in culture media to allow exposure of cultured cells to
DAC. Fresh DAC was used because the drug is classified by Sigma as very unstable in solution.
After 5 days, BMDMs were dissociated using cell dissociation solution (Sigma) and stained with
trypan blue to allow manual cell viability analysis (Louis and Siegel, 2011) and counting. DNA
from these cells was extracted as described in the next section.
2.1.3 Bisulfite Sanger sequencing
WKY and Lew genomic DNA was extracted from macrophages using the Qiamp DNA mini
kit (Qiagen, UK) according to manufacturers instructions and then bisulfite converted with
the Methylcode bisulfite conversion kit (Invitrogen). Polymerase chain reaction (PCR) was
performed either as a semi-nested reaction using Biotaq DNA pol (Bioline, UK) or as a single
round of PCR using PFU turbo Cx taq polymerase (Agilent, Europe). Primers were designed
specifically for the amplification of bisulfite converted DNA using the methprimer program (Li
and Dahiya, 2002). Amplified products were run on 2% agarose to confirm size and integrity
and then cleaned up using the Qiaquick PCR purification kit (Qiagen). Products were then
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Sanger sequenced using an ABI 3730 capillary sequencer (Applied Biosystems) by the MRC
CSC Genome Core. Alignment was performed in Sequencher versions 4.9 and 5.0 (Gene Codes
Corporation, USA). Methylation status of individual CpG dinucleotides was determined semi-
quantitatively using the relative peak height of cytosine and thymine electropherograms after
alignment (see figure 2.1 top panel). In order to assess eﬃciency of bisulfite conversion of
DNA, all cytosine bases occurring outside of the CpG context were checked to ensure that
they were read as thymidines in the sequencing products (see figure 2.1 bottom panel). This
is because one can assume that all non-CpG cytosines should be unmethylated and therefore,
read as thymidines after sequencing (Section 1.10.1.3). Only amplicons meeting this criteria
were included in the analysis.
2.1.4 Whole genome shotgun bisulfite sequencing
Fragmented DNA libraries for whole genome shotgun bisulfite sequencing were generated using
a protocol developed by the MRC CSC Physiological Genomics & Medicine Group and pub-
lished in Johnson et al. (2012) with modifications. The main modifications were in the bisulfite
conversion step (section 2.1.4.3) and in subsequent purification of the bisulfite converted library
(section 2.1.4.4), and details of these modifications are included in the relevant sections.
2.1.4.1 Shearing, purification and quantification of genomic DNA
A total of 6µg of genomic DNA was mixed with 10ng of unmethylated cl857 Sam7 lambda DNA
(Promega, Southampton, UK) and made up to 130µl with nuclease free water. This mixture was
transferred to a 6mm x 16mm Covaris microtube (KBiosciences, Hertfordshire, UK) and sheared
using a Covaris System S-series model S2 (KBiosciences) with the following settings: Duty Cycle
10%, Intensity 5, Cycles per Burst 200, Frequency Sweeping for 90 seconds. Subsequently, 6.5µl
of sheared DNA was then diluted in 13.5µl of water and loaded on a 2% EX E-gel (Invitrogen,
Paisley, UK) with 200ng of quick load 50bp ladder (New England Biolabs, Hertfordshire, UK)
and run on an E-gel electrophoresis system (Invitrogen) using the pre-programmed 2% program.
A high intensity picture of the gel was used to determine peak size of sheared DNA and assess
fragment length distribution. The remainder of the sheared sample was then purified using the
QIAquick PCR purification kit (Qiagen, West Sussex, UK) as per manufacturers instructions.
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Figure 2.1: Bisulfite Sanger sequencing provides a semi-quantitative analysis of
CpG methylation
Top panel: “Genomic base” is the expected base using the genomic sequence at that position;
“Sequenced base call” follows bisulfite conversion, sequencing and alignment. When the base
call is C this represents a methylated CpG. Where T, unmethylated; where C/T the percentage
methylation is derived from the relative peak heights of the C and T peaks
Bottom panel: BS-Sanger sequence visualised in Sequencher 5.0. Black box & arrow show a
partially methylated cytosine, whilst grey box & arrow show non-CpG cytosine read as thymine
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2.1.4.2 End-repair, A-tailing, adapter ligation and size selection of DNA libraries
The end-repair reaction was carried out in thin-walled PCR tubes using 57µl of sheared DNA;
28µl water, 10µl of 10x NEBNext End Repair Reaction Buﬀer and 5µl NEBNext End Repair
Enzyme Mix (both New England Biolabs). This 100µl mixture was incubated at 20C for 30
minutes in a thermocycler and then purified using the QIAquick PCR purification kit with a
final elution volume of 42µl.
This purified, end-repaired sample of 42µl was subsequently used in a 50µl total volume reaction
mix containing 5µl of 10x NEBNext dA-Tailing Reaction Buﬀer and 3µl of Klenow Fragment
(both New England Biolabs). This mix was incubated in a thermocycler for 30 minutes at
37C and then purified with the MinElute PCR purification kit (Qiagen) in a total final elution
volume of 28µl. 1µl was then quantified using the Qubit dsDNA HS assay.
The next step was ligation of Illumina Early Access Methylation adapter oligos (Illumina Essex,
UK); adapters are added to 25µl of the A-tailed DNA sample, 10µl 5x NEBNext Quick Ligation
Reaction Buﬀer, 5µl of Quick T4 DNA ligase (both New England Biolabs) and a variable amount
of water to make a total reaction volume of 50µl. This mixture was incubated in a thermocycler
for 30 minutes at 20C and then purified using the QIAgen MinElute purification kit in a final
elution volume of 15µl.
Adapters are added at a 10:1 molar ratio of adapter to DNA library. This calculation was
carried out using the following formula:
V ol =
DNA×1000
Peak×660×10
25
Where: DNA = quantity of dA-tailed purified DNA & Peak = mean peak size of sheared DNA.
Libraries were then purified on a 2% 1xTAE agarose gel to remove non-ligated adapters and
adapters which have ligated to each other, and to size select templates for further library gen-
eration. This was achieved by loading the 15µl library purified from the ligation reaction mixed
with 5µl of loading buﬀer and then running at 120V for 1 hour with both 50bp and 2log quick
load ladders (New England Biolabs). Following running, the gel was soaked in 200ml 1xTAE
containing 20µl 10000xSYBR Gold nucleic acid gel stain (Invitrogen) at room temperature for
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45 minutes. Gel fragments of size 325-475 bp were then extracted on a Dark Reader transillu-
minator (Clare Chemical Research, CO, USA) and purified with the MinElute Gel Extraction
Kit (Qiagen) with a final elution volume of 30µl. Libraries were then quantified with the Qubit
dsDNA HS assay.
2.1.4.3 Bisulfite conversion
Bisulfite conversion in libraries used for sequencing was achieved using the Epitect Bisulfite kit
(Qiagen). This is diﬀerent from the method described in Johnson et al. (2012) as subsequent
work in the group demonstrated superior rates of bisulfite conversion with the Epitect kit as
compared to the Zymo Research method described in Johnson et al. (2012). All subsequent
reagents named in this section are from the Epitect kit unless otherwise stated
To achieve bisulfite conversion; 450ng of purified DNA library was mixed with 85µl of bisulfite
mix and 15µl of DNA protect buﬀer and a variable amount of water to make a total volume of
140µl. Samples were then incubated in a thermocycler with the following program: 95C for 5
minutes, 60C for 25 minutes, 95C for 5 minutes, 60C for 85 minutes, 95C for 5 minutes, 60C
for 175 minutes and then 3x repeat of 95C for 5 minutes and 60C for 180 minutes and held at
20C. The treated samples were then purified as per manufacturers instructions. Briefly, 310µl
BL buﬀer containing 10µg/ml carrier RNA (in order to enhance binding of DNA libraries to
the spin column membranes) and 250µl 100% ethanol was added to samples prior to transfer to
EpiTect spin columns and centrifugation at maximum speed. Samples were then washed with
500µl buﬀer BW, incubated at room temperature for 20 minutes in 500µl BD (desulfonation)
buﬀer, centrifuged and washed twice more in BW buﬀer prior to elution in 40µl of elution buﬀer.
Eﬃciency of this bisulfite conversion step is achieved by analysis of sequence gained from the
spiked-in cl857 Sam7 lambda DNA (Section 2.1.4.1). This lambda DNA is entirely unmethylated
therefore, all cytosine bases in the lambda genome should undergo bisulfite conversion and no
cytosine bases should be read in the lambda sequence post-BS conversion (Section 1.10.1.3).
Only libraries with bisulfite conversion rates over 99% were used and base calls were corrected
for less than 100% conversion as described in Section 2.2.2.
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2.1.4.4 Amplification and purification of bisulfite converted library
This step enriches DNA fragments to which adapter has bound in order to facilitate flow cell
binding during the sequencing process. This initially takes place by means of a PCR in which
the 40µl of DNA library were added to a mix containing 5µl 10x Pfu Turbo Cx reaction buﬀer
(Agilent, Cheshire, UK), 1.25µl 10mM dNTP (Bioline), 1µl of 25µM primers and 1µl of Pfu
Turbo Cx DNA polymerase (Agilent). This mix was amplified on a thermocycler using a protocol
of 95C for 2 minutes, 98C for 30 seconds, then 10x cycles of: 98C at 15 seconds, 60C for 30
seconds and 72C for 4 minutes, followed by 72C for 10 minutes and then a hold at 4C.
This PCR enriched product was then purified by use of Agencourt AMPure XP beads (Beckman
Coulter, Bucks, UK); the library was first added to 90µl of homogenous beads and vortex mixed,
transferred to a DynaMag-2 magnetic particle concentrator (Invitrogen) and the beads allowed
to adhere to the concentrator for 3 minutes. The clear liquid was then discarded and the adhered
beads washed twice with 500µl of 70% ethanol. Residual ethanol was then evaporated over a
37C heat block for 3 minutes and the beads then resuspended in 15µl of nuclease free water,
vortex mixed and incubated at room temperature for 2 minutes before being re-transferred to the
magnetic concentrator. The mix was left for 3 minutes in the concentrator and the supernatant,
representing purified library, then removed to a new tube for subsequent gel extraction.
This gel extraction proceeded identically to that described above with the only diﬀerence being
that excised fragments were in the range of 350-450 bp. Excised fragments were then purified
using the MinElute Gel Extraction kit (Qiagen). These purified fragments represent the whole
genome bisulfite converted library.
2.1.4.5 Pre-sequencing quality control
1µl of the library was quantified using the Qubit dsDNA HS assay and a subsequent 1µl run
on the Agilent Bioanalyzer 2100 Expert High Sensitivity DNA Assay. This allowed accurate
assessment of the average fragment size of the library and a representative trace can be seen in
Figure 2.2. This fragment size and the concentration from the Qubit measurement can be used
to calculate the molarity of the sample:
Molarity(nM) =
Conc
mass× length
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Where: Conc = Qubit library concentration (ng/liter); mass = molecular mass of a basepair
(650 Da); length = average length of the library (bp) from bioanalyzer
Marker! Marker!
Sample Peak !
393bp!
Figure 2.2: Representative Bioanalyzer trace from WGBS library
Marker peaks and main sample peak with a size of 393 base pairs are indicated (black arrow).
Oblique numbers (example indicated by red arrow) refer to size in base pairs of insignificant
peaks
2.1.4.6 Sequencing of WGBS libraries
The preceding subsections of Section 2.1.4 describe the preparation of WGBS libraries. Sequenc-
ing data was generated from these libraries using the HiSeq 2000 platform (Illumina, UK). The
associated laboratory work for sequencing of libraries was carried out by the MRC CSC Genome
Core and is described in Johnson et al. (2012). Briefly, libraries were quantified using quan-
titative PCR and then denatured into single stranded fragments. These fragments were then
amplified (see Figure 1.3) by the Illumina cluster robot and transferred to the HiSeq 2000 for
sequencing. Initial bioinformatic analysis to assess quality of the sequencing was performed by
the MRC CSC Genome Core prior to data release.
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2.1.5 Multiplexed PCR sequencing using the Fluidigm access array
The Fluidigm access array is a microfluidic target enrichment system that was used in this
project to allow multiple PCR reactions to be performed on multiple samples at the same time.
In this project 46 independent DNA samples from basic BMDM preparations, BMDM prepara-
tions treated with DAC and DNA extracted from nephritic glomeruli were used. The BMDM
preparations were those used for the WGBS libraries to allow validation of WGBS methylation
profiles. Whilst the other samples were used to assay the eﬀects of DAC on methylation.
Internal controls were produced using whole genome amplification with or without subsequent
SssI methylase treatment using the method of Hughes and Jones (2007). Here, genomic DNA is
whole genome amplified using the REPLI-g mini kit (Qiagen, UK) according to manufacturers
instructions. This results in methylation-free DNA, as a result of the absence of methylase ac-
tivity for the enzyme phi29 polymerase which mediates the whole genome amplification (WGA)
(Hughes and Jones, 2007). Subsequent to the amplification, some of the WGA DNA was treated
with the CpG methylase, SssI (New England Biolabs, Hertfordshire, UK) according to manu-
facturers instructions. SssI is a CpG methylating enzyme that methylates all cytosine residues
within the recognition sequence 5’...CG...3’. As a result, WGA DNA untreated with SssI should
show no methylation and WGA DNA treated with Sssi should be fully methylated (Hughes and
Jones, 2007). Only samples in which these conditions were met were included in the analysis.
Sample genomic DNA was bisulfite converted using the Methylcode bisulfite conversion kit.
50ng of bisulfite converted DNA per reaction was PCR amplified using the Fluidigm 48.48
Access Array. Each PCR reaction used a mix based on the FastStart High Fidelity PCR
System (Roche, Europe) and primer pairs designed using the Sequenom primer program (http:
//www.epidesigner.com). PCR amplification was performed using a protocol of 70C for 20
minutes, 95C for 10 minutes, then 40x cycles of: 95C for 15 seconds, 57C for 30 seconds, 72C
for 60 seconds. PCR products were cleaned up using Agencourt AMPure XP beads (Beckman
Coulter) and then barcoded using Fluidigm 384 Barcodes (Fluidigm, Europe) combined with
a Roche FastStart High Fidelity PCR mix and amplified by thermal cycling at 95C for 10
minutes, 15 cycles of: 95C for 15 seconds, 60C for 30 seconds, 72C for 1 minute and then
a 3 minute period at 72C. Barcoded PCR products were cleaned up again using Agencourt
AMPure XP beads and then pooled and quantified using the Agilent Bioanalyzer 2100 Expert
High Sensitivity DNA Assay. A representative bioanalyzer trace from a pooled library can be
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seen in Figure 2.3. Sequencing libraries were then prepared from pooled samples and sequenced
on the Illumina MiSeq platform by the MRC CSC Genome Core facility.
Sample Peak !
Figure 2.3: Representative Bioanalyzer trace from Fluidigm library
The main sample peak has five visible peaks due to the pooled PCR products within the sample
2.1.6 Nephrotoxic nephritis experiments
2.1.6.1 In vivo procedures
8-10 week old male WKY rats were used for NTN experiments. Nephrotoxic serum (NTS) was
raised in rabbit against rat glomerular basement membrane antiserum (rabbit anti-rat GBM
antiserum). Rat GBM antigen is produced by the formation of a glomeruli enriched fraction
derived by the sequential sieving of rat kidney tissue. This fraction is sonicated to disrupt cells
and lypophilised prior to injection into rabbits. Rabbits are bled at day 28 post inoculation
for extraction of rabbit anti-rat GBM antiserum. Intravenous injection of 0.1ml of NTS was
used to induce nephrotoxic nephritis (Procedure performed by Dr Steve McAdoo, Dept of Renal
Medicine, Imperial College London).
After induction, rats were either treated with 5mg/kg IP injection of 5-aza-2’-deoxycytidine
(DAC; Sigma) or PBS vehicle. DAC was dissolved at 50mg/ml in 50% acetic acid and then
diluted in PBS for IP injection. PBS for vehicle injections was spiked with the same volume
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of 50% acetic acid used to dissolve the DAC prior to use. Doses of DAC or vehicle were given
every 3 days, as this dosing regimen has been previously shown to aﬀect DNA methylation in
vivo in the rat (Archer et al., 2010), beginning on the day of induction, for 10 days.
On the 9th post-induction day, urine was collected by placing rats in metabolic cages for 24
hours with free access to food and water. Proteinuria was quantified using sulphosalicylic acid
method. Urine samples, diluted between 1:3 to 1:100 in water, were added to a 96-well microtitre
plate in triplicate. 10µl of 25% sulphosalacylic acid was added to two of three replicates, and
10µl of water to the third replicate in order to provide a blank reading for that sample. Known
quantities of bovine serum albumin (BSA; Sigma) in water were used to define a standard curve,
and absorbance read at 450nm on a microplate reader and associated software (Biotek EL800;
Gen5 Analysis Software; both Biotek Instruments Ltd, Potton, UK). The protein concentration
in each sample was calculated from a regression equation described by the standard curve,
and the 24 hour protein excretion rate was calculated by multiplying by the total urine volume.
These proteinuria quantifications were performed by Dr Steve McAdoo, Dept of Renal Medicine,
Imperial College London.
Rats were killed on day 10 and long bones harvested as well as samples of kidney, spleen, liver
and lung, which were fixed in formalin, buﬀered, processed and embedded in paraﬃn wax.
At the time of killing, blood was taken by cardiac puncture and haematological parameters
were produced in blood samples by the clinical haematology laboratory of the Hammersmith
Hospital. Glomeruli were isolated by sequential sieving of kidney homogenates using stainless-
steel meshes of 250, 150 and 75µm in cold PBS followed by centrifugation at 500g for 5 min and
stored in TRIzol reagent prior to use.
2.1.6.2 Histological analysis
To allow quantification of glomerular crescents following NTN induction, 4µm formalin-fixed
paraﬃn-embedded kidney sections were stained with haematoxylin and eosin (H&E), and pe-
riodic acid-Schiﬀ (PAS). 100 consecutive glomeruli were examined under a light microscope
whilst blinded to treatment group, and the number of severely crescentic glomeruli expressed
as a percentage of total glomeruli examined.
Macrophage infiltration into glomeruli was assessed in formalin-fixed, paraﬃn embedded kid-
ney sections stained with a primary mouse monoclonal antibody ED-1 (Serotec Ltd., UK). A
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commercial secondary antibody detection system (Dako Ltd, UK) comprising a peroxidase-
conjugated polymer backbone which carries secondary antibody molecules raised in goat and
directed against rabbit or mouse immunoglobulins was used. Specifically in this experiment, a bi-
otinylated rabbit anti-mouse immunoglobulin (Sigma; dilution 1:100) was followed by Extravadin-
HRP (Sigma; dilution 1:100). Subsequent development used 3,3’-Diaminobenzidine. Image
analysis software was used to calculate the percentage of 20 consecutive glomeruli per animal
that showed ED-1 staining and the mean calculated.
2.2 Bioinformatics and statistical methods
2.2.1 Microarray analysis
Microarray datasets used were from Maratou et al. (2011) or from experiments performed by Dr
R Hull of the Physiological Genomics and Medicine group (PGM), MRC CSC, London (later
published in Hull et al. (2013)). The Maratou et al. (2011) data was used in processed form,
whilst the raw data from Dr Hull was analysed de novo by me. The rest of this section refers
to analysis performed on the Hull dataset.
Microarrays used were Gene Chip Rat Gene 1.0 ST Arrays (Aﬀymetrix, Santa Clara, CA,
USA). Probe result intensity (CEL) files were produced using GeneChip Operating Software
and quality tested using the Aﬀymetrix Expression Console.
Analysis of the CEL files used software from the bioconductor repository for the R software envi-
ronment (http://www.r-project.org). Background correction, normalisation and expression
summarization were performed using the robust multichip average function in the aﬀy R pack-
age (Gautier et al., 2004). The resulting expression set was filtered for genes which do not vary
and/or are not expressed using the genefilter package in R (Gentleman et al. (2010); see sec-
tion 3.2.1.2 & figure 3.2). A list of diﬀerentially expressed genes was derived from this filtered
expression set using the limma R package (Smyth, 2004) with P-value correction for multiple
testing using Benjamini and Hochbergs method to control the false discovery rate (FDR) (Ben-
jamini and Hochberg (1995); for full description of FDR see Section 2.2.4). Gene ontology (GO)
terms were assigned to diﬀerentially expressed genes using the Database for Annotation, Visu-
alization and Integrated Discovery (DAVID) v6.7 (http://david.abcc.ncifcrf.gov) (Huang
et al., 2009a,b). DAVID software was also used for functional annotation analysis. Semantic
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similarity of assigned GO annotations was calculated using the GOSemSim R package (Yu et al.,
2010). Each comparison used the top 10 GO biological process (BP) terms from relevant groups
as input and Wang’s algorithm was used to calculate the similarity (Yu et al., 2010).
2.2.2 Whole genome shotgun bisulfite read mapping and processing
This bioinformatic protocol has been previously published in Johnson et al. (2012). Initially,
reads were pre-processed by conversion of all C bases to T bases in read 1 and all G bases to
A bases in read 2. This masks the bisulfite conversion status of read pairs. Next, the first base
of all reads was clipped oﬀ. This is because following fragmentation any potentially methylated
bases are replaced by unmethylated bases during the end-repair step. As a result, removal of
the first base removes any potential false-negative methylation calls. All of the above steps were
achieved using custom perl scripts taken from Johnson et al. (2012).
Reads pre-processed as above were aligned to the rat reference genome using BWA (Li and
Durbin, 2009) version 0.6.1 with 3’ end quality trimming using a Q score cutoﬀ of 20. Con-
verted and clipped reads 1 and 2 were mapped to two in silico converted versions of the reference
sequence; firstly, where all Cs are converted to Ts, thus mapping reads from the bisulfite con-
verted forward strand of sample DNA and secondly, where all Gs are converted to As which
maps reads from the converted reverse strand. The rat genome assembly RGSC3.4 (rn4) was
used as the reference sequence. This sequence was downloaded in FASTA format from the UCSC
genome browser website (ftp://hgdownload.cse.ucsc.edu/goldenPath/rn4/chromosomes).
Unmethylated phage lambda control DNA which was spiked in to samples during library prepa-
ration was mapped to an in silico bisulfite converted version of the lambda reference genome
(Genbank accession NC 001416.1).
Mapped reads were post-processed by clipping of the 3’ end of overlapping read pairs in order
to avoid duplicate methylation readings from overlapping regions. This was achieved using
NxtGenUtils (Johnson et al., 2012); a suite of tools for analysis of WGBS data. Mapped reads
were then filtered by removal of:
1. Clonal reads
2. Reads with a mapping quality of <20
3. Read pairs mapping to both in silico converted forward and reverse strands
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4. Reads with an invalid mapping orientation
Steps 1 and 2 were achieved using the Samtools set of utilities (Li et al., 2009); which allow
manipulation of alignments in BAM file format. BAM files are binary modified SAM (Sequence
Alignment/Map) files, where SAM files are generic tab-delimited text files for storing large
nucleotide sequence alignments. Alternatively, steps 3 and 4 were performed using NxtGenUtils
(Johnson et al., 2012).
Reads which had been mapped, processed and filtered in this way were piled up using samtools
and the number of cytosine and thymine base calls at each cytosine position counted. This
allowed calculation of relative methylation at each cytosine as cytosine base calls divided by the
total number of cytosine and thymine base calls expressed as a percentage. This profile was
produced using NxtGenUtils. In brief: methylation calls were corrected for incomplete bisulfite
conversion by subtracting the average number of expected unconverted cytosines at the depth of
coverage at the respective position, given the bisulfite conversion rate for the respective sample,
prior to calculating relative methylation levels. Bisulfite conversion rate was calculated from the
frequency of unconverted cytosines in the unmethylated lambda control spike-ins. For example
if BS conversion rate was 99% at a cytosine base with 10x coverage, 99% x 10 cytosines would
be predicted to be BS converted. This is equal to 9.9 of the 10 cytosines for which data is
available from 10x coverage and therefore one would subtract 0.1 reads from the data at this
cytosine. Bisulfite conversion rates were >99% for all samples.
2.2.3 Analysis of multiplexed PCR products
This section refers to the analysis of data produced by multiplexed PCR sequencing using the
Fluidigm access array (as described in Section 2.1.5). Sequences were demultiplexed by the
MRC CSC Genome Core bioinformatics team and then first base clipped, C to T and G to
A converted, mapped to the in silico BS converted reference genome and 3’ end clipped as
described for WGBS data in Section 2.2.2. Mapped reads were then piled up and methylation
profiles produced also as described in Section 2.2.2. The output of this analysis was methylation
profiles of approximately 200 CpG dinucleotides spread across 48 individual PCR products.
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2.2.4 Diﬀerential methylation analysis
Methylation profiles produced as above were tested for diﬀerential cytosine methylation using
Fisher’s exact test on a 2x2 contingency table that tested for a) independence of strain and b)
the frequency of unconverted and converted cytosines across all replicates, using a custom R
script.
Following Fisher’s exact testing, methylation profiles were subject to three further filtering
steps. Firstly, cytosine bases with a minimum combined read coverage of less than 5x across
a minimum of three separate biological replicates were removed. This was performed using a
custom perl script. Secondly, CpN dinucleotides aﬀected by sequence variation between WKY
and Lewis rat strains were removed using publicly available SNPs and indels data between WKY
and Lew strains (Atanur et al., 2013). Removal of CpGs from the CpG profiles was completed
by using BED files of the SNP and indel co-ordinates. BED files are a well recognised and
flexible file format for genomic data analysis and storage (Quinlan and Hall, 2010). They have
three required columns citing 1) the chromosome of the locus of interest 2) the start co-ordinate
and 3) the end co-ordinate, followed by a number of optional fields. The intersectBED command
from BEDTools; a suite of utilities for working with BED files (Quinlan and Hall, 2010), was
used to remove the CpN dinculeotides which spanned known SNPs or indels.
Thirdly, P-values produced by Fisher’s exact testing were adjusted for multiple testing using the
Benjamini-Hochberg false discovery rate (FDR) (Benjamini and Hochberg, 1995). Adjustment
is necessary because consideration of multiple inferences simultaneously can result in a greatly
increased rate of conclusions which incorrectly reject the true null hypothesis, otherwise known
as false positives or type I errors (Benjamini and Hochberg, 1995). As a result, some control
of the probability of committing type I errors is desirable. A number of methods (reviewed
in Benjamini and Hochberg (1995)) are available for this, but the FDR controls the expected
proportion of falsely rejected null hypotheses or false discoveries (Benjamini and Hochberg,
1995). In large datasets, such as whole genome analysis, the FDR approach is preferable to
other methods such as the Bonferroni correction (applied in Section 3.2.2) which seeks to reduce
the probability of any false discoveries at all (Dunn, 1961), because the FDR method increases
the statistical power of the testing. Most statistical programs allow the permitted FDR to be
controlled at a certain proportion, for example 5%.
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2.2.5 Analysis of read number and depth of coverage
Numbers of reads were extracted using the samtools view command (Li et al., 2009). Mapped
reads shared between forward and reverse strand mappings (see section 2.2.2) were found using
samtools merge command on the files of reads mapped to in silico converted forward and reverse
strands.
The Genome Analysis Toolkit (GATK) (McKenna et al., 2010) version 2.1-8 was used to calcu-
late depth of coverage. Genome wide coverage was computed on the non-gapped rat reference
genome assembly RGSC3.4 downloaded from the UCSC genome browser. For calculation of
CpG island coverage, coordinates of CpG islands (cpgIslandGgfAndyMasked) were obtained
from the UCSC genome browser (http://genome.ucsc.edu). Whilst for coverage specific to
genes; gene start, end, chromosome and strand information from rat genome assembly RGSC3.4
was obtained from the Ensembl database (http://www.ensembl.org) version 69.
2.2.6 Hierarchical clustering of methylation profiles
In order to visualise the similarity of methylation profiles, CpG dinucleotides with at least
10x coverage in each replicate were subject to hierarchical clustering. This technique allows
assessment of the similarity of datasets, in this case methylation profiles, based on a calculated
diﬀerence between the component parts of the dataset. In this study, CpG methylation was
clustered according to the pairwise euclidean distance between the vectors of methylation levels
for each animal scaled down to 10x coverage using the dist function in R. Following distance
calculations, a linkage criterion is used to determine the distance between sets of observations.
Wards minimum variance method was used as the linkage criterion in this study using the hclust
function in R (Ward, 1963).
2.2.7 Data annotation
Annotations for transcripts and their respective start sites were retrieved from Ensembl version
69, whilst annotations for CpG islands were downloaded from UCSC, both as listed in 2.2.5.
Annotation of sequencing data with either transcriptional elements or CpG island labels was
performed either with BEDTools (Quinlan and Hall, 2010) or the GenomicRanges package in
R (Lawrence et al., 2013).
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2.2.8 Linking CpG methylation and expression of related genes
Expression information for 27,507 transcripts from RGSC3.4 was derived from the microarray
analysis described in Section 2.2.1. The GenomicRanges R package was used to allocate all CpG
dinucleotides in the genome which passed filtering (Section 4.2.1.1) to the nearest strand-specific
transcript and the distance from the CpG to the start of this transcript was calculated.
2.2.9 Enhancer analysis
Enhancer regions were defined using areas of high H3K4me1and low H3K4me3 as a proxy for
enhancer activity after Ghisletti et al. (2010) and Heintzman et al. (2007). broadPeak files for
these two histone modifications in mouse bone marrow-derived macrophages and mouse bone
marrow were downloaded from the UCSC table browser. The two modifications in each cell
type were overlapped and only those regions containing an H3K4me1 peak and excluding an
H3K4me3 peak were retained as enhancers. This operation was performed using BEDTools. The
union of these enhancer regions from the two cell types was found using the GenomicRanges R
package, and these were denoted as the enhancer regions for further study. Syntenic rat genome
regions for these mouse enhancers were downloaded from the UCSC table browser to form the
syntenic enhancer set.
Diﬀerentially methylated CpGs within the syntenic enhancer set were found using the subset-
ByOverlaps command in GenomicRanges. In order to test whether the proportion of dmCpGs
within the syntenic enhancers represented an enrichment I conducted the following analysis:
>90% of the 47,994 syntenic enhancer regions were <2500bp in length. Therefore, I resized all
those syntenic enhancer regions <2500bp in length (43,737) to 2500bp to form a test set. Next,
using the “random genome fragments” tool from the Regulatory Sequence Analysis Tools suite
(Thomas-Chollier et al., 2011), I randomly drew 25 sets of 43,737 regions of 2500bp from the rat
genome to form a control set. Using this control set I calculated an expected proportion of re-
gions containing a dmCpG and then performed a binomial test (using the binom.test command
in R) to assess whether the proportion of the test set containing a dmCpG was significantly
diﬀerent from this expected proportion.
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2.2.10 Transcription Factor Binding Site analysis
Transcription factor binding sites (TFBS) around diﬀerentially methylated CpGs were found in
a two step process using tools from the MEME suite web server (Bailey et al., 2009). Firstly,
the DREME tool (Bailey, 2011) was used to discover enriched short regular expression motifs in
the provided dataset. DREME focuses on 4 to 8 bp motif discovery using the IUPAC alphabet,
which adds eleven wildcard characters to the standard DNA alphabet of ACGT (Bailey, 2011).
The output of DREME is an E-value. The E-value, or enrichment P-value, is calculated for each
motif by multiplying a Fisher’s Exact Test P-value by the number of candidate motifs tested.
In this study the input to DREME was formed from 120bp sequences centred on dmCpGs
found in the WGBS dataset. This sequence length was chosen based on the optimal abilities of
DREME to detect enriched motifs (Bailey, 2011).
Enriched motifs found by DREME were then submitted to the TOMTOM algorithm (Gupta
et al., 2007). TOMTOM produces a measure of motif-motif similarity by reporting a list of
motifs matching between input files and a central database (see next paragraph for details). A
q-value, or minimal false discovery rate at which the observed similarity is deemed significant
is reported, thus allowing assessment of whether input motifs resemble motifs from an existing
database (Gupta et al., 2007).
In this study, the existing database used was the “JASPAR CORE vertebrates” database of
experimentally defined transcription factor binding sites for eukaryotes (Mathelier et al., 2013).
As a result, TOMTOM analysis allowed investigation of whether the enriched motifs around
dmCpGs were known to be transcription factor binding sites.
2.2.11 Statistical analysis and plotting
All statistical analysis was performed with software for R and the test used is indicated in the
text. Distributions are compared using an unpaired Wilcoxon rank sum test, which is equivalent
to the Mann-Whitney test when two unpaired populations are used (Dalgaard, 2008). When
very significant P-Values are reported by R they are printed by default to <2.2× 10−16.
Graphics were generated either with base R software, the limma R package, the ggplot2 package
for the implementation of the Grammar of Graphics in R software (Wickham, 2009), or the
extension of ggplot2 for genomic data; ggbio (Yin et al., 2012).
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A number of specific plot types were used. Some distributions in the project are represented as
violin plots. These plots combine a box plot with a density trace, thus retaining the ability of a
box plot to provide information about the centre and spread of a distribution and supplementing
this with information about the characteristics of a distribution provided by a density trace
(Hintze and Nelson, 1998). Examples of a box plot and a violin plot representing the same data
set can be seen in Figure 2.4. In this figure, the violin plot provides a better indication of the
shape of the plotted distribution, demonstrating that the data has a bimodal appearance with
clusters at approximately 2 and 4.5 units on the y axis. Violin plots have proved popular in the
representation of DNA methylation data (Consortium, 2012; Ziller et al., 2013).
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Figure 2.4: Violin plots (right) contain additional information when compared to
box plots (left)
The bimodal nature of the data is only seen in the violin plot and not the box plot. Plots were
produced from the “faithful” dataset in R. These data were also used to demonstrate violin
plots in the paper of Hintze and Nelson (1998)
Specific plots in the project required pre-processing and analysis of data. For Figure 5.1, CpG-
transcript pairs were formed as described in Section 2.2.8 and transcripts sorted in to bins
depending on expression percentiles. ggplot2 was used to fit a smoothed curve using a general-
ized additive model for methylation percentages for each expression bin depending on distance
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to the gene start. Figure 5.3 was created using ggbio (Yin et al., 2012). This package generates
the exact proportional lengths of the chromosomes in the ideogram by using the AnnotationDbi
package to retrieve the chromosome lengths from Ensembl. Then, the transcript and methyla-
tion tracks are added using objects from the GenomicRanges package, thus ensuring that points
in these tracks are placed at the exact points along the ideogram chromosomes. Additionally,
the “layout circle” command in ggbio allows the displacement of the points in the methylation
tracks to represent the methylation diﬀerence between the WKY and Lew rat strains. The red
and black bars representing transcripts on the ideogram are placed at the midpoint of the tran-
script length. In addition, ggbbio was also used to make Figure 5.4 and Figure 5 in Appendix
to Chapter 5. GATK (McKenna et al., 2010), used to calculate the sequence coverage, produces
a file called “sample interval summary” which segments the genome into 138,115 regions and
computes the average coverage for each region. Each black point in the average coverage panels
of Figure 5.4, corresponds to one of these regions in the relevant chromosome. Points are plotted
at the midpoint of the region on the x-axis.
Chapter 3
Investigating the Relationship
Between Cytosine Methylation and
Gene Expression: Proof of Concept
3.1 Introduction
The aim of the work presented in this chapter is to investigate whether genes shown to be
diﬀerentially expressed in macrophages from WKY and Lew rats have associated diﬀerences
in DNA cytosine methylation in their promoter regions. Such methylation diﬀerences could
then be used as proof of concept to support progression to genome wide analysis of single base
resolution cytosine methylation by WGBS (Chapter 4).
Diﬀerentially expressed genes were identified by new analysis of data from Gene Chip Rat Gene
1.0 ST Arrays from Aﬀymetrix and DNA methylation of promoters of genes identified in this
analysis was subsequently performed using BS-Sanger sequencing.
3.1.1 Genome-wide analysis has revealed transcriptomic diﬀerences between
WKY and Lew rats
Previously published microarray experiments have demonstrated widespread transcriptomic dif-
ferences between bone marrow-derived macrophages in the WKY and Lew rat strains both in
the basal state and after treatment with LPS (Maratou et al., 2011). It is noteworthy that the
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data for LPS stimulation in the paper of Maratou et al. (2011) was produced following 24 hours
of LPS treatment. Major transcriptomic changes have been demonstrated in macrophages after
only minutes of LPS stimulation (Ramirez-Carrozzi et al., 2009). The work in this chapter used
two published datasets produced by the Physiological Genomics & Medicine Group at the MRC
CSC:
• The raw data of Hull et al. (2013), which used four biological replicates per strain in
WKY and Lew, was analysed de novo by me to assay transcriptomic diﬀerences in the
basal state and following 2 and 4 hours of LPS stimulation
• The processed data of Maratou et al. (2011); which used four technical replicates from a
single animal of each rat strain, was used as a comparative dataset
3.1.2 DNA cytosine methylation changes in response to environmental stim-
uli
The rationale for using the shorter period of LPS stimulation is two-fold. Firstly, as introduced
above, dynamic changes in the macrophage transcriptome can be demonstrated over this short
time period (Hull et al., 2013; Ramirez-Carrozzi et al., 2009).
Secondly, changes in CpG methylation have been revealed in response to environmental stimuli
over time periods of hours. One informative example is the promoter of the oestrogen sensitive
gene, pS2. This promoter shows dynamic cycling of CpG methylation following oestrogen stim-
ulation (Kangaspeska et al., 2008; Me´tivier et al., 2008). This cycling can be observed within 2
hours of oestrogen exposure and appears to aﬀect both transcribed and non-transcribed strands
of DNA with initial demethylation aﬀecting only the transcribed strand. Individual CpG dinu-
cleotides within a ∼1kb window around oestrogen sensitive promoters show diverse changes in
their methylation status in response to oestrogen stimulation. These changes include persistent
strand-specific demethylation; initial demethylation coinciding with transcriptional activation
followed by remethylation on return to transcriptional quiescence, and peaks of gain in methy-
lation following oestrogen binding to the promoter (Me´tivier et al., 2008).
These studies suggest that changes in DNA methylation in response to an inflammatory stimulus
may be observed in macrophage genes whose transcription is dependent on LPS stimulation.
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3.2 Results
3.2.1 Genes are diﬀerentially expressed according to strain and lipopolysac-
charide stimulation in rat macrophages
3.2.1.1 Analysis of basal gene expression
The raw microarray data from Hull et al. (2013) was analysed as described in Section 2.2.1.
Briefly, following normalisation of probe level data the limma R package (Smyth, 2004) was used
to find diﬀerentially expressed genes between the WKY and Lew macrophages in the basal state.
This analysis demonstrated 1037 probesets corresponding to 1025 unique genes which showed
diﬀerential expression with an FDR adjusted P-value <0.05. The numbers and proportions of
diﬀerentially expressed probesets in the basal state can be seen in Table 3.1.
Total Significant Diﬀerential Expression 1,037 (3.77%)
Increased Expression in Lew 493 (1.79%)
Increased Expression in WKY 544 (1.98%)
Table 3.1: Number of diﬀerentially expressed probesets between WKY & Lew
basal macrophages
Numbers in brackets represent percentage of total probes assayed. False Discovery Rate <5%
Functional annotation clustering groups genes with similar function together forming a biolog-
ically useful read out of the categories of genes that are diﬀerentially expressed (Huang et al.,
2009a,b). The top 10 most enriched clusters are shown in Supplementary Figure 1 in the Ap-
pendix to Chapter 3. Table 3.2, shows the top 10 most statistically significant gene ontology
(GO) terms contained within the annotated clusters shown in Supplementary Figure 1. As
can be seen these terms represent functionally relevant categories such as cytokine production,
inflammatory response and membrane processes that may be relevant to phagocytosis. This
suggests that the limma analysis captured diﬀerential expression for gene categories relevant to
macrophage activation.
Of the diﬀerentially expressed transcripts 95% demonstrate a fold change between 1 and ∼1.333
regardless of which strain shows greater gene expression. A subset of 15 genes show very strong
diﬀerential expression of ￿5 fold (Table 3.3).
Given that a previous transcriptomic study has been performed on WKY and Lew macrophages
(Maratou et al., 2011), comparison of these datasets is possible. The genes represented in Table
3.3 show limited (18.5%) overlap with those shown to have a ￿5 fold diﬀerence in expression by
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GOBPID Count Fold Enrichment P-Value FDR Term
GO:0009611 47 2.48 1.74× 10−8 3.13× 10−5 Response to wounding
GO:0010324 22 3.20 4.49× 10−6 8.08× 10−3 Membrane invagination
GO:0006897 22 3.20 4.49× 10−6 8.08× 10−3 Endocytosis
GO:0005925 15 4.27 7.78× 10−6 1.09× 10−2 Focal adhesion
GO:0005924 15 4.05 1.48× 10−5 2.07× 10−2 Cell-substrate adherens junction
GO:0001817 21 3.05 1.74× 10−5 3.14× 10−2 Regulation of cytokine production
GO:0030055 15 3.81 3.11× 10−5 4.35× 10−2 Cell-substrate junction
GO:0006954 25 2.58 3.59× 10−5 6.46× 10−2 Inflammatory response
GO:0016044 30 2.32 3.84× 10−5 6.91× 10−2 Membrane organization
GO:0002673 9 6.51 4.64× 10−5 8.35× 10−2 Regulation of acute inflammatory response
Table 3.2: Functional annotation clustering of diﬀerentially expressed genes be-
tween strains in basal macrophages shows enrichment of functionally relevant cat-
egories
False Discovery Rate <5%
Ensembl transcript ID Gene symbol Gene name P-value Fold change
ENSRNOT00000027756 Fads2 Fatty acid desaturase 2 8.33× 10−5 11.45
ENSRNOT00000012977 Cyp2j4 cytochrome P450, family 2, subfamily j, polypeptide 4 7.15× 10−5 8.96
ENSRNOT00000011955 F1LZQ6 RAT Angiomotin-like 1 2.31× 10−4 8.44
ENSRNOT00000027860 Htra1 serine protease HTRA1 6.61× 10−5 6.40
ENSRNOT00000006832 Plekhh2 pleckstrin homology domain-containing family H member 2 1.46× 10−5 6.13
ENSRNOT00000025820 Zfp334 zinc finger protein 334 6.61× 10−5 5.65
ENSRNOT00000006243 Tm7sf4 transmembrane 7 superfamily member 4 2.08× 10−3 5.63
ENSRNOT00000057338 Tgfb2 Transforming growth factor beta-2 1.17× 10−5 -5.04
ENSRNOT00000020265 Ifitm3 Interferon-induced transmembrane protein 3 2.99× 10−2 -5.33
ENSRNOT00000003313 Tgfb2 Transforming growth factor beta-2 1.46× 10−5 -5.49
ENSRNOT00000048692 Sh2d1b SH2 domain containing 1B 2.47× 10−5 -5.61
ENSRNOT00000014041 Mmp7 matrix metalloproteinase-7 1.80× 10−4 -9.18
ENSRNOT00000011904 Nov nephroblastoma overexpressed gene 6.61× 10−5 -9.31
ENSRNOT00000047349 Fcgr2a Low aﬃnity immunoglobulin gamma Fc region receptor III 1.46× 10−5 -20.70
ENSRNOT00000042553 Trpc6 short transient receptor potential channel 6 6.61× 10−5 -25.37
Table 3.3: Transcripts with ￿5-fold diﬀerence in expression between WKY and
Lew BMDMs in the basal state
These data are from a re-analysis of the microarray data published in Hull et al. (2013). Fold
change comparisons are WKY versus Lew. P-values are adjusted by the Benjamini-Hochberg
method. Pseudogenes are excluded.
the analysis of Maratou et al. (2011). The fact that this overlap is not 100% led me to investigate
further how these datasets of basal expression diﬀerences vary. Maratou et al. (2011) report
798 diﬀerentially expressed transcripts between WKY and Lew macrophages in the basal state
as opposed to 1037 reported in this analysis. Notably, only 137 of these transcripts are shared
between the 2 datasets. Comparison of these shared transcripts at the level of fold change and
significance of diﬀerential expression can be seen in Figure 3.1. The genes shared between the two
analyses demonstrate relative conservation of fold change magnitude and direction (Left panel
Figure 3.1; adjusted r2= 0.75, P-Value <2.2× 10−16). However, there is increased variability
in the associated adjusted P-Values and therefore, the statistical significance of the diﬀerential
expression detected (Right panel Figure 3.1; adjusted r2= 0.14, P-Value = 4.7× 10−6). The
analysis of Maratou et al. (2011) assigns a greater number of highly significant P-Values than
that performed here, with 29 of the 137 transcripts having a −log10 P-Value >5 in Maratou
et al. (2011) compared with none in this analysis.
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Figure 3.1: Diﬀerentially expressed genes shared between reanalysis of Hull et al.
(2013) & Maratou et al. (2011) show agreement in fold changes but diﬀerences in
statistical significance of diﬀerential expression
Left panel: plot of log2 FC of shared genes. x-axis: this analysis, y-axis: Maratou et al. (2011).
Adjusted r2= 0.75 P-Value <2.2× 10−16
Right panel: plot of −log10 P-Value of shared genes. Axes as left panel. Adjusted r2= 0.14
P-Value = 4.7× 10−6
The reasons for these diﬀerences may be related either to the experimental design as performed
by Dr Richard Hull from whom the raw microarray data was gained, or to the downstream data
analysis.
The experiments diﬀered in that the data presented here are from Aﬀymetrix Rat Gene 1.0 ST
arrays whilst that of Maratou et al. (2011) used Rat Exon 1.0 ST arrays. However, a majority of
probes on the Gene arrays are derived from the Exon arrays and therefore the two arrays bear a
close resemblance to one another (Ha et al., 2009). Additionally, the two studies used diﬀerent
iterations of aﬀymetrix reagent kits which may have aﬀected results. Finally, the BMDM culture
protocol has undergone optimisation since used by Maratou et al, such that BMDM culture is
now 5 days (see materials and methods) as opposed to 6 days, and cells no longer undergo
a period of serum starvation (Maratou et al., 2011), as this has been demonstrated to aﬀect
cellular phenotypes (Pirkmajer and Chibalin, 2011).
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With regards to diﬀerences in the downstream analysis, the “limma” R package was used in the
present analysis whilst Maratou et al. (2011) used Partek Genomics Suite 6.4 (Partek Incorpo-
rated, St Louis, MO, USA). Partek uses a standard ANOVA model to generate raw P-Values
for diﬀerential expression. Alternatively, “limma” uses a method called “empirical Bayes” to
borrow information across individual genes included in the analysis to shrink sample variances
towards a pooled estimate and therefore make the analysis stable with the small sample sizes
seen in microarray experiments (Smyth, 2004). The second diﬀerence in analysis is that the
genomes of both WKY and Lew strains were sequenced after the publication of Maratou et al.
(2011), allowing microarray probesets containing WKY v Lew SNPs to be filtered out prior to
the present analysis (see Section 2.2.1).
3.2.1.2 Analysis of eﬀect of rat strain and lipopolysaccharide stimulation on gene
expression
I next used microarray data gained from macrophages following LPS stimulation. Following nor-
malisation, non-expressed genes were filtered by removal of probesets with an average expression
that is less than the fifth percentile of the distribution of expression across all microarrays (Fig-
ure 3.2; left panel). Given that the macrophage response to LPS is know to involve thousands of
genes, probesets were further filtered by removing genes which did not show significant variation
in their expression across the diﬀerent experimental conditions. This was achieved by removing
transcripts with a coeﬃcient of variation of beneath the median value across all transcripts
and conditions (Figure 3.2; right panel). This filtering produced a set of 14,576 transcripts for
further study.
In addition to analysis of two groups as described in Section 3.2.1.1, the limma R package allows
statistically robust analysis of factorial experiments where more than one experimental condition
is being varied and combinations of treatment conditions are considered in the analysis (Smyth,
2004). In this analysis the factors of interest are rat strain and treatment. For simplicity,
only one time point of LPS treatment (4 hours) was used, thus allowing generation of lists of
diﬀerentially expressed genes for the following three contrasts:
1. Genes responsive to LPS stimulation in WKY macrophages
2. Genes responsive to LPS stimulation in Lew macrophages
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Figure 3.2: Pre-analysis filtering of LPS stimulated microarray data removes genes
which are expressed at low levels (<5th percentile of expression) and which show
little variation (coeﬃcient of variation less than the median across all transcripts)
between samples
Probesets were filtered according to expression (left panel) and coeﬃcient of variation (right
panel). Black vertical lines represent the values beneath which probesets were excluded from
further analysis
3. Genes that respond diﬀerently to LPS stimulation according to rat strain. This may take
one of the following forms:
(a) Both strains show a statistically significant change in expression following LPS stim-
ulation but with an opposed fold change. For example, where expression increases in
WKY after LPS stimulation but decreases in Lew
(b) Both strains show a significant change in expression following LPS stimulation in
the same direction, but this is of a statistically diﬀerent magnitude between the two
strains. For example, where the fold change post LPS is ∼4 in WKY and ∼0.4 in
Lew
(c) Both strains change expression after LPS stimulation but this only reaches statistical
significance in one strain
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The number of diﬀerentially expressed genes across these contrasts with <5% FDR can be seen
in Table 3.4.
LPS response WKY Lew Strain diﬀerence
Decreased expression 5086 (34.9%) 5403 (37.1%) 3a 32 (0.2%)
Increased expression 3511 (24.0%) 5290 (36.3%) 3b 343 (2.3%)
3c 158 (1.1%)
Total 8597 (59.0%) 10693 (73.3%) Total 533 (3.7%)
Table 3.4: Number of diﬀerentially expressed transcripts according to response to
4hrs LPS stimulation in a reanalysis of Hull et al. (2013) microarray data
False Discovery Rate <5%. Labels in column titled “strain diﬀerence” refer to text at Point 3 in
Section 3.2.1.2. Values in brackets represent diﬀerentially expressed transcripts as a percentage
of filtered transcripts (14,576)
It can be seen in Figure 3.3 that the majority of diﬀerentially expressed genes following LPS
stimulation are common between the two strains and that the Lew strain shows a greater
number of genes which are diﬀerentially expressed following LPS stimulation that are unique to
this strain.
WKY + LPS Lew + LPS
Different behaviour
according to strain 3471
57
2010
644
592
191
6546
1065
Figure 3.3: The majority of diﬀerentially expressed genes following LPS stimulation
are shared between WKY and Lew strains
Number at bottom right corner represents those genes which are not diﬀerentially expressed in
this analysis
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Hierarchical clustering of transcripts that respond diﬀerently in WKY compared to Lew macrophages
can be used to plot a heatmap as in Figure 3.4. This heatmap facilitates visualisation of the
distinct categories a-c as defined at point 3 in section 3.2.1.2.
!"#$%!&'$
()*$%!&'$
!"#$+!&'$
()*$+!&'$
,-$./012$
!3$./012$
Figure 3.4: Hierarchical clustering reveals genes that show a significant change
in expression with opposed fold change between strains after LPS (black arrow);
genes that show the same fold change direction but of diﬀerent magnitude in the
two strains (blue arrow) and genes that only show a significant expression change
in one strain (arrow head)
These changes are referred to as the ‘interaction variable’ and are described in section 3.2.1.2
Functional annotation analysis (Table 3.5) of genes responsive to LPS stimulation in both the
WKY and Lew strains shows that annotated clusters are enriched for highly similar gene on-
tology terms. This is likely because 6,546 out of 14,576 analysed transcripts (44.9%) show the
same response to LPS as assessed by limma analysis (Figure 3.3).
Comparison of GO annotations using measures of similarity between gene terms can provide
a quantitative way to assess the functional equivalence of genes and gene groups (Yu et al.,
2010). Here, use of this method (described in Section 2.2.1), shows that enriched gene ontology
terms are most similar in the genes which are significantly diﬀerentially expressed after LPS
stimulation in the WKY and Lew rat strains (Figure 3.5 black bar). Diﬀerentially expressed
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Genes responsive to LPS stimulation in WKY macrophages
GOBPID Count Fold Enrichment P-Value FDR Term
GO:0010941 168 1.99 1.60× 10−19 3.01× 10−16 Regulation of cell death
GO:0042981 166 2.00 1.51× 10−19 2.83× 10−16 Regulation of apoptosis
GO:0043067 168 2.00 1.01× 10−19 1.89× 10−16 Regulation of programmed cell death
GO:0045449 305 1.55 4.41× 10−17 8.28× 10−14 Regulation of transcription
GO:0043068 94 2.31 3.85× 10−15 7.29× 10−12 Positive regulation of programmed cell death
GO:0043065 93 2.30 7.44× 10−15 1.40× 10−11 Positive regulation of apoptosis
GO:0010942 94 2.29 7.04× 10−15 1.31× 10−11 Positive regulation of cell death
GO:0010627 73 2.44 3.24× 10−13 6.09× 10−10 Regulation of protein kinase cascade
GO:0070013 214 1.57 1.42× 10−12 2.08× 10−9 Intracellular organelle lumen
GO:0032553 282 1.48 4.14× 10−13 6.80× 10−10 Ribonucleotide binding
Genes responsive to LPS stimulation in Lew macrophages
GOBPID Count Fold Enrichment P-Value FDR Term
GO:0010941 169 1.99 8.59× 10−20 1.61× 10−16 Regulation of cell death
GO:0042981 167 2.00 7.99× 10−20 1.50× 10−16 Regulation of apoptosis
GO:0043067 169 2.00 5.36× 10−20 1.01× 10−16 Regulation of programmed cell death
GO:0032553 291 1.52 4.41× 10−15 7.31× 10−12 Ribonucleotide binding
GO:0070013 223 1.64 3.65× 10−15 5.36× 10−12 Intracellular organelle lumen
GO:0032555 291 1.52 3.92× 10−15 6.39× 10−12 Purine ribonucleotide binding
GO:0017076 303 1.51 2.62× 10−15 4.39× 10−12 Purine nucleotide binding
GO:0043233 225 1.60 5.75× 10−14 8.42× 10−11 Organelle lumen
GO:0031981 183 1.71 3.91× 10−14 5.72× 10−11 Nuclear lumen
GO:0031974 229 1.59 1.00× 10−13 1.47× 10−10 Membrane-enclosed lumen
Genes that respond diﬀerently to LPS stimulation according to rat strain
GOBPID Count Fold Enrichment P-Value FDR Term
GO:0005125 16 6.00 5.80× 10−8 8.44× 10−5 Cytokine activity
GO:0009611 32 3.10 3.93× 10−8 6.87× 10−5 Response to wounding
GO:0005615 29 2.69 3.03× 10−6 4.04× 10−3 Extracellular space
GO:0044421 35 2.31 6.71× 10−6 8.94× 10−3 Extracellular region part
GO:0010740 17 4.11 3.67× 10−6 6.42× 10−3 Positive regulation of protein kinase cascade
GO:0006955 28 2.78 2.86× 10−6 5.00× 10−3 Immune response
GO:0010627 21 3.54 1.98× 10−6 3.46× 10−3 Regulation of protein kinase cascade
GO:0006468 35 2.33 6.36× 10−6 1.11× 10−2 Protein amino acid phosphorylation
GO:0009967 22 3.17 5.92× 10−6 1.03× 10−2 Positive regulation of signal transduction
GO:0010647 23 2.96 1.08× 10−5 1.89× 10−2 Positive regulation of cell communication
Table 3.5: Functional annotation clustering of genes according to response to LPS
shows that genes responsive to LPS are enriched for similar terms in WKY & Lew
macrophages
genes in the basal state and those which are diﬀerentially expressed but behave diﬀerently
according to LPS (Point 3 in Section 3.2.1.2) are more similar (Figure 3.5 red bar) than those
which are diﬀerentially expressed in each strain after LPS stimulation compared to basally
diﬀerentially expressed genes (Figure 3.5 green bars).
3.2.2 Analysis of cytosine methylation within the promoters of diﬀerentially
expressed genes
The next hypothesis for investigation was that diﬀerences in gene expression due to rat strain,
might also vary after LPS stimulation, and may be associated with diﬀerences in DNA cytosine
methylation in gene promoter regions. As can be seen from the analyses in Section 3.2.1,
1037 genes show significant diﬀerential expression between WKY and Lew macrophages (Table
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Figure 3.5: Semantic similarity of diﬀerentially expressed genes shows that GO
terms are most similar in genes which change expression after LPS in WKY and
Lew macrophages (black bar)
(Black bar) Similarity comparison of genes which are diﬀerentially expressed after LPS stim-
ulation in WKY and Lew strains. (Red bar) Basally diﬀerentially expressed genes compared
to genes responding diﬀerently to LPS in the 2 strains (Diﬀ). (Green Bars) Genes which are
diﬀerentially expressed after LPS stimulation in WKY & Lew compared to basally diﬀerentially
expressed genes
3.1). Following stimulation of macrophages with LPS, 8,597 genes change expression in WKY
macrophages and 10,693 genes change expression in Lew macrophages (Table 3.4). 533 genes
change their expression in macrophages following LPS stimulation in a way that is not conserved
between the two rat strains (Table 3.4). The majority of diﬀerentially expressed genes after LPS
stimulation are conserved across the two rat strains (Figure 3.3)
Therefore, one could investigate a putative association of diﬀerential gene expression and dif-
ferential DNA cytosine methylation in macrophages by:
1. Examining cytosine methylation in basal macrophages from WKY and Lew rats to see
whether genes known to be diﬀerentially expressed in the basal state show diﬀerential
methylation in promoter regions
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2. Assaying cytosine methylation in macrophages following LPS stimulation to see if genes
known to be diﬀerentially expressed following LPS stimulation show diﬀerential methyla-
tion
A significant number of gene promoters are known to contain CpG islands, and given previ-
ous work suggesting an association between promoter CpG methylation and gene expression
(Kuroda et al., 2009; Thomson et al., 2010) one could hypothesise that these regions may show
measurable variability in DNA methylation. In order to investigate this hypothesis a promoter
region was defined as 1.5 kilobases upstream of exon 1 in genes of interest. This large distance
was chosen because promoters which contain CpG islands, so called high-CG promoters, are as-
sociated with multiple transcription start sites and therefore span larger genomic regions than
low-CG promoters (Lenhard et al., 2012). High-CG promoters have been demonstrated up to
2.2kb upstream of annotated 5’ gene sequences (Yoshimura et al., 1991).
Genomic co-ordinates of 1.5kb promoter regions defined as above were overlapped with co-
ordinates of all the CpG islands in the rat genome (Baylor 3.4/rn4 exported from the UCSC
genome browser) thus producing co-ordinates of promoter regions containing a CpG island.
Bisulfite PCR and Sanger sequencing (BS-Sanger) of amplicons from within these regions was
performed to assess whether diﬀerential methylation between amplicons was detectable. BS-
Sanger sequencing used macrophage preparations from 3 animals per strain, either in the basal
state or following stimulation with LPS for 2 or 4 hours.
31 genes were selected for BS-Sanger sequencing analysis (see additional file sanger.amplicons.xlsx).
These genes were selected because they showed significant diﬀerential expression in WKY and
Lew BMDMs and could have sequencing primers designed for their promoter regions. Nine of
these were genes that the study of Maratou et al. (2011) had shown to be diﬀerentially expressed
between WKY and Lew BMDMs. 22 genes were selected that had shown diﬀerential expression
in WKY and Lew BMDMs in the results of my own microarray analysis. 7 of these 22 were
selected from the analysis of basal gene expression described in Section 3.2.1.1. The remaining
15 out of 22 were chosen from the limma analysis described in 3.2.1.2. The genes and their
rationale for selection are listed in additional file sanger.amplicons.xlsx. BS-Sanger sequencing
results are summarised in Table 3.6.
There was a significant drop out rate of assays (22 out of 31), either due to lack of PCR amplifi-
cation (even at a range of annealing temperatures) or failure of Sanger sequencing. Reproducible
sequence data was gained for nine amplicons; four in basal macrophage preparations only, and
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Gene Name Amplicon co-ordinates Fold Change P-Value CpGs sequenced Conditions sequenced Diﬀerentially methylated CpGs
Htra1 chr1: 190,256,612 - 886:+ 6.40 6.61× 10−5 14 LPS & basal 0
Cd24 chr20: 47,501,534 - 752:+ 2.27 1.01× 10−4 13 LPS & basal 2
Dusp10 chr13: 100,021,744 - 921:+ 3.88 7.20× 10−10 12 LPS & basal 0
Ier3 chr20: 3,076,060 - 255:- 1.74 3.65× 10−4 6 LPS & basal 0
Slc37a1 chr20: 9,688,594 - 869:+ 1.44 2.55× 10−3 6 LPS & basal 4
Tuba4a chr9: 74,495,899 - 74,496,149:- 1.63 9.49× 10−3 9 Basal 0
P2rx7 chr12: 35,117,473 - 785:- 4.07 3.16× 10−8 8 Basal 0
Kit chr14: 34,985,733 - 940:- 2.85 2.32× 10−5 7 Basal 0
Igf2bp1 chr10: 84,671,417 - 675:- 11.27 1.81× 10−8 2 Basal 0
Table 3.6: BS-Sanger sequencing of nine promoter amplicons shows six CpG dinu-
cleotides that are diﬀerentially methylated according to strain of origin but do not
change methylation after LPS stimulation
Fold Change & P-Value are for diﬀerential expression after 4hrs LPS stimulation. “Conditions”
sequenced column: LPS & Basal: BS-Sanger data for basal & LPS samples; Basal: for basal
samples only
five in both basal and LPS stimulated macrophage preparations. In the four amplicons for
which only basal sequencing data was gained (Tuba4a, P2rx7, Kit and Igf2bp1 ) no diﬀerences
in CpG methylation were demonstrated (Table 3.6).
Five amplicons gave data in both basal and LPS stimulated macrophages; (Htra1, Cd24, Dusp10,
Ier3 and Slc37a1 ; Table 3.6 rows where ‘Conditions sequenced’ column lists ‘LPS & basal’).
Percentage methylation levels were subjected to two-way analysis of variance (ANOVA) to
assess whether any observed diﬀerences in methylation across factors were due to strain, LPS
stimulation or an interaction of these two variables. Statistical stringency was imposed on the
model by Bonferroni correction for multiple testing. A P<0.05 was denoted as significant.
Six out of 51 CpG dinucleotides across these five amplicons reached statistical significance in this
analysis (Table 3.6; “Diﬀerentially methylated CpGs” column). The amplicons for Htra1, Cd24,
Dusp10 and Slc37a1 showed generally low levels of methylation. Of the 39 CpGs across these
amplicons that did not show significant methylation diﬀerences (14 for Htra1, 11 for Cd24, 12 for
Dusp10, and 2 for Slc37a1 ), 17 were entirely unmethylated (7 in Htra1, 2 in Cd24, 6 in Dusp10
and 2 in Slc37a1 ). The remaining CpGs showed low methylation with a median methylation
percentage of 9.1% in Htra1, 12.0% in Cd24 and 13.2% in Dusp10.
Alternatively, the 6 CpGs sequenced from the Ier3 amplicon, none of which showed diﬀerential
methylation (Table 3.6; “Diﬀerentially methylated CpGs” column), all showed high methylation
with a median CpG methylation percentage of 77.0%.
All six of the CpG dinucleotides that exhibited significant diﬀerential methylation (Figure 3.6),
showed a significant eﬀect of strain on methylation percentage.
One of these six CpG dinucleotides, CpG 10 in the amplicon for Slc37a1 (Figure 3.6 middle row
left panel), also showed both a significant eﬀect of LPS stimulation and the interaction between
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Figure 3.6: BS-Sanger sequencing of promoter amplicons demonstrates diﬀerences
in CpG methylation in gene promoter regions
CpGs shown are from genes Cd24 & Slc37a1 and show significantly diﬀerent methylation ac-
cording to rat strain of origin. CpG number refers to the position of the CpG in the sequenced
amplicon
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the two variables on two-way ANOVA testing described above. However, use of ANOVA tests in
statistical analysis is dependent upon assumptions of data normality and equality of variances.
Given the small size of the data set, I formally checked these assumptions in those data points
scored as statistically significant by two-way ANOVA using Bartletts test (Dalgaard, 2008).
Data from these amplicons failed to meet the assumptions of equality of variance, therefore,
I performed Kruskal-Wallis one-way ANOVA on each factor initially scored as significant by
two-way ANOVA. This non-parametric analysis failed to validate diﬀerential methylation for
CpG 10 in Slc37a1 attributable to both LPS and an interaction between strain and LPS, but
confirmed diﬀerential methylation according to rat strain in CpG 10 and the remaining five
CpGs dinucleotides shown in Figure 3.6.
These results suggest that despite limitations of sample size and the assumptions of the statistical
test, the experiment had suﬃcient power to capture some signals for diﬀerential methylation as
a result of strain of origin, suggesting that the WKY and Lew rat strains may show methylation
diﬀerences at CpG dinucleotides.
3.3 Discussion
Here, reanalysis of gene expression data has showed that the transcriptomes of bone marrow-
derived macrophages from WKY and Lew rat strains have significant diﬀerences both in basal
conditions and following stimulation with LPS. The transcriptome diﬀerences between macrophages
from the two strains in basal conditions show enrichment for immune and inflammatory gene
ontology terms as well as those related to adhesion and endocytosis (Table 3.2). Following LPS
stimulation, there is a significant transcriptional response involving thousands of genes. Many
LPS responsive genes show similar transcriptomic changes in WKY and Lew macrophages,
whilst a much smaller number of genes show diﬀerent responses to LPS depending on the rat
strain (Table 3.4). The genes that respond to LPS in a similar fashion in the two rats strains
show functional annotation favouring cell death and apoptosis-related molecular processes, thus
suggesting that these mechanisms may be generally induced by LPS stimulation in macrophages
from both strains. Interestingly, the gene ontology terms associated with those genes that re-
spond diﬀerently to LPS in the diﬀerent rat strains are closer to those seen in the basally
diﬀerentially expressed genes than the genes at basal level which respond to LPS stimulation
(Figure 3.5). This may suggest that any mechanisms underlying basal diﬀerential expression
Chapter 3. Proof of Concept Studies 81
may also be involved in the diﬀerential response to LPS stimulation, arguing that this may be
heritably mediated in the two strains.
Additionally, I have demonstrated an association between rat strain and DNA methylation
in the putative promoters of 2 genes which are detected as diﬀerentially expressed between
macrophages from WKY and Lew rats (Table 3.6). These inter strain diﬀerences in CpG
methylation were from 10 to 30%, which is in keeping with reported strain diﬀerences in CpG
methylation by whole genome bisulfite sequencing which are typically greater than 10% (John-
son, Mueller & Aitman personal communication). Also, the fact that the CpGs are methylated
at a low level; 10-30% (see Figure 3.6) is in keeping with the fact that these promoter re-
gions were selected for their location in CpG islands which are known to be hypomethylated in
comparison to the whole genome (Illingworth and Bird, 2009).
These data support the existence of cytosine bases in CpG island containing regions around the
gene start that show diﬀerential methylation according to rat strain in bone marrow-derived
macrophages and can therefore be associated with diﬀerent susceptibility to glomerulonephritis
in these rat strains. This preliminary observation requires validation in a larger set of genes
but serves as proof of concept that an unbiased, genome wide analysis of DNA methylation in
basal macrophages may be informative of regions of diﬀerential CpG methylation that may be
associated with glomerulonephritis susceptibility.
In this experiment, five studied loci selected for diﬀerential expression in WKY and Lew
macrophages, showed no changes in DNA methylation following stimulation of macrophages
with LPS for 2 and 4 hours. Possible explanations for this are that chosen genes displayed
only moderate log fold changes across the microarray experiments (between -3 and +1) and
therefore, genes with larger fold changes after LPS stimulation may be more likely to demon-
strate changes in DNA methylation. Alternatively, the BS-Sanger sequencing method used in
this study could have insuﬃcient sensitivity to detect methylation changes following LPS stim-
ulation, or detectable changes in DNA methylation downstream of LPS simulation may occur
at time points distinct from the 2 and 4 hours used here. This may also be a result of the
fact that the group of genes studied in this part of the project were selected to contain CpG
islands in their promoters. Recent work in mouse macrophages has shown that the first genes
to be activated by LPS, termed primary response genes, are commonly associated with CpG
island containing promoters (Section 1.8.1; (Ramirez-Carrozzi et al., 2009)). This enrichment of
CpG islands appears to result in an increase in DNA accessibility at the promoters of primary
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response genes, thus facilitating the rapid transcription of these genes. Although this study is in
murine macrophages and none of the genes studied for LPS associated changes in DNA methy-
lation (Table 3.6) are known to be primary response genes, it has been suggested that some
CpG promoters may have evolved to regulate rapid signal-induced transcription in response to
diverse stimuli (Singh, 2009) and therefore these genes may be thought of as unlikely to show
detectable methylation changes.
Chapter 4
Base-Pair Resolution DNA
Methylation Sequencing of
Macrophages from WKY and Lew
Rats
4.1 Introduction
This chapter presents results of whole genome shotgun bisulfite sequencing (WGBS) of bone
marrow derived macrophages from WKY and Lew rat strains. This experiment was performed
to assess the distribution of cytosine methylation in a fully diﬀerentiated mammalian cell type
and to define CpG dinucleotides which are diﬀerentially methylated in these two rat strains.
4.1.1 Complete methylome analysis of bone marrow derived macrophages is
a novel experiment
DNA methylation has been widely studied in both cell diﬀerentiation and malignant transfor-
mation (Baylin and Jones, 2011; Ji et al., 2010). Although a number of studies have looked
at methylation diﬀerences in mature cells and pathological specimens from neoplastic diseases
(Kulis et al., 2012; Shen et al., 2013), relatively little work has focused on mature immuno-
logical cells with the goal of defining diﬀerentially methylated regions that may associate with
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non-neoplastic pathology. Eﬀorts to explore the role of DNA methylation in immune processes
have converged upon two areas. Firstly, delineating diﬀerences in DNA methylation during
haematopoiesis as a means of defining how methylation may aﬀect specific diﬀerentiated im-
munological phenotypes (Suarez-Alvarez et al., 2012). Secondly, the use of array based tech-
nologies on mature cell populations of whole blood to define diﬀerentially methylated regions
between patients and controls and therefore seek to link CpG methylation directly to disease
phenotypes (Javierre et al., 2010).
The generation of base-pair resolution methylomes in macrophages presented here represents an
original attempt to both assay CpG methylation in a primary non-malignant cell type and to
link methylation diﬀerences in these cells to a disease process by use of an established disease
model of macrophage mediated crescentic glomerulonephritis; nephrotoxic nephritis (NTN) (see
Behmoaras et al. (2008); Tam et al. (1999) and Section 1.4).
4.1.2 The importance of WGBS
A typical approach to examination of genome-wide DNA methylation is to utilise a complexity
reduction method which focuses on CpG dense regions of the genome known as CpG islands
(for example, reduced representation bisulfite sequencing (RRBS)) (Akalin et al., 2012; Meissner
et al., 2008). These CpG islands are typically >200bp in length, have a GC content of >50%
and an observed-to-expected CpG ratio that is greater than 60%. However, recent studies
suggest that diﬀerences in CpG methylation occur in cancer samples at sites distinct from CpG
islands (Irizarry et al., 2009). The sites showing these diﬀerences were up to 2 kb distant from
CpG islands and have been termed ‘CpG island shores’ (Irizarry et al., 2009). In addition,
it has been shown that CpG methylation in shores can be strongly linked to expression of
related genes and appears to be tissue specific across diﬀerent species (Irizarry et al., 2009).
The apparent importance of these shore regions is further confirmed by the observation that
regions termed ‘CpG island shelves’, which lie a further 2kb distant from CpG islands, contain
diﬀerentially methylated sites less frequently than shores (Reinius et al., 2012) (Figure 4.1).
Given that methods such as RRBS would have less power to assay these non-CpG enriched
regions, single nucleotide resolution sequencing approaches may be able to uncover biologically
important methylation diﬀerences not found by RRBS.
Additionally, array based technologies, such as the Illumina Infinium Methylation Assay and
associated bead chips, focus on gene promoters which are known to often contain CpG islands.
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Figure 4.1: CpG islands, shores & shelves
Lollipops represent CpG dinucleotides with enrichment of these in the CpG island. Red lollipops
in island shore are linked to gene expression & predict tissue of origin whilst green lollipops do
not. Distances in kb refer to distance from the end of the CpG island
Several lines of evidence now suggest that diﬀerential methylation may be detectable in inter-
genic regions in diﬀerent tissues (Antequera and Bird, 1993; Illingworth and Bird, 2009), and
in the same tissue from diﬀerent rat strains (Johnson, Mueller & Aitman, unpublished observa-
tions), suggesting that these regions may correspond to cis-regulatory regions modifying gene
expression. Hence, biologically relevant information in this area may be gained from the WGBS
approach. Therefore, in summary, the use of WGBS should allow a comprehensive interrogation
of cytosine methylation in diverse regions of the genome related to both CpG density and gene
regulatory elements.
4.2 Results
4.2.1 Single-base resolution maps of DNA methylation in macrophages from
two rat strains
In order to obtain single base-resolution methylomes, whole-genome shotgun bisulfite sequencing
(WGBS) of rat DNA was performed as described in Section 2.1.4. WGBS was performed for
bone marrow-derived macrophage preparations from four biological replicates of the two rat
strains, WKY and Lew, in order to assess variability in CpG methylation both within strain
replicates and between strains. Each individual animal was sequenced using one lane on the
Illumina HiSeq 2000 to achieve necessary sequencing depth and ensure data reproducibility.
Library preparation and sequencing on the Illumina HiSeq 2000 resulted in approximately 1.6
billion total sequencing reads. Reads were mapped to two in silico converted reference sequences;
a reference with all Cs converted to Ts to allow mapping of the bisulfite converted forward
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strand of DNA, and a reference with Gs converted to As to map reads from the reverse strand
of bisulfite converted genomic DNA (see Section 2.2.2 for further details). Approximately 50%
of reads in each sample mapped to the in silico converted forward and reverse reference strands
respectively. Reads were filtered for low mapping quality and to remove non-uniquely mapped
reads and clonal reads. Following filtering this equated to 79.9 billion mappable bases across
both strains, with 13.5x coverage in Lew and 17.6x coverage in WKY (Table 4.1).
Mapped Reads
Sample Total Reads Forward Strand Reverse Strand Mapped Bases after Filtering Depth of Coverage after Filtering
Millions Millions % Millions % Billions x
L1 203 114 56 114 56 12.1 4.7
L2 112 57 51 57 51 5.4 2.1
L3 107 61 57 61 57 6.4 2.5
L4 228 120 53 121 53 10.7 4.2
Lew 650 352 54 353 54 34.6 13.5
W1 345 190 55 190 55 18.7 7.3
W2 161 83 52 83 52 8.2 3.2
W3 172 81 47 81 47 6.9 2.7
W4 240 119 50 119 50 11.4 4.4
WKY 918 474 51 474 51 45.3 17.6
Table 4.1: Mapping and filtering statistics for WKY & Lew rats
Summary of the number of reads obtained for each sample, the proportion of reads mapped to
either strand of the bisulfite-converted genome and the depth of coverage of the genome after
quality filtering of the data set. The genome is defined as the mappable (ungapped) sequence
of the RGSC3.4 reference assembly
Although greatest depth of coverage was seen in CpG islands, a reasonable uniformity in depth
of sequencing across both the whole genome and known genes when compared to CpG islands
was seen, suggesting that this dataset may be able to assay biologically important methylation
diﬀerences outside of CpG islands (Figure 4.2)
4.2.1.1 Quality control and sequence filtering
I detected approximately 38 million CpG dinculeotides which were covered by at least one
mapped read from either strand and in either strain. These CpGs were subject to filtering
prior to further investigation. Firstly, in order to remove any eﬀect of low sequencing depth
or poor cross-replicate reproducibility on diﬀerential methylation calls, only CpG dinculeotides
which had a sequence depth of greater than 5x in three or more biological replicates within each
rat strain were retained. This reduced the number of CpG dinucleotides for further study to
14,753,548 which were used in the following analysis.
Secondly, potential bias in CpG methylation values introduced by sequence variation between
the two strains was addressed by the removal of CpG dinucleotides which spanned either known
SNP or indel positions between the two strains. This was performed in order to ensure that a
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Figure 4.2: Depth of sequencing according to genomic annotation shows a bias
towards coverage of CpG islands
The genome is defined as the mappable (ungapped) sequence of the RGSC3.4 reference assembly,
gene annotations used were also from this genome build
sequence variant between the two strains could not result in a false call of 0% methylation at a
position inferred to be a cytosine in the reference sequence. These positions are known because
of the recent publication of the complete genomic sequences of the WKY and Lew rat strains
(Atanur et al., 2013). 162,520 CpGs containing SNPs and 11,085 CpGs spanning indels were
removed, thus leaving 14,444,093 high-confidence CpGs for further analysis.
4.2.1.2 Whole-genome distribution of CpG methylation
First, the whole-genome distribution of CpG methylation was examined and compared to avail-
able published datasets.
Global analysis of CpG dinucleotide methylation of the ∼14.5 million CpGs outlined above
revealed a bimodal pattern of methylation frequency with the majority of CpGs showing either
high (>50%) or low (<10%) methylation in each strain (Figure 4.3). This is in keeping with
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a number of published studies in diverse cell populations (Akalin et al., 2012; Meissner et al.,
2008; Stadler et al., 2011).
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Figure 4.3: DNA from Lew macrophages shows greater methylation at CpG dinu-
cleotides analysed for diﬀerential methylation
Left panel: Lew & Right: WKY strain. Blue = unmethylated CpGs (0-10%), Red = low
methylated CpGs (10-50%), Green = Fully methylated CpGs (>50%). See text for details
An important recent paper in this field (Stadler et al., 2011), found that in addition to the
bimodal distribution, CpG dinucleotides with intermediate methylation levels between 10 and
50% appear to form clusters which are termed low methylated regions (LMRs). They also
found that CpGs with 0-10% methylation and >50% methylation clustered into regions they
termed unmethylated (UMRs) and fully methylated (FMRs), respectively. LMRs are enriched
for enhancer function and are therefore attractive candidates to act as regulatory regions (Stadler
et al., 2011).
Stadler et al found that approximately 4% of CpG dinucleotides in mouse pluripotent embryonic
stem (ES) cells exhibit 10-50% methylation. The data presented here (Figure 4.3, regions marked
with red line) shows that 6% of CpGs in rat macrophages fall into the 10-50% methylation
category. This is also in keeping with a recent study (Akalin et al., 2012), which reported that
∼6% of CpGs in the human colon carcincoma cell line, HCT116, showed 10-50% methylation.
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Additionally, the Stadler et al. (2011) data suggest that 6.5% of mouse ES cells show 0-10%
methylation, which diﬀers from the 16% seen in WKY and Lew macrophages (Figure 4.3, marked
with blue line). However, HCT116 cells have been found to show ∼30% of CpGs within this
category (Akalin et al., 2012). These diﬀerences between CpG methylation levels in diverse cell
types are supported by the recent publication of the ENCODE project which showed that 96%
of CpGs exhibit diﬀerential methylation in at least one of the 82 cell types and tissues studied
(Consortium, 2012).
CpG islands have been demonstrated to be robust regions of relative genomic hypomethylation
(Illingworth and Bird, 2009). This can also be seen in the dataset presented here. 3,263,241 of
the CpG dinucleotides (22.6%) studied after filtering occur within the 91,098 annotated CpG
islands in the rat genome. CpG dinculeotides within CpG islands showed a distinct methylation
profile, with a high density of CpGs showing 0-10% methylation (Figure 4.4). These comparisons
with published datasets showed that the distribution of methylation data generated in WKY
and Lew bone marrow derived macrophages reproduce expected patterns (Figures 4.3 & 4.4).
I went on to investigate variability of CpG methylation profiles within the biological replicates
of each strain and between the strains. Hierarchical clustering of the methylation profiles was
performed using Ward’s minimum distance method on CpG dinucleotides with ￿10x coverage.
10x coverage was used here to ensure that only high sequence depth bases were used and to
therefore, remove the eﬀect of any spurious correlations between or within strains due to low
signal-to-noise ratio in the data. The average distance between biological replicate methylation
profiles within each strain was 3-6 times lower than that between the two rat strains, suggesting
that the strains were likely to show detectable cytosine methylation diﬀerences (Figure 4.5).
I previously showed that whole-genome distribution of of CpG methylation is bimodal. To
assess better the shape of the WGBS data distribution and reveal distinctive patterns within
CpG methylation profiles, I here use violin plots to represent the data distribution. Compared
with box plots, the use of violin plots (Figure 4.6) to visualise the distribution of CpG dinu-
cleotide methylation data sees addition of a probability density function (explained in Section
2.2.11 & Hintze and Nelson (1998)). Figure 4.6 shows a significant diﬀerence in baseline median
CpG methylation (black dots on violin plots; P-value <2.2× 10−16; Wilcoxon rank sum test),
and using violin plots it can be revealed that the Lew strain has a greater proportion of CpG
dinucleotides with very high methylation percentages as indicated by the wider flat density at
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Figure 4.4: CpG dinucleotides within CpG islands are relatively hypomethylated
compared to the whole genome
The density curve labelled “Genome” (blue) is plotted from all CpGs retained after filtering
∼14.5 million, whilst the “CpG.islands” curve (black) represents the ∼3.2 million CpGs within
CpG islands
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Figure 4.5: Methylation profiles from WKY & Lew macrophages cluster according
to strain of origin
CpG methylation profiles from individual animals are more similar within strains suggesting
that diﬀerences in CpG methylation between strains may be detectable
100% methylation (Figure 4.6). The significant diﬀerence in the medians suggests that repro-
ducible methylation diﬀerences are observable in the rat strains which may be associated with
their diﬀerential susceptibility to crescentic glomerulonephritis. This baseline diﬀerence in the
whole-genome distribution of methylation could be underpinned by the eﬀect of specific sub-
sets of CpG dinculeotides and regions of CpG dinucleotides which show diﬀerential methylation
between the strains.
The finding that the WKY strain has relative DNA hypomethylation compared to the Lew strain
(Figure 4.6) is of particular interest because DNA hypomethylation has been associated with
SLE, which is associated with CRGN, in a number of contexts (Section 1.9.1.1). For example,
very early studies in this field were able to show a global hypomethylation of T-cells in SLE
patients (Richardson et al., 1990), and since then, regulatory regions for interferon-responsive
genes in the T cells of SLE patients have been found to be hypomethylated (Richardson and
Patel, 2014). Additionally, hypomethylation events near to interferon signalling related genes
have recently been shown in monocytes (Absher et al., 2013).
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Figure 4.6: Baseline CpG methylation distributions are significantly diﬀerent be-
tween strains
Violin plot of baseline CpG methylation profiles. Black dots represent median methylation
percentage, therefore, Lew macrophages have greater methylation than WKY. Wilcoxon rank
sum test P-value <2.2× 10−16
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4.2.1.3 Validation of WGBS methylation values using multiplexed PCR sequenc-
ing
To validate the methylation values produced by the WGBS analysis, I performed multiplexed
Illumina sequencing of PCR products from bisulfite converted DNA of four biological replicates
per rat strain. 50 CpG dinculeotides were produced by multiplexed Fluidigm amplification and
Illumina sequencing which had significant high-quality coverage in both the fluidigm and WGBS
data sets across all biological replicates from both rat strains (The genomic location of these 50
CpGs is shown in Supplementary Table 2 in the Appendix to Chapter 4). The selected CpGs
cover a range of P-Values for diﬀerential methylation and values of between-strain methylation
diﬀerence. In addition, they were at variable distances from gene starts and distributed across
a range of genomic elements. Details of sequenced amplicons and associated primer sequences
can be seen in Supplementary Table 3 in the Appendix to Chapter 4.
As can be seen in Figure 4.7 the two data sets produced CpG methylation measurements which
were highly concordant (adjusted r2= 0.98 P-value <2.2× 10−16).
4.2.2 Subsets of CpG dinucleotides are diﬀerentially methylated between
WKY & Lew rat strains
Given the observed diﬀerences in whole-genome CpG methylation profiles between the two
rat strains (see Section 4.2.1.2), I investigated individual CpG dinucleotides for diﬀerential
methylation between WKY and Lew, using Fisher’s exact testing (see Section 2.2.4). A set of
CpG dinucleotides that were diﬀerentially methylated between the animals from WKY and Lew
was defined at a false discovery rate of <5%; termed here as diﬀerentially methylated CpGs
or dmCpGs. Of the 14,444,093 CpGs analysed, 13,553 (0.09%) were found to be diﬀerentially
methylated (seen in additional file dmcpgs.supp.xlsx).
4.2.2.1 Diﬀerentially methylated CpGs and CpG islands
The dmCpGs were distributed by CpG island annotation as follows: 2,172 (16%) occurring
within CpG islands, 3,946 (29%) within CpG island shores, 3,517 (26%) within CpG island
shelves and 3,918 (29%) having no CpG island annotation (Figure 4.8). In order to allow
comparison of the absolute numbers of dmCpGs distributed to CpG islands, shores and shelves
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Figure 4.7: Validation of WGBS methylation values using Fluidigm sequencing of
PCR amplicons
Methylation values of CpGs sequenced both by WGBS (x-axis) and using amplicon BS-
Sequencing (y-axis) show significant correlation. Adjusted r2= 0.98 P-value <2.2× 10−16
between the two rat strains, each dmCpG was labelled as either Lew or WKY depending on
which of the strains showed greater methylation percentage at that dmCpG. Chi-square testing
of CpGs labelled in this way showed no significant diﬀerence in numbers within CpG islands,
shores or shelves (χ2 = 2.77, df = 2, P-Value = 0.250). However, as it can be seen in Figure 4.9,
all of the dmCpGs in islands, shores and shelves show greater methylation in the WKY strain
despite the fact that the Lew strain has greater methylation at the whole genome level (Figure
4.6).
4.2.2.2 Diﬀerentially methylated CpGs and genomic elements
All dmCpGs were annotated according to genomic elements derived from the Ensembl database.
In March 2012, the RGSC3.4 assembly of the rat genome, which dated from 2004, was updated
to Rnor 5.0. The last genebuild based on RGSC3.4 (referred to henceforth as RGSC3.4) con-
tained 22,938 coding genes and 39,549 gene transcripts, whilst the first genebuild associated
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Figure 4.8: CpG island annotation of diﬀerentially methylated CpG dinucleotides
See text at section 4.1.2 for explanation of CpG island annotations
with Rnor 5.0 has 22,941 coding genes and 29,189 gene transcripts. Initially, the diﬀerentially
methylated CpGs were annotated using both the RGSC3.4 and Rnor 5.0 genebuilds; this showed
that the majority of the dmCpGs are intergenic (73% in RGSC3.4 and 88% for Rnor 5.0), with
a relatively small number within genes (23.5% RGSC3.4 & 10.7% Rnor 5.0), at the TSS (2.2%
RGSC3.4 & 0.8% Rnor 5.0) or at promoters of genes (1.0% RGSC3.4 & 0.5% Rnor 5.0) (Figure
4.10). Given that the majority of published literature alluding to the CRGN model and to
the wider field of rat genetics still makes reference to RGSC3.4, this genebuild was used for all
subsequent annotation.
The “promoter” and “TSS” annotations used in Figure 4.10 were derived from RGSC3.4. With
“promoters” labelled as occurring 1kb upstream from the transcript start annotated by Ensembl
and “TSSs” as ±1kb from the transcript start. These definitions may not be adequate as
there has been a significant recent expansion in knowledge concerning mammalian TSSs and
promoters. Cap analysis of gene expression (CAGE), allows sequencing of short nucleotide
fragments derived from 5’ ends of capped mRNA transcripts. These sequences can be mapped
back to the reference genome and therefore the exact position of the specific TSS used for
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Figure 4.9: Methylation percentages of dmCpGs within CpG islands, shores &
shelves according to rat strain
In each plot black dots represent medians. P-Values from Wilcoxon rank sum test
transcription of captured RNAs can be determined (Haberle, 2013). CAGE data from mouse
and human suggests that gene transcription may proceed from distinct promoters depending
upon the tissue studied and the specific gene of interest (Kodzius et al., 2006). There is no
similar data that is publicly available in the rat and therefore the Ensembl annotated transcript
start shall henceforth be referred to as “gene start”. In order not to miss relevant features of the
data due to overly restrictive definitions of a TSS and promoter regions, dmCpGs were grouped
into three categories according to distance from the gene start for further analysis; those ±5kb
of a gene start site, those >5kb upstream of gene start sites, and CpGs within gene bodies but
>5kb from the start site (see Figure 4.11).
4.2.2.3 Diﬀerentially methylated CpGs and distance from gene start sites
Figure 4.12 illustrates that dmCpGs were often located at a significant distance from the gene
start. Those dmCpGs within gene bodies occurred at a median distance of 27.2kb from gene
starts with an interquartile range of 60.7kb. In contrast, those dmCpGs which were in intergenic
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Figure 4.10: Annotation of diﬀerentially methylated CpG dinucleotides shows that
the majority are intergenic
“Ensembl Version” refers to whether annotations are from RGSC3.4; labelled as 3.4, or Rnor 5.0,
labelled as 5. dmCpGs are labelled as “Promoters” if occurring 1kb from the Ensembl annotated
TSS and “TSS” if ±1kb from this
Figure 4.11: Categories defined for analysis of CpGs according to distance to gene
start
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regions were a median distance of 151.6kb from gene starts with an interquartile range of
349.2kb.
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Figure 4.12: Distance to gene start of diﬀerentially methylated CpG dinucleotides
Distance is to the gene start of the nearest gene on the same strand as the dmCpG. Median
distances to gene start of dmCpGs in gene bodies (green vertical line) & intergenic regions
(orange vertical line) are shown. Black vertical lines are 5kb from the gene start
Using the categories defined in Figure 4.11, 9,560 of the dmCpGs (70.5%) were located at
distances greater than 5kb upstream of the nearest gene start site (green box in Figure 4.11).
928 dmCpGs (6.8%) were located within 5kb of a gene start (blue box in Figure 4.11) and 3,045
(22.5%) were located within a gene body but greater than 5kb from the gene start (pink box
Figure 4.11).
Violin plots of the CpG methylation values plotted according to rat strain in each of these three
categories show that, similar to the plots for the CpG island annotations (Figure 4.9), the WKY
strain has greater methylation values than the Lew strain (Figure 4.13). The magnitude of this
diﬀerence is smallest in those dmCpGs that are within 5kb of a gene start site, with a diﬀerence
between median methylation in WKY and Lew of 13.6%, compared with 36.8% in dmCpGs
>5kb upstream and 30.3% in those dmCpGs within gene bodies but >5kb from the gene start.
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Median methylation percentage of dmCpGs is lowest within 5kb of gene starts (45.9% versus
46.3% in CpGs >5kb upstream and 46.9% in CpGs in gene bodies >5kb from the gene start).
CpGs within CpG islands are relatively hypomethylated and CpG islands are enriched around
gene starts (Figure 4.4), therefore this lower median methylation is likely due to a significantly
greater number of dmCpGs located within 5kb of gene starts occurring within CpG islands
(blue box Figure 4.11), compared to the dmCpGs a greater distance away (green and pink
boxes figure 4.11). To test this hypothesis, I carried out a χ2 test of the number of dmCpGs
within CpG islands present within 5kb of the gene start compared to the number of all other
dmCpGs present within CpG islands. This showed a highly significant enrichment of dmCpGs
within CpG islands within 5kb of the gene start: χ2 = 113, df = 1, P-Value <2.2× 10−16.
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Figure 4.13: Methylation percentages of dmCpGs within 5kb of gene start, greater
than 5kb upstream of a gene start & within gene bodies but greater than 5kb from
the gene start according to rat strain
In each plot black dots represent medians. P-Values from Wilcoxon rank sum test
4.2.3 Gene level analysis of diﬀerentially methylated CpG dinucleotides
The 13,553 dmCpGs were analysed with respect to related annotated genes. When dmCpGs
were allocated to the nearest upstream transcript on the same strand, these dmCpGs represented
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5,612 unique genes (626 dmCpGs cannot be allocated to any transcript of the Ensembl RGSC3.4
annotation. See additional file dmcpgs.supp.xlsx).
4.2.3.1 Gene ontology analysis of genes associated with diﬀerentially methylated
CpG dinucleotides
First, I carried out functional annotation analysis of genes associated with the dmCpGs. As
reported in numerous studies (for example Absher et al. (2013) and Maratou et al. (2011)) and
Section 3.2.1, functional annotation analysis of high throughput data is useful in the discovery
of biologically similar genes within a data set. It is therefore unsurprising that these techniques
have been applied to high throughput methodolgies assaying CpG methylation (Irizarry et al.,
2009). A recently published investigation of standard approaches to functional annotation
analysis in CpG methylation data has demonstrated that a significant bias may occur unless
correction for the a priori likelihood of given genes appearing in the results is used (Geeleher
et al., 2013). This problem is also known to be particularly important in RNA-seq experiments
where the likelihood of any given gene appearing in a given dataset is exquisitely sensitive
to the length of the associated transcript and as a result, analysis tools have been developed
to counteract this problem by taking length bias into account (Young et al., 2010). These
approaches also aﬀect results in array based studies of CpG methylation where the a priori
likelihood is dependent upon the number of probes allocated per gene, with genes towards which
more probes are designed more likely to be detected as significant in the analysis (Geeleher et al.,
2013). Similar to the length bias seen in RNA-seq, this bias resulting from probe number can
also be seen to be a surrogate of the gene length.
Figure 4.14 illustrates that the number of CpG dinucleotides seen within a gene is linearly
related to gene length, suggesting that gene ontology analysis of the genes associated with the
dmCpGs may benefit from correction for number of CpGs in genes.
To further investigate this, the 3,650 of the 13,553 dmCpGs which are within 1,875 unique
gene bodies were subject to standard functional annotation analysis with DAVID (Huang et al.,
2009a,b). 88 gene ontology terms were found to be enriched at a 5% false discovery rate and the
top ten of these can be seen in Table 4.2 (All 88 GO terms are listed in Table 4 in Appendix to
Chapter 4). Plotting the mean number of CpG dinucleotides observed in the constituent genes
of each of the top ten gene ontology terms, shows that these groups are associated with a large
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Figure 4.14: The number of CpG dinucleotides within a gene is linearly related to
gene length
Adjusted r2= 0.93 P-value <2.2× 10−16. Points represent the 29,516 genes from Ensembl
RGSC3.4
number of CpGs per gene compared to all genes in the genome, suggesting that length bias may
be an issue in this analysis (Figure 4.15).
GOBPID Count Fold Enrichment P-Value FDR Term
GO:0030054 86 2.29 2.74× 10−13 4.00× 10−10 Cell junction
GO:0030030 71 2.33 2.36× 10−11 4.35× 10−8 Cell projection organization
GO:0043005 78 2.09 4.51× 10−10 6.58× 10−7 Neuron projection
GO:0045202 70 2.15 1.00× 10−9 1.46× 10−6 Synapse
GO:0005856 131 1.63 1.11× 10−8 1.62× 10−5 Cytoskeleton
GO:0019899 80 1.91 1.95× 10−8 3.14× 10−5 Enzyme binding
GO:0060589 53 2.29 1.97× 10−8 3.17× 10−5 Nucleoside-triphosphatase regulator activity
GO:0030695 52 2.30 2.44× 10−8 3.93× 10−5 GTPase regulator activity
GO:0000902 61 2.12 2.68× 10−8 4.94× 10−5 Cell morphogenesis
GO:0000267 131 1.58 6.32× 10−8 9.21× 10−5 Cell fraction
Table 4.2: Functional annotation clustering of unique genes associated with dm-
CpGs within gene bodies
To account for this potential bias, the bioconductor package “GOseq” (Young et al., 2010) was
used to perform an additional functional annotation analysis. This package corrects for the a
priori likelihood of genes appearing as significant based on gene length. Here, a modification
of this method was implemented to analyse methylation data, with the correction based on the
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Figure 4.15: The average number of CpGs within those genes associated with the
top ten gene ontology terms from dmCpGs within gene bodies is greater than for
all genes within the genome
Error bars represent standard error of the means. See Table 4.2 for relevant gene ontology terms
number of CpGs in each gene. After this correction there was a general significant decrease in
the magnitude of the P-values associated with functional annotation enrichment. None of the 88
gene ontology terms scored as significant by DAVID remained significant at 5% FDR following
the “GOseq” analysis. This suggests that the results of the original functional annotation
analysis by DAVID were severely biased by the number of CpGs within genes.
4.2.3.2 Analysis of biologically relevant candidate genes associated with diﬀeren-
tially methylated CpGs
As reported in Section 4.2.3, 5,612 genes are represented by the dmCpGs found by the WGBS
analysis. I sought to elucidate genes associated with dmCpGs from this group that might be
relevant to CRGN.
With the growth of high-throughput experiments that produce data on a genome-wide scale
(e.g. genome sequencing, RNA-seq or proteomic data), prioritisation of genes, transcripts or
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proteins from genome-scale datasets has become an area of much interest. There has been
a development of ad hoc computational tools for prioritisation which use diverse approaches
(Moreau and Tranchevent, 2012; Tranchevent et al., 2008).
The majority of available computational tools typically use only a limited number of rele-
vant information sources to prioritise genes. Methods like the Endeavour (Aerts et al., 2006;
Tranchevent et al., 2008) gene prioritisation tool and the ToppGene suite (Chen et al., 2009)
use a set of user-supplied “training genes” to extract information from a wide variety of data
sources including gene ontology, protein domain databases, mining of the published literature,
gene expression data, sequence homology, protein-protein interactions and transcription factor
binding motifs. Large gene lists can be analysed and genes of interest are then ranked according
to their similarity to the “training gene set” provided by the user and these rankings are then
fused to provide a single overall ranking for each test gene’s similarity to the training set. Whilst
these tools clearly require an informed approach to the choice of the training genes, they oﬀer
the advantage of exploiting multiple data sources. As a result, these tools were used here to
prioritise genes associated with dmCpGs that are relevant to the CRGN model by either being
linked to crescentic glomerulonephritis or macrophage activation.
A set of 21 “training” genes for analysis was defined by searching the Online Mendelian Inher-
itance in Man database (OMIM; www.omim.org) using the terms “crescentic glomerulonephri-
tis” and “macrophage activation” (Table 4.3). OMIM is a catalogue of predominantly human
genes, genetic disorders and traits that seeks to link genetic variation to phenotype. The term
“crescentic glomerulonephritis” was used in order to prioritise genes which are relevant to the
disease phenotype of the model (CRGN). “macrophage activation” was used as numerous stud-
ies have implicated this as one of the key underlying mechanisms involved in the pathogenesis of
glomerular crescents in the CRGN model (Behmoaras et al., 2008, 2010; Deplano et al., 2013).
OMIM search term Gene Name
“Crescentic Glomerulonephritis” Cxcr4, Hbegf, Vhl, Wt1,
Coq2, Egfr, Ccr5, Jund
“Macrophage Activation” Il19, Gdf15, Zc3h12a,
Havcr2, Clec10a, Shpk,
Trem2, Zc3h12c, Rab27a,
Zc3h12d, Kcnn4, Chia, Chuk
Table 4.3: List of “training genes” used for gene prioritisation
The 928 diﬀerentially methylated CpGs that fall within 5kb of a gene start were used for
Endeavour and ToppGene analysis. These dmCpGs represent 602 unique genes. This distance
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restriction was imposed in order to use only those dmCpGs that may directly, or more strongly,
aﬀect gene expression by their occurrence at gene promoters and transcription start sites. This
may allow further work to examine the link between CpG methylation and gene expression.
Gene ontology terms were excluded from ranking calculations due to the results shown in Section
4.2.3.1.
Endeavour was able to use 588 of the 602 genes in the analysis whilst ToppGene could use only
478. This is because ToppGene is reliant on input genes having an Entrez Gene ID. The top 20
genes prioritised by either of the two tools can be seen in Table 4.4.
Gene Symbol Gene Name Methylation Diﬀerence P-Value Diﬀ Exp Endeavour Rank ToppGene Rank
Atf1 Activating transcription factor 1 61.5 2.2× 10−5 N 383 20
Aurka Serine/threonine-protein kinase 6 -91.3 6.0× 10−6 N 4 450
Ccr7 C-C chemokine receptor type 7 -94.4 3.4× 10−3 N 1 4
Ccrl1 C-C chemokine receptor-like 1 -87.1 1.5× 10−3 N 510 3
Ccrl2 C-C chemokine receptor-like 2 -54.1 5.5× 10−3 Y 8 8
D4A0X9 RAT Uncharacterized protein 74.1 1.4× 10−7 N 20 N/A
D4A3V3 RAT Uncharacterized protein 23.9 2.9× 10−2 N 9 N/A
Ephb1 Ephrin type-B receptor 1 -84.4 2.4× 10−5 N 6 366
Ereg Epiregulin 100.0 2.1× 10−3 Y 3 5
F1M8C9 RAT Uncharacterized protein -89.1 1.2× 10−11 N 19 N/A
Fam3c Protein FAM3C -62.3 2.9× 10−4 N 178 17
Fen1 Flap endonuclease 1 -34.6 3.5× 10−2 N 555 9
Fgfr2 Fibroblast growth factor receptor 2 42.5 2.2× 10−2 N 17 6
Fgfr4 Fibroblast growth factor receptor 4 47.0 2.1× 10−2 N 10 455
Gpr37l1 Endothelin B receptor-like protein 2 -47.3 2.3× 10−3 N 12 336
Gpr61 G protein-coupled receptor 61 36.4 3.4× 10−2 N 11 190
Il15 Interleukin-15 52.0 2.5× 10−2 N 18 94
Irak4 Interleukin-1 receptor-associated kinase 4 43.5 3.7× 10−2 Y 13 60
Itga2 Uncharacterized protein -90.3 2.2× 10−7 N 397 13
Map3k14 Mitogen-activated protein kinase kinase kinase 14 -61.5 4.4× 10−5 Y 2 352
Mt4 Metallothionein-4 -84.6 3.6× 10−2 N 424 14
Myh9 Myosin-9 61.4 6.7× 10−3 N 396 12
Ntf3 Neurotrophin-3 78.3 3.2× 10−3 N 37 11
Phc3 Polyhomeotic-like protein 3 -90.7 3.9× 10−14 N 7 140
Ppp2r4 Serine/threonine-protein phosphatase 2A activator 96.4 8.3× 10−10 Y 293 19
Ptk6 Protein-tyrosine kinase 6 -70.3 1.1× 10−4 N 21 18
Qrfpr Pyroglutamylated RF amide peptide receptor 34.2 4.9× 10−2 N 14 387
Rara Retinoic acid receptor alpha -100.0 5.5× 10−9 Y 208 2
Rft1 RFT1 homolog (S. cerevisiae) 94.1 9.9× 10−7 N 377 10
Ryk Tyrosine-protein kinase RYK -69.2 3.1× 10−2 N 16 420
Slc38a1 Sodium-coupled neutral amino acid transporter 1 -39.6 2.9× 10−3 Y 288 7
Syncrip Heterogeneous nuclear ribonucleoprotein Q 78.9 1.2× 10−4 N 144 16
Tgfa Transforming growth factor alpha -88.9 9.8× 10−5 N 5 1
Tie1 Tyrosine-protein kinase receptor Tie-1 -74.2 6.6× 10−3 N 15 15
Table 4.4: Top 20 Genes produced by two gene prioritisation tools
35 unique genes appear in either of the two top 20 lists. The six genes that appear in both
lists are in bold. “Methylation Diﬀerence” is Lew-WKY, therefore positive values are hyperme-
thylated in Lew & vice versa. P-Value is for the methylation diﬀerence between strains of the
nearest dmCpG to gene start. See text for details of tools whose names are given in the table
header
Six genes appear in both top 20 rankings. Ccr7, CCR7 chemokine (C-C motif) receptor 7, is
a G protein coupled receptor with established expression in diverse immune cell types. Ccr7
was highly prioritised by both tools based on high scores derived from functional analysis of its
protein sequence and notably for the CRGN model it has been implicated in the migration of
cells from the myeloid lineage (Feig et al., 2011). This is important because the CRGN phe-
notype is dependent upon macrophage infiltration into glomeruli. Additionally, depleted levels
of CCR7 protein have been associated with spontaneous autoimmunity in mice, manifested by
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widespread lymphocytic infiltration of organs and deposition of IgG in glomeruli (Fo¨rster et al.,
2008). The dmCpG associated with CCR7 is on chromosome 10 at position 87,932,239-40 and
is hypermethylated in the WKY strain. The surrounding region from 87,225,575 to 89,128,985
contains nine dmCpGs all of which are hypermethylated in the WKY strain suggesting that
this is a robust inter-strain methylation diﬀerence.
Ereg, Epiregulin, is a member of the epidermal growth factor family, another member of which is
transforming growth factor-a, Tgfa, which is also one of the six genes highly prioritised by both
tools. Ereg has been demonstrated to have DNA methylation dependent expression in malignant
tissue (Yun et al., 2012) and is associated with a single dmCpG that is hypermethylated in the
Lew strain. The nearest dmCpG is located approximately 300kb away from that which tags
Ereg. In the case of Tgfa, this gene has a dmCpG both ∼2,800bp downstream from the TSS
and ∼50kb upstream. Both of these dmCpGs are hypermethylated in Lew, but neither occurs
as part of a cluster of dmCpGs.
Chemokine (C-C motif) receptor-like 2, Ccrl2, is highly expressed in neutrophils and pri-
mary monocytes, and is further upregulated on neutrophil activation and during monocyte
to macrophage diﬀerentiation (Galligan et al., 2004). A single dmCpG near to the TSS of the
gene is found in the dataset and is hypermethylated in WKY. This dmCpG occurs as a cluster
of four dmCpGs spanning ∼150kb which all show hypermethylation in WKY.
The fifth gene prioritised by both tools is Tie1, tyrosine kinase with immunoglobulin-like and
EGF-like domains 1, which is prioritised on the basis of direct and indirect protein-protein
interactions of the protein associated with this gene. Three dmCpGs are associated with Tie1,
two of these are <5kb downstream from the TSS and occur in a cluster of seven dmCpGs spread
across ∼620kb of chromosome 5. Although five out of seven of this cluster are hypermethylated
in WKY, one of the dmCpGs associated with Tie1 is hypermethylated in Lew. Fgfr2, fibroblast
growth factor receptor 2, is the last gene prioritised by both tools. This gene has been associated
with a number of diverse cancer types including gastric cancer and breast cancer (Fletcher
et al., 2013; Katoh, 2008) but has little association with macrophage function in the literature.
Fgfr2 is prioritised by Endeavour and ToppGene on the basis of sequence comparison to the
training genes and predicted protein-protein interactions. There are two dmCpGs associated
with Fgfr2 which occur approximately 4 and 6.5kb downstream of the TSS of this gene and are
hypermethylated in the Lew strain.
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Seven genes that are prioritised by these tools are known to be diﬀerentially expressed between
WKY and Lew macrophages. As discussed above, 928 dmCpGs within 5kb of a gene start
were used for the Endeavour and ToppGene analysis in order to try and assay CpG sites that
could exert a cis-eﬀect on gene expression. As a result, the seven genes which are diﬀerentially
expressed could be prioritised for further study. In particular, Ccrl2 and Ereg are known to be
diﬀerentially expressed between the 2 rat strains and also appear in both top 20 rankings.
4.3 Discussion
Here, whole-genome shotgun bisulfite sequencing of genomic DNA libraries from rat macrophages
shows that the methylation profile of CpG dinucleotides produced is in broad agreement with
that seen in a number of studies looking at diverse cell types. The distribution of methylation is
bimodal, and a greater number of unmethylated (0-10%) CpGs are seen in macrophages (Figure
4.3) when compared to ES cells. In addition, the CpGs contained within CpG islands are shown
to be hypomethylated compared to the whole genome (Figure 4.4).
Multiplexed PCR sequencing of genomic DNA provided robust validation of WGBS methyla-
tion calls. This suggests that the CpG methylation calls produced by this WGBS laboratory
and bioinformatic pipeline can be reproduced by a distinct technique, and therefore, that the
dmCpGs can be used as a basis for further laboratory work in the CRGN model. In addition
to this, methylation profiles are significantly more variable between strains than within the bi-
ological replicates of an individual strain (Figure 4.5) suggesting that there may be a heritable
component to CpG methylation and therefore, the diﬀerent susceptibility of these rat strains to
CRGN may be associated with diﬀerential CpG methylation.
13,553 diﬀerentially methylated CpGs (dmCpGs) between the strains were identified at a FDR<5%
(Section 4.2.2). The majority of these CpGs occurred outside gene promoters and CpG islands.
This suggests that these diﬀerences might not have been detected by other sequencing method-
ologies. Previous work has suggested that CpG island shores are enriched for diﬀerentially
methylated CpGs in malignant tissues. There was no enrichment for dmCpGs in CpG island
shores in this dataset.
The foundational data for promoter annotation of the rat genome lags behind that of mouse and
human (Section 4.2.2.2). Therefore, in line with previous studies (Sun et al., 2011), dmCpGs
5kb either side of the gene start were analysed together in order to avoid an overly restrictive
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definition of gene TSSs and promoters (Section 4.2.2.3). Only 6.8% of dmCpGs were 5kb up
or downstream of a gene start. The majority (70.5%) of dmCpGs were >5kb upstream of gene
start sites. The diﬀerence in methylation between strains was smallest 5kb up or downstream
of a gene start as a result of the fact that a greater number of dmCpGs within this region occur
in CpG islands which are relatively hypomethylated compared to the rest of the genome (figure
4.13).
Standard approaches to gene ontology analysis of genes associated with dmCpGs were found to
be strongly influenced by gene CpG content (Section 4.2.3.1). The 88 gene ontology terms that
were significantly enriched by functional annotation clustering on non-adjusted results were not
found to be significantly enriched after correction for number of CpGs within the gene.
The use of gene prioritisation based on similarity to genes known to be involved in crescentic
glomerulonephritis and macrophage activation, prioritised growth factor and chemokine recep-
tors, some of which had previously been linked to immune or neoplastic processes (Table 4.4).
The genes used in the prioritisation analysis were restricted to those which demonstrated a
dmCpG 5kb up or downstream of a gene start. This was to seek to investigate those dm-
CpGs that might be direct regulators of expression of their associated genes by interfering with
methylation in promoter regions. However, examination of dmCpGs greater than 5kb up or
downstream from a gene start (the complete list of all dmCpGs is in supplementary file dm-
cpgs.supp.xlsx), shows that the nearest transcripts to dmCpGs include Fads2, Plekhh2, Tgfb2,
Fcgr2a and Trpc6, which are amongst those with ￿5-fold diﬀerence in expression between WKY
and Lew basal macrophages as seen in Table 3.3. Additionally, genes which have been strongly
implicated in the CRGN model; Jund, Arg1 and P2rx7 (Behmoaras et al., 2008; Deplano et al.,
2013; Hull et al., 2013), are found to be the nearest transcript to some dmCpGs (supplementary
file dmcpgs.supp.xlsx).
The dmCpGs associated with the genes listed in the above paragraph are often a considerable
distance from the gene starts of their associated genes (minimum distance 20kb, maximum
distance 550kb). For example, the dmCpG whose nearest strand-specific gene is P2rx7 is
20,043 base pairs upstream of the start of this gene. As a result, they were excluded from the
gene prioritisation analysis. However, authors (for example, Ernst et al. (2011)) have assigned
biological meaning to methylation diﬀerences at this distance from known genes. Moreover, the
genes Plekhh2, Tgfb2, Fcgr2a, Trpc6 and P2rx7 are the nearest genes to clusters of dmCpGs
suggesting possible biological relevance.
Chapter 5
Investigation of the Relationship
Between CpG Methylation and
Transcription
5.1 Introduction
The work presented in this chapter seeks to explore the relationship between CpG methylation
and transcription, both at the genome-wide scale and with regards to CpG dinucleotides that
are diﬀerentially methylated between the WKY and Lew rat strains. This analysis integrates
the WGBS data presented in Chapter 4 and the microarray gene expression data presented in
Chapter 3 and provides insight in to the relationship between expression and methylation in a
fully diﬀerentiated cell type and with regards to the CRGNmodel. In addition to examining gene
expression, I use ENCODE data to examine putative enhancer regions in the rat in the context
of CpG methylation, thus investigating distant gene regulatory sequences in the CRGN model.
Furthermore, I explore the association of diﬀerentially methylated CpGs with transcription
factor binding sites (TFBS).
5.1.1 CpG methylation and gene expression
The relationship between gene expression and CpG methylation is complex and dependent upon
a number of factors. A significant amount of investigation into the relationship between CpG
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methylation and gene expression has focused on CpG dinucleotides occurring in the CpG island
context. Methylation of CpG islands is often associated with gene silencing either through the
direct inhibition of recruitment of DNA binding proteins or via the recruitment of methyl-CpG-
binding domain (MBD) proteins which cause a downstream remodelling of histone modifications
and chromatin structure that is unfavourable for gene transcription (Section 1.7). Conversely,
unmethylated CpG islands create an environment favourable for transcription by recruiting
CXXC finger protein 1 (Cfp1), which then leads to the formation of a chromatin structure
necessary for transcription (Thomson et al., 2010).
It has recently been observed that full methylation of CpG dinucleotides occurring in CpG
island shores (Figure 4.1) closely predicts transcriptional silencing and that CpG dinucleotides
in shores show variability between diverse tissues, normal and disease specimens and cells at
diﬀerent developmental stages (Doi et al., 2009; Irizarry et al., 2009). This suggests that CpG
dinucleotides in CpG island shores may be a compelling area of study in a fully diﬀerentiated
cell type that mediates susceptibility to a disease, as is the case of macrophages in CRGN.
CpG islands are often associated with gene promoters and methylation of CpGs within CpG
islands with gene silencing. Conversely, when methylation of CpG dinucleotides occurs within
gene bodies it may be associated with transcriptional activation (Kulis et al., 2012; Portela
and Esteller, 2010) and it has been reported that many widely expressed genes show full CpG
methylation in their gene bodies (Hellman and Chess, 2007).
5.2 Results
5.2.1 The genome-wide link between CpG methylation and gene expression
To investigate the relation of CpG methylation to gene expression at the genome level, I used
the microarray data previously referred to in Chapter 3 and published in Hull et al. (2013).
Although the microarray and WGBS experiments are not on matched BMDM preparations,
the reproducibility of the experimental protocol for BMDM preparation is well established
(Behmoaras et al., 2008; Hull et al., 2013), and use of non-matched but comparable samples is
a feature of many published studies which use genome scale data (see for example, Akalin et al.
(2012); Tan et al. (2013)).
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The ∼14.5 million CpG dinucleotides which passed filtering (Section 4.2.1.1) were assigned to
the nearest strand-specific transcript that was represented on the microarray data (total number
of transcripts; 27,507. For method see Section 2.2.8).
To determine if there is a relationship between CpG methylation and gene expression levels in
rat macrophages, I classified genes present on the microarrays into five groups based on the
expression level of their associated transcripts; top 20% of expression, 20-40%, 40-60%, 60-
80% and the bottom 20% of expression. I then fitted a smoothed curve of CpG methylation
percentage for each of these groups between 5kb upstream of the gene start and 5kb downstream
of the gene start (described in Section 2.2.11). As shown in Figure 5.1, genes with high expression
levels in both the Lew and WKY strains showed a relative depletion of CpG methylation around
the gene start, especially within 2.5kb either side of the gene start. Genes with lower expression
showed higher percentage CpG methylation in the same regions.
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Figure 5.1: CpG methylation is reduced around gene starts with more highly ex-
pressed genes showing lower percentage CpG methylation in rat macrophages
Genes were separated into five groups (top 20% most expressed transcripts, 20-40%, 40-60%,
60-80% and bottom 20%) and CpG methylation of the five groups were plotted around the gene
start. Negative numbers = upstream, positive = downstream. Curves represent smoothed CpG
methylation values of all relevant CpGs. 95% confidence interval for each curve is marked in
grey
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Greater CpG methylation in gene bodies has been associated with greater expression of as-
sociated genes (described in Section 5.1.1). Therefore, I investigated this in WKY and Lew
macrophages. All ∼14.5 million CpG dinucleotides were labelled according to their distance to
the gene start and separated according to whether they were 5kb up or downstream of the gene
start, >5kb upstream or >5kb downstream (i.e. within the gene body) (as described in Figure
4.11). CpGs were then further divided into either “high” (>50%) or “low” (<50%) methylation
and the microarray expression of transcripts associated with the CpGs plotted on violin plots
(Figure 5.2).
Median Transcript Expression
Position Number of CpGs in group High Methylation Low Methylation
±5kb of Gene Start 1,617,574 7.22 8.26
>5kb Upstream of Gene Start 9,963,665 7.25 7.50
>5kb from Gene Start within Gene Body 2,873,848 7.65 7.23
Table 5.1: Values associated with Figure 5.2
3rd & 4th columns correspond to medians plotted on Figures 5.2. All P-Values <2.2× 10−16
as shown on plots
The violin plots are informative for a number of reasons. Firstly, the plot of CpGs within 5kb of
the gene start (Figure 5.2 top panel) shows that the relative density of “low methylated” CpGs
in these regions is greater than that seen in the CpG dinucleotides which are >5kb from the gene
start either in the the upstream region or gene body (Figures 5.2 middle and bottom panels
respectively). This is likely due to an enrichment of CpG islands within 5kb of gene starts
as CpG dinucleotides within CpG islands have been shown to be relatively hypomethylated
compared to the CpGs outside these regions (Illingworth and Bird, 2009) and this finding is
reproduced in my data (Figure 4.4).
Secondly, Figure 5.2 and the associated Table 5.1, provide support for the idea that highly
expressed genes have hypermethylated gene bodies. This is because when CpG dinucleotides
are associated with transcripts based on their distance from the gene start, the groups of CpGs
that are ±5kb from the gene start (Figure 5.2 top panel) and >5kb upstream of the gene start
(Figure 5.2 middle panel) show greater median transcript expression associated with those CpGs
that have “low” methylation (Medians can be seen in first two rows of Table 5.1. Wilcoxon Rank
sum test P-Value <2.2× 10−16 for both). Alternatively, the CpG dinucleotides that are within
gene bodies (Figure 5.2 bottom panel and Table 5.1 3rd row) have greater median expression
of associated transcripts when associated with “high” methylation (Wilcoxon Rank sum test
P-Value <2.2× 10−16). Table 5.1 reports the median values of microarray transcript expression
associated with the “high” and “low” methylation groups in each distance category. As can
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Figure 5.2: CpG methylation signatures in gene bodies are opposed to those at
gene starts and upstream
Black dots represent median values shown in Table 5.1.“Hi Meth”: >50% CpG methylation.
“Lo Meth”: <50% CpG methylation. P-Values from Wilcoxon rank sum test of microarray
expression in “Hi Meth” & “Lo Meth” groups
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be seen from this table, the absolute diﬀerences in the medians are small (Columns 3 and 4),
but due to the large number of genome-wide CpG dinucleotides in each comparison (Column
2) these diﬀerences are highly statistically significant (P-Values are reported in Figure 5.2).
5.2.2 Investigation of the relation between gene expression and CpG methy-
lation in diﬀerentially methylated CpG dinucleotides
I next sought to investigate the association between CpG methylation and gene expression
with respect to those 13,553 CpGs that were defined as diﬀerentially methylated between the
WKY and Lew rat strains in Chapter 4. For each dmCpG I found the nearest annotated
strand-specific gene from the microarray analysis. Out of these 13,553 dmCpG-transcript pairs,
610 were associated with one of the 1,037 transcripts which were found to be significantly
diﬀerentially expressed in the microarray analysis of basal macrophages described in Chapter
3 (Table 3.1). A chromosome ideogram representing both the dmCpGs and the diﬀerentially
expressed transcripts can be seen in Figure 5.3.
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Figure 5.3: Ideogram of diﬀerentially methylated CpGs and diﬀerentially expressed
genes in basal macrophages
Grey rectangles represent chromosomes as labelled, MT = mitochondrial DNA
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The chromosome ideogram indicates that particular regions; the X chromosome, and parts of
chromosomes 4, 14 and 18 for example, contain relatively fewer dmCpGs than other regions of
the genome (Figure 5.3). In order to investigate whether this was the result of variability in
sequencing depth across the genome, I plotted a curve of average sequencing coverage across
the genome and the number of dmCpGs detected (Figure 5.4 shows chromosomes 14 and X; all
chromosomes are plotted in Figure 5 of Appendix to Chapter 5; plot generation is described in
Section 2.2.11).
Although there is not a one to one correspondence between low coverage and lack of dmCpG
detection, qualitative analysis of Figure 5.4 illustrates an example of a region of sparse dmCpG
detection that is associated with a low average sequencing depth in this region (Figure 5.4;
Chromosome 14 purple bar). The general lack of dmCpG detection in the X-chromosome
is associated with a general low attained sequencing depth in this chromosome (Figure 5.4;
Chromosome X). One possible reason for this poor coverage may be the low GC content and
relative depletion of CpG islands seen in the X chromosome of the rat genome (Gibbs et al.,
2004) as the Illumina platform is known to under-represent regions that are either extremely
GC-rich or GC-poor (Aird et al., 2011).
5.2.2.1 Diﬀerentially methylated CpG dinucleotides, gene expression and distance
to the gene start
Violin plots, similar to those in Figure 5.2, were used to investigate the relation between prox-
imity to the gene start, CpG methylation and gene expression in the 13,553 dmCpG-transcript
pairs (Figure 5.5).
For dmCpGs that are ±5kb of the gene start, the median expression of transcripts associ-
ated with low methylated (<50%) CpGs versus high methylated CpG associated transcripts
is marginally statistically significantly diﬀerent only in the WKY strain (Figure 5.5 top right
panel; P = 0.028 Wilcoxon rank sum test). In the WKY, the low methylated CpG associ-
ated transcripts have a median expression of 7.46 whilst those transcripts associated with high
methylated CpGs have a median expression of 7.32. This is in keeping with the genome-wide
scale results, where low methylated transcripts are associated with greater median transcript
expression (Figure 5.2 top panel). While the diﬀerences in median transcript expression ob-
served in WKY and LEW have similar magnitudes, the Lew strain does not reach statistical
significance for the diﬀerence between the median transcript expression values related to high
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Figure 5.4: Detection of dmCpGs depends on coverage
Plots of average sequencing depth of chromosomes 14 & X in WKY & Lew rat strains and
detected dmCpGs (blue points). Red curves = smoothened estimate of average coverage across
length of each chromosome. Chromosome 14: purple bar shows a region of low sequencing
depth and few dmCpGs, orange bar indicates a region of high sequencing depth and a greater
number of detected dmCpGs. Chromosome X: shows low sequencing depth along its full
length and few detected dmCpGs
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Figure 5.5: Diﬀerentially methylated CpGs have a diverse relationship with gene
expression
y-axis: microarray expression from relevant rat strain. Black dots represent median values which
are also marked on each violin plot. “Hi Meth”: >50% CpG methylation, “Lo Meth”: <50%
CpG methylation. P-Values from Wilcoxon rank sum test of expression values. “Hi >Lo”:
Median expression of genes with “Hi Meth” greater then “Lo Meth” & “Lo >Hi” represents
vice versa. NS = non-significant. n = Number of CpG transcript-paris in each group
(7.24) and low (7.56) methylated CpGs (Figure 5.5 top left panel; P = 0.086 Wilcoxon rank
sum test). However, similar to the WKY strain, transcripts associated with low methylated
CpGs show a greater median expression. Though the non-parametric test used here to assess
diﬀerences in median transcript expression is robust to skewed data and outliers, this diﬀerence
could reflect the diﬀerent number of genes tested in the diﬀerent strains as indicated to the left
of the plots for each group.
Diﬀerentially methylated CpGs (dmCpGs) that are >5kb upstream of the gene start (Figure 5.5
middle row) show opposed patterns of associated transcript expression according to strain. In
the Lew strain CpGs with high methylation show a greater median transcript expression (7.45)
than those with low methylation (7.16; P = 1.2× 10−5), whilst in WKY, transcripts associated
with low methylation show a greater median expression (7.40) than those associated with high
methylation (7.21; P = 7.0× 10−4). Therefore, the whole genome pattern of CpGs with low
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methylation values being associated with genes with higher expression (Figure 5.2 middle panel
and Table 5.1, 2nd row) is not detected in the Lew strain in dmCpGs that are >5kb upstream
of gene starts.
In those dmCpGs which are >5kb from the gene start and within gene bodies (Figure 5.5 bottom
row), the WKY transcripts associated with CpGs with low methylation values show a greater
median expression (8.00) than those transcripts associated with high methylated CpGs (7.55; P
= 1.0× 10−4). Alternatively, the Lew transcripts associated with highly methylated CpGs are
more highly expressed than those transcripts with low methylated linked CpGs (7.91 v 7.42; P
= 1.3× 10−4). As a result, when dmCpGs are >5kb from the gene start and within gene bodies
it is the WKY strain which loses the pattern observed at the genome level (Figure 5.2 bottom
panel).
5.2.2.2 Genes associated with diﬀerentially methylated CpGs show significant dif-
ferential expression
When the 13,553 dmCpGs are allocated to the nearest strand-specific gene, 610 of these din-
ucleotides are allocated to genes that show significant diﬀerential expression (False Discovery
Rate <5%) in WKY and Lew basal macrophages according to the microarray analysis in Chap-
ter 3. 490 dmCpGs of the 610 are upstream of genes and 120 within gene bodies. These 610
dmCpG-transcript pairs represent 240 unique genes. The dmCpGs are often some distance
from gene starts with the median distance of the 490 upstream dmCpGs being ∼108kb and the
median distance of those 120 dmCpGs within genes to the gene start being ∼4kb.
The association of DNA methylation and gene expression at regions which are diﬀerentially
methylated between diﬀerent cell populations has proved to be complex. For example, a recent
study (Akalin et al., 2012) that examined primary human bone marrow specimens from patients
with various forms of acute myelogeneous leukaemia (AML) found that these subtypes of AML,
which have distinct underlying genetic lesions, display opposed DNA methylation patterns. In
addition, the correlation between the diﬀerentially methylated regions and expression of associ-
ated genes was dependent on the underlying genetic lesion, with cells derived from AML patients
with a mutation in isocitrate dehydrogenase (IDH) genes showing only a significant correlation
with expression in core promoter regions, whilst AMLs with chromosomal translocations involv-
ing chromosome 11q23 show a correlation with expression at core promoters, upstream regions
and CpG islands and shores (Akalin et al., 2012).
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I investigated the presence of any correlation between the 610 dmCpg-transcript pairs that have
significant diﬀerential methylation and expression of associated genes. I used non-parametric
Spearman’s correlation, that is robust to the normality assumption and outliers, to assess the
link connecting methylation diﬀerence between WKY and Lew macrophages at the dmCpGs
and the log2fold change of the associated transcripts. In line with the analysis presented in
Akalin et al. (2012), I performed correlation analysis at gene starts, in upstream regions and
gene bodies (both in dmCpGs up to 10kb distant from the gene start) and for dmCpGs contained
in CpG islands that are located within 5kb of the TSS (results of this analysis in CpG island
shores are presented in Section 5.2.2.3).
As the core promoter regions of the rat genome are poorly annotated in comparison to human
and mouse (see Section 4.2.2.2), I correlated methylation and expression using both the definition
of Akalin et al. (2012); TSS ±300bp, and the broader “gene start” definition of 5kb either side
of the Ensembl annotated TSS (outlined in Figure 4.11). The correlation analysis results can
be seen in Table 5.2.
Correlation Analysis
Position of dmCpGs Number of CpGs in group Spearman’s ρ P-Value
±300bp of Gene Start 10 0.73 0.016
±5kb of Gene Start 95 0.057 0.59
Upstream <10kb 47 -0.082 0.58
Gene Bodies <10kb 91 0.062 0.56
CpG islands within 5kb 31 -0.17 0.35
Table 5.2: Correlation of dmCpGs with diﬀerential gene expression
dmCpGs were sorted into groups depending on their position with regard to gene starts &
analysed for correlation with expression. Significant values are in bold.
The analysis presented in Table 5.2 shows that those dmCpGs which are within “core” pro-
moters (as defined by Akalin et al. (2012); ±300bp) are significantly correlated with diﬀerential
expression of associated transcripts. The reported Spearman’s ρ of 0.73 for dmCpG-transcript
pairs within 300bp of the gene start fits with an inverse relationship between methylation and
expression in these regions as suggested in Figure 5.1. 10 dmCpG-transcript pairs representing
six diﬀerent genes are included within this category (Figure 5.6). Nine of the dmCpG-transcript
pairs fit the inverse relationship (Figure 5.6). However, it is important to notice that although
the diﬀerential expression of each of the transcripts is statistically significant, the fold changes
associated with the diﬀerential expression may be of small biological significance (range of log2
Fold Change of diﬀerential expression 0.24 - 2.41). None of the other position categories for
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Figure 5.6: Ten diﬀerentially methylated CpGs ±300bp of Gene Starts are signifi-
cantly correlated with diﬀerential expression
dmCpGs from row 1 of Table 5.2. x-axis: methylation diﬀerence at dmCpGs = Lew-WKY;
y-axis = Fold change (FC) for diﬀerential gene expression: negative FC denotes increased
expression in Lew strain
the correlation analysis of dmCpG methylation and gene expression reach significance (Table
5.2). This is analogous to IDH mutated AMLs as reported by Akalin et al. (2012) and outlined
above.
5.2.2.3 Diﬀerentially methylated CpG dinucleotides, gene expression and CpG
island shores
In their initial description of CpG island shores, Irizarry et al. (2009) used a microarray method
for high-throughput measurement of DNA methylation which they termed comprehensive high-
throughput arrays for relative methylation or CHARM. Using this platform they noted that
methylation levels at diﬀerentially methylated regions showed a strong inverse relationship with
diﬀerential gene expression in CpG island shores, where high methylation was associated with
low gene expression. This association between methylation and expression persists in diﬀeren-
tially methylated regions up to 2kb from human TSSs (Irizarry et al., 2009).
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Although my data allow high-resolution analysis and assessment of individual CpG dinucleotides
as opposed to regions, I examined whether such associations could be found in CpG dinucleotides
5kb either side of the gene start. 3,931 of the dmCpGs are contained within CpG island shores.
Of these, 419 are within 5kb of a strand-specific gene start and, in line with the analysis of
Irizarry et al. (2009), 243 dmCpGs are within 2kb.
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Figure 5.7: Gene expression is not correlated with dmCpGs at CpG island shores
x-axis: methylation diﬀerence at dmCpGs = Lew-WKY; y-axis = Fold change for diﬀerential
gene expression: negative FC denotes increased expression in Lew strain. Shaded quadrants
are those which would be densely populated if there was a strong inverse correlation between
methylation of plotted CpG dinucleotides and expression. Blue points are within 2kb up or
downstream of the gene start, red from 2-5kb up or downstream. Black Percentage = amount
of the total dataset contained in each quadrant; blue percentage = amount of those CpGs within
2kb of gene start
Figure 5.7 plots log2 fold change of genes which are diﬀerentially expressed between WKY and
Lew macrophages, with a negative fold change representing increased expression in Lew and
vice versa, against methylation diﬀerence of the dmCpGs. In this analysis, a negative log2
fold change corresponds to greater expression of the associated gene in the Lew strain and,
as can be seen from the x-axis label, a negative methylation diﬀerence corresponds to greater
methylation at the dmCpG in the WKY strain. Therefore, if it is assumed that there is an
inverse relationship between methylation and expression as reported by Irizarry et al. (2009),
Chapter 5. The relationship between CpG methylation & transcription 121
the two quadrants outlined with the dashed line should contain significantly more points than
the opposite quadrants. As can be seen from the percentages of points contained within each
quadrant (Figure 5.7), such a relationship is not detected either at a distance of 5kb or 2kb.
This lack of an enrichment for this relationship is confirmed by χ2 testing of the number of
dmCpGs within 5kb of the gene start showing an inverse methylation-expression relationship
within CpG island shores compared to all dmCpGs within 5kb of the gene start. At a distance
of 5kb (all points Figure 5.7): χ2 = 1.43, df = 1, P-Value = 0.23, whilst at a distance of 2kb
(red points Figure 5.7): χ2 = 1.87, df = 1, P-Value = 0.17.
Two of the key findings of Irizarry et al. (2009), were that identifiable methylation diﬀerences
in CpG island shores seemed to diﬀerentiate between tissue of origin, and that there is no-
table overlap with diﬀerentially methylated regions between normal and malignant samples.
Diﬀerentially methylated regions found by Irizarry et al. (2009) showed significant evolution-
ary conservation between human and mouse tissues and could separate tissue types regardless
of species of origin. As well as using a diﬀerent experimental platform, my analyses of CpG
methylation were carried out in the same fully diﬀerentiated non-malignant cell type from two
inbred rat strains. Consequently, if the diﬀerential methylation associated with CpG island
shores is best detected in diverse tissues it is perhaps not surprising that we do not reproduce
their findings.
5.2.3 CpG methylation and histone modifications: an exploratory analysis
Diﬀerentially methylated CpGs which occur ±5kb from a gene start may be expected to exert a
direct eﬀect on transcription of associated genes if these CpGs occur within core gene promoters.
As can be seen from Section 4.2.2.3, 6.8% of dmCpGs detected are within ±5kb. One other way
in which the dmCpGs may exert an influence over transcription is if they are located within gene
regulatory elements. Recently, WGBS data from 30 diﬀerent human cell types has shown that
CpGs which show variation in methylation according to cell type co-occur with gene-regulatory
elements, particularly enhancers (Ziller et al., 2013).
A number of publications have used publicly available datasets, largely published as part of the
ENCODE project (Consortium, 2012), to aid similar analyses to that published by Ziller et al.
(2013) (for example, Treppendahl et al. (2012); Zhang et al. (2012)). However, the ENCODE
project has focused on the human and mouse genomes and no rat data are available to date.
Cross-species comparison between the rat, mouse and human genomes (Gibbs et al., 2004) has
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suggested that approximately 40% of the euchromatic rat genome (i.e that portion thought
to be accessible for transcription) is shared amongst the three species, whilst 30% of the rat
genome aligns specifically to that of the mouse.
Two further properties of this three species comparison are of particular relevance to this project.
Firstly, the distribution of GC content of the rat genome more closely resembles that of the mouse
than the human (Gibbs et al., 2004). Secondly, prior to the use of ChIP-seq for detection of
regulatory regions (see Section 1.6.2), regulatory function of genomic regions was inferred from
detection of highly conserved noncoding sequences (Thomas et al., 2003). Genome-wide human,
rat and mouse alignments showed that highly conserved regions extended over regions calculated
to have a high likelihood of being regulatory as opposed to neutral DNA (Gibbs et al., 2004),
suggesting that regulatory elements such as enhancers may be functionally conserved across
species. These findings suggest that use of mouse ENCODE data sets may be informative for
comparison with the methylation data generated in the rat in this project.
Conversely, one disadvantage of using ENCODE data from a diﬀerent species is especially
applicable to this analysis. ChIP-Seq experiments have defined a chromatin signature of H3K4
monomethylation (H3K4me1) combined with low amounts of H3K4 trimethylation (H3K4me3)
as suggestive of enhancer regions (Heintzman et al., 2007). Additional binding of the acetyl
transferase and transcriptional co-regulator, p300, is thought to label core enhancers within
these broader H3K4me1hi/H3K4me3lo regions (Heintzman et al., 2007). A recent ChIP-Seq
study used mouse macrophages stimulated with LPS to uncover stimulation-responsive binding
of p300 to H3K4me1hi/H3K4me3lo regions (Ghisletti et al., 2010), and thus uncover a group
of enhancers activated by the specific inflammatory stimulus of LPS. This LPS-inducible set of
enhancers were not enriched in regions of the mouse genome that are highly conserved between
humans and rodents (Ghisletti et al., 2010).
Previous work has showed that enhancers in regions that are highly conserved between humans
and rodents are involved in development (Visel et al., 2008). One may hypothesise that mouse
ENCODE enhancer data may be more likely to uncover developmental enhancers, rather than
capture tissue specific enhancers or those associated with inflammatory stimuli.
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5.2.3.1 Comparative genomic analysis of dmCpGs and enhancers
Here, I perform an exploratory analysis of the co-occurrence of enhancer regions detected in
bone marrow and macrophages in mouse and dmCpGs in rat macrophages. This is described in
detail in Section 2.2.9 and summarised in Figure 5.8. Briefly, ENCODE peak locations for the
histone modifications H3K4me1 and H3K4me3 were downloaded in two mouse samples; bone
marrow-derived macrophages and bone marrow, using the UCSC table browser (Meyer et al.,
2012) (Figure 5.8 yellow table rows). H3K4me1 peaks which did not overlap with H3K4me3
were designated as enhancer regions in the two cell types (Figure 5.8 blue table row). The union
of all such enhancer regions from the two cell types was used to ensure that all possible regions
were retained but not counted twice, leaving 136,013 peaks (Figure 5.8 green box). Syntenic
regions in the rat genome were then found for these peaks resulting in 47,994 regions (Figure
5.8 rose box). Of the 13,553 dmCpGs, 780 (5.76%) were located within a syntenic enhancer
region (Figure 5.8 orange box).
Dataset! BMDM! Bone Marrow!
H3K4me1 peaks! 122,295! 76,790!
H3K4me3 peaks! 22,238! 19,377!
H3K4me1hi/
H3K4me3lo 
(enhancers)!
104,873! 65,443!
Union of enhancers in BMDM & bone marrow!
136,013!
Enhancer regions with syntenic region in rat !
47,994!
dmCpGs contained within enhancer regions!
780!
dmCpGs!
13,553!
Figure 5.8: Schema for enhancer analysis
See text of Section 5.2.3.1 for details
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In order to investigate whether diﬀerentially methylated CpGs were enriched in the syntenic
enhancer regions, I used a binomial test where the null proportion of dmCpGs occurring within
an enhancer region was derived from random sampling of the occurrence of ∼1.2 million genomic
regions of similar length to the enhancer regions (for detailed method see Section 2.2.9). This
analysis showed that dmCpGs were significantly enriched in these enhancer regions (Binomial
test, P-Value = 3.6× 10−109) (Figure 5.9 left panel). Additionally, the dmCpGs located within
the syntenic enhancer regions were more frequently hypermethylated in the Lew strain (propor-
tion of dmCpGs hypermethylated in Lewis in all dmCpGs: 0.45 versus proprortion in enhancer
regions: 0.58; P-Value = 8.1× 10−13, Fisher’s exact test).
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Figure 5.9: Enrichments for dmCpGs in enhancer analyses
Left panel: The occurrence of dmCpGs is enriched in syntenic enhancer regions compared
to randomly sampled genome segments. P-Value = 3.6× 10−109; binomial test. Right panel:
dmCpGs located within enhancers are hypermethylated in Lew. P-Value = 8.1× 10−13; Fisher’s
exact test
This analysis is clearly limited by the fact that the histone modification datasets used are
derived from the mouse and based on the use of syntenic regions between the mouse and rat.
However, the significant enrichment of diﬀerentially methylated CpGs between the two strains in
syntenic enhancer regions suggests that ChIP-Seq experiments assaying histone modifications in
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the WKY and Lew rat strains may uncover diﬀerences which could be linked to gene expression
and the disease phenotype. Furthermore, the dmCpGs occurring within enhancer regions are
more commonly hypermethylated in the Lew strain. This may suggest that the two rat strains
have broad diﬀerences in the layout of gene regulatory elements as the ENCODE project found
that enhancer regions and weak enhancer regions showed diverse patterns of DNA methylation,
with the weak enhancer state showing higher methylation than the standard enhancer state
(Consortium, 2012).
5.2.4 CpG methylation and transcription factor binding sites
Stadler et al. (2011) examined whole genome CpG methylation in both mouse pluripotent em-
bryonic stem (ES) cells and neuronal progenitor (NP) cells. They found that low methylated
CpGs (showing between 10 and 50% methylation; LMRs; see Sections 1.7 & 4.2.1.2) that were
specific to either ES or NP cells were enriched for cell type specific transcription factors (TFs)
suggesting that there may be a functional relationship between DNA methylation and TF bind-
ing. I, therefore, investigated if TF binding sites (TFBS) relevant to macrophage biology are
enriched around those dmCpGs in which one rat strain showed LMR level of methylation.
The method for this investigation is described in Section 2.2.10. In outline, the DREME algo-
rithm (Bailey, 2011) was used to find motifs which were statistically enriched in the genomic
sequence of 120bp regions centred on dmCpGs found in the WGBS data. Diﬀerentially methy-
lated CpGs were selected according to whether they showed an LMR level of methylation (10-
50%) in either or both the WKY and Lew rat strains. 4,732 out of 13,553 (34.9%) of the total
dmCpG set showed LMR methylation.
DREME analysis of these 4,732 CpGs found 23 motifs of between 5 and 8 bp in length that were
statistically enriched in the 120bp around the dmCpGs. Next, these 23 motifs were analysed
using the TOMTOM tool (Gupta et al., 2007) to find known TFBS within these motifs. As can
be seen from Figure 5.10, four of the 23 motifs; RGGAAR, AAATGAMA, CCACGHGG, CCM-
CGCCC1 showed statistically significant enrichment for known vertebrate TFBS (left panel).
These four motifs shown in the left panel of 5.10 were represented by 13 known TFBS (Figure
5.10 right panel).
1Using the IUPAC alphabet, R denotes base A or G; M denotes C or A and H denotes either A, C or T
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Figure 5.10: DNA motifs & TFBS enriched at dmCpGs
Left panel: Motifs detected by DREME analysis associated with known TFBS by TOMTOM
analysis. For each bar beneath a motif diagram, the colour corresponds to the plot in the right
panel and therefore denotes the motif associated with the TFBS. Figures in the coloured bar
represent number of positive matches detected in the dmCpG flanking sequences for each motif
(left) and E-value for enrichment (right). Right panel: Plot of known TFBS enriched around
dmCpGs. TF name is given on y-axis and associated motif denoted by colour of bar. x-axis is
-log(p-value) with dashed line representing p=0.05 at 5% false discovery rate
2,269 of 4,732 (48.0%) sequences from LMR containing dmCpG regions contain the RGGAAR
motif, this motif is associated with enrichment for binding sites for STAT3, SPI1, FEV and
ELF5 (Figure 5.10 Purple bars). STAT3 and SPI1 are both known to have roles in the regu-
lation of monocyte and macrophage diﬀerentiation. STAT3 binds to the TTCC(G/C)GGAA
motif (Valledor et al., 1998) and has been implicated both in the terminal diﬀerentiation of
macrophages (Valledor et al., 1998) and the formation of the M2 macrophage phenotype (intro-
duced in Section 1.3) in response to IL-10 signalling (Sica and Mantovani, 2012). The Spi1 gene
encodes the PU.1 transcription factor which is essential for macrophage development (Valledor
et al., 1998). PU.1 is a member of the ets proto-oncogene family and is seen as essential for
macrophage development (Burda et al., 2010). Current evidence suggests that the main role of
PU.1 is in cell fate control of haematopoietic stem cells (HSC) rather than in the maturation
of terminally diﬀerentiated macrophages (Burda et al., 2010). FEV and ELF5 are members of
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the ets family like PU.1, but neither have known roles in macrophage biology.
Six separate TFs containing the CCACGHGG motif are enriched in 66 (1.4%) sequences (Figure
5.10 green bars). The six TFs; USF1, MYCN, MYC, MAX, ARNT and a heterodimer of MYC
and MAX (denoted MYC::MAX in the figure) are members of the basic helix-loop-helix (bHLH)
family of transcriptional regulators (Jones, 2004). Myc proteins are widely expressed and can
regulate initiation of translation initiation and activate transcription when heterodimerised with
Max (Jones, 2004). C-Myc is highly expressed in diﬀerentiating cells of the myeloid lineage and
then strongly repressed after induction of terminal diﬀerentiation into macrophages (Valledor
et al., 1998). However, when mature macrophages are stimulated with IL-4 c-Myc activity is
further induced (Sica and Mantovani, 2012). Arnt is the constitutively expressed part of the
heterodimer that forms the Hypoxia Inducible Factor 1 (HIF1) TF. HIFs have been broadly
implicated in macrophage functions in inflammation (Nishi et al., 2008). The USF1 TF has not
been implicated in macrophage function.
The third enriched motif is CCMCGCCC (101 sequences, 2.1%; Figure 5.10 turquoise bars).
The TFs enriched; KLF4 and SP1 belong to the specificity protein/Kru¨ppel-like factor family
and have both been implicated in macrophage biology. KLF4 appears to play an important role
in formation of the M2 macrophage phenotype as it is robustly expressed in M2 macrophages
and regulates a transcriptional program that mediates expression of M2 phenotypic genes (Liao
et al., 2011). SP1 also plays a role in macrophage function with several studies demonstrating
the importance of an Sp1 binding motif in the IL-10 promoter for transcription of the gene
(Brightbill et al., 2000; Chanteux et al., 2007).
A single TF; Stat1 reaches statistical significance from the final enriched motif of AAATGAMA
(47 sequences, 1.0%; Figure 5.10 salmon bar). Stat1 is indirectly activated by LPS-induced type
I IFN in macrophages and this activation promotes further expression of LPS-inducible genes
suggesting that this TF has a role in macrophage contribution to innate immunity (Ohmori and
Hamilton, 2001).
Thus, one can see that binding sites of functionally important TFs are enriched in dmCpGs
in which one rat strain has between 10 and 50% CpG methylation. This may suggest that
TF binding may be an important diﬀerence in the WKY and Lew rat strains underlying their
diﬀering macrophage phenotypes.
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5.3 Discussion
In this chapter I performed an investigation of the relationship between cytosine methylation and
gene expression in bone marrow-derived macrophages fromWKY and Lew rats. On the genome-
wide scale I paired all ∼14.5 million CpGs for which there was robust sequencing data, with the
nearest of the 27,507 transcripts from linked aﬀymetrix gene expression microarray data. This
showed that in macrophages, lower levels of CpG methylation around the gene start (±5kb) are
associated with higher gene expression (Figures 5.1 and 5.2 top panel), and that this is likely
due to the expected over-representation of CpG islands in these regions shown in Chapter 4
(Figure 4.4). Conversely, where CpG dinucleotides are located within gene bodies, higher CpG
methylation is associated with higher expression. This is qualitatively visible in Figure 5.1,
where the rightward parts of the curves, representative of those CpG dinucleotides within gene
bodies show greater CpG methylation. This trend is quantified for CpG dinucleotides within
gene bodies that are greater than 5kb from the gene start, in Figure 5.2 and the linked Table 5.1.
These data show that when the approximately 2.9 million CpGs within gene bodies are divided
in to high (>50%) or low (<50%) methylation, the transcripts linked to high methylated CpG
dinucleotides show greater median transcript expression (Table 5.1 bottom row).
The patterns of CpG methylation and expression described in the above paragraph for regions
around the gene start and within gene bodies, have been widely described in previous studies,
the majority of which have been with human and mouse data (Kulis et al., 2012; Portela and
Esteller, 2010). The annotation of both human and mouse genomes with respect to promoters
and transcription start sites is significantly more advanced than in rat (Kodzius et al., 2006;
Lenhard et al., 2012), hence why I used the distance subsets described in Figure 4.11. The fact
that the results presented in this chapter reproduce previously published patterns linking CpG
methylation and gene expression is therefore, reassuring as an indirect test of the quality of the
annotation of transcription start sites in the rat genome.
When the analysis focuses on those CpG dinucleotides which are diﬀerentially methylated be-
tween the WKY and Lew strains (dmCpGs), we find that 610 out of the total 13,553 (4.5%)
dmCpG-transcript pairs show both diﬀerential methylation and diﬀerential expression. The use
of a chromosome ideogram to seek topographical association between diﬀerentially methylated
CpGs and diﬀerentially expressed transcripts shows that genomic regions with a smaller number
of detected dmCpGs also have decreased depth of sequencing coverage, suggesting that detec-
tion is a function of coverage (Figure 5.3). When the association of methylation and expression
Chapter 5. The relationship between CpG methylation & transcription 129
is examined at dmCpGs we find that around the gene start there are probably too few points
to reach statistical significance, whilst in upstream regions the diﬀerential methylation means
that the Lew strain shows greater expression of genes associated with high methylated CpGs
which is diﬀerent to the genome wide scale (Figure 5.5 middle row). Alternatively, within the
gene body, it is the WKY which departs from the genome wide pattern with high methylated
CpGs associated with lower expression of linked transcripts (Figure 5.5 bottom row). However,
although statistically significant diﬀerences can be gained from this data, it is uncertain whether
the small diﬀerences seen between microarray expression values (no diﬀerence is greater than
1 unit of microarray expression) are likely to be biologically relevant or attributable to DNA
methylation.
An analysis of the correlation between dmCpGs and resultant expression changes only showed
a significant inverse correlation within a very limited window of 300bp around the gene start
(Table 5.2 and Figure 5.6). This Chapter does not reproduce the finding of Irizarry et al. (2009),
that an inverse relationship between methylation and expression is particularly notable in CpGs
located within CpG island shores (Figure 5.7). Irizarry et al. (2009) also showed that dmCpGs
of interest to them were enriched in CGI shores. As shown in Figure 4.8, I did not find any
enrichment of dmCpGs in CGI shores, suggesting that these shores may be of less interest in
the CRGN model.
A simple inverse relationship between methylation and expression has been diﬃcult to illustrate
in a number of studies, and this has been attributed to experimental reasons, the presence
of diverse cell types in samples, or distant regulatory events. Recently, interest has begun to
focus on the possibility that contemporary analysis methods may not be sophisticated enough
to recognise relationships involving more complex methylation patterns (VanderKraats et al.,
2013). The fact that these datasets derived from pure preparations of bone marrow-derived
macrophages do not illustrate a simple relationship between methylation and expression, may
suggest that an investigation into distant regulatory sequences may be instructive. To this end,
I carried out an exploratory analysis of any link between dmCpGs and putative enhancer regions
derived from mouse ENCODE data. This showed that dmCpGs are strongly enriched in putative
syntenic enhancers suggesting that this may be an important direction for future study (Figure
5.9). In addition, the data in Section 5.2.4 illustrates that diﬀerential methylation between the
WKY and Lew rat strains may be significantly distributed around TFBS. Transcription factor
binding is a key event in transcription and the AP-1 TF JUND has already been shown to have
a key role in the pathogenesis of the CRGN model (see review in Section 1.4.2). In Section 5.2.4
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I show that a number of TFs with key roles in macrophage biology associate with dmCpGs
chosen for methylation profiles favourable to TF binding, indicating that ChIP-seq experiments
mapping TF binding sites in the two rat strains may be a fruitful avenue of further study.
Chapter 6
The eﬀect of 5-aza-2’-deoxycytidine
on Nephrotoxic Nephritis and
cytosine methylation
6.1 Introduction
This chapter examines the eﬀect of the DNA methylation inhibitor, 5-aza-2’-deoxycytidine
(DAC), on glomerular injury in the nephrotoxic nephritis model of CRGN, and on DNA cyto-
sine methylation. The NTN model of CRGN is macrophage dependent (Aitman et al. (2006)
& Section 1.2), so the baseline diﬀerences in DNA cytosine methylation in macrophages from
the WKY and Lew rat strains shown in Chapter 4 can be used to infer an association between
cytosine methylation and CRGN. In addition, cytosine methylation could be further associated
with CRGN by showing that perturbation of DNA methylation modifies this phenotype.
6.1.1 Pharmacological studies in nephrotoxic nephritis
The histological phenotype of NTN is very similar to that seen in humans and is highly re-
producible, making NTN a valuable animal model of human GN and a useful tool to study
both the role of macrophages in crescent formation and to test novel therapeutic approaches
to CRGN. As presented in Section 1.4.1, the eﬀects of a wide variety of compounds have been
studied in the NTN model, including cytokines such as IL-4 (Cook et al., 1999) and IL-11 (Lai
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et al., 2001), established drugs such as anti-TNF-α monoclonal antibody (Khan et al., 2005)
and more experimental therapies, for example the Syk inhibitor R788 (fostamatinib disodium)
(Smith et al., 2010). It can therefore be hypothesised that the NTN model represents an attrac-
tive candidate in which to investigate the eﬀect of pharmacological manipulation of epigenetic
modifications and therefore gain some insight into the role of such modifications in CRGN.
6.1.2 Inhibition of DNA methylation using 5-aza-2’-deoxycytidine
5-aza-2’-deoxycytidine (Decitabine, DAC) is an analogue of cytosine. To achieve therapeutic
eﬀect, DAC is converted into deoxynucleotide triphosphate form and then included in DNA in
place of cytosine in replicating cells. Therefore DAC is only active in cells replicating DNA in
S-phase (Egger et al., 2004). Once incorporated in place of cytosine in DNA, DAC covalently
binds to DNA methyltransferase enzymes (DNMTs) resulting in the depletion of active DNMTs
and passive DNA de-methylation (see Section 1.6.1; summarised in Figure 6.1).
DAC is a licensed therapy for the preleukaemic haematological disease myelodysplastic syn-
drome, and has shown promise as a treatment for established leukaemias and advanced lung
cancer (Tsai et al., 2012). Wide study of DAC has made it unclear whether the treatment eﬀect
of this molecule is due to the inhibition of DNA methylation or another eﬀect, such as direct
cytotoxicity of the DAC-DNMT product (Figure 6.1 red arrow) or induction of cell-cycle arrest
when the therapy is given at high doses (Laird, 2010; Shen et al., 2013).
6.2 Results
6.2.1 Use of 5-aza-2’-deoxycytidine in nephrotoxic nephritis
To assess whether use of 5-aza-2’-deoxycytidine (DAC) has an eﬀect on the NTN model of
CRGN an in vivo experiment was performed as outlined in Section 2.1.6. The renal injury seen
in NTN is well characterised with rapid disease inception, maximal macrophage infiltration into
glomeruli between days four and seven and cellular crescents in most glomeruli by day seven
(Smith et al., 2010; Tam et al., 1999). In this experiment, NTN was induced in 8-10 week
old male WKY rats. Two groups of six rats were used, one group treated with 5mg/kg IP of
DAC and the other with phosphate buﬀered saline vehicle. Treatment was given every three
days prior to sacrifice at 10 days starting on the day of NTN induction. Consequently, this
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Figure 6.1: Mechanism of action of 5-aza-2’-deoxycytidine
DAC molecules (represented by orange circles labelled Z) are converted to triphosphate and once
incorporated into DNA bind covalently to DNMTs, depleting active enzymes and demethylating
DNA. Pink circles, methylated CpG; white circles, unmethylated CpG; red arrow, DAC-DNMT
product
Figure and adapted text reproduced from Egger et al, Epigenetics in human disease and
prospects for epigenetic therapy in Nature 429, 457-463 (27 May 2004).
experiment is a useful examination of the eﬀect of DAC in prevention of glomerular disease in
NTN (experimental schema shown in Figure 6.2).
6.2.1.1 Eﬀect of 5-aza-2’-deoxycytidine on peripheral markers of bone marrow in
rats with NTN
Current use of epigenetic therapies in malignant disease is associated with significant toxic
sequelae mostly related to bone marrow suppression such as anaemia, leukopaenia, neutropaenia
and thrombocytopaenia (Scandura et al., 2011). These eﬀects are persistent at doses classified
as “low” by experts (Kantarjian et al., 2006). The use of therapies such as cyclophosphamide
which are associated with bone marrow suppression, in CRGN associated human diseases is
well studied (Pani, 2013). I, therefore, examined the eﬀect of a course of 5mg/kg IP DAC doses
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Day 0!
Day 3!
Day 6!
Day 9!
Day 10!
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DAC!
DAC!
DAC!
Treatment!
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Samples taken:!
Kidney sections for crescents & ED-1 staining, 24hr urine collection, !
blood samples, glomeruli extracted!
Figure 6.2: Experimental schema to assess the eﬀect of DAC on NTN
on bone marrow markers in WKY rats with NTN to assess if any observed treatment eﬀect in
CRGN could be due to bone marrow suppression or a possible epigenetic eﬀect.
Whilst bone marrow parameters in rats with NTN show a trend towards reduction in DAC
treated animals (Figure 6.3), only total peripheral white blood cell count (Figure 6.3 left column
middle panel; P-Value 0.036; Mann-Whitney U test) and peripheral neutrophil count (Figure
6.3 right column top panel; P-Value 0.036; Mann-Whitney U test) show statistically significant
eﬀects. All results shown in Figure 6.3 were derived from WKY rats in whom NTN had been
induced. As a result, it is possible that any observed diﬀerences in peripheral blood counts could
be related to the overall degree of inflammation induced by NTS, and further investigation of the
blood and bone marrow eﬀects of DAC could be performed by performing a similar experiment
in rats treated with DAC but without induction of NTN.
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Figure 6.3: White blood cell count and neutrophil count are significantly lower in
WKY rats with NTN treated with DAC compared to vehicle treated controls
Hb, haemoglobin; WBC, white blood cell count. P-Values are from Mann-Whitney U test
6.2.1.2 Eﬀect of 5-aza-2’-deoxycytidine on nephrotoxic nephritis-related pheno-
types
Previous studies of the NTN model of CRGN have investigated a group of phenotypes; per-
centage of glomeruli showing crescents, proteinuria and infiltration of ED-1-positive cells into
glomeruli (Aitman et al., 2006; Behmoaras et al., 2008). The first two of these phenotypes are
direct markers of renal damage, whilst ED-1 is the rat homologue of CD68, a glycoprotein which
binds to low density lipoprotein and is a specific marker of macrophages (Holness and Simmons,
1993). Therefore, ED-1 staining is a measure of macrophage infiltration into glomeruli.
Treatment with DAC reduced the severity of glomerular insult after 10 days as shown by a 39%
decrease in glomerular crescents (group means: 92% vehicle versus 56% DAC; Mann-Whitney
P-Value = 4.8× 10−3. Figure 6.4 left panel), a 50% lowering of proteinuria (group means:
87mg/24hr vehicle versus 43mg/24hr DAC; Mann-Whitney P-Value = 4.3× 10−3. Figure 6.4
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centre panel) and a 36% depletion of macrophage infiltration as shown by ED-1 immunohisto-
chemistry (group means: 16% vehicle versus 11% DAC; Mann-Whitney P-Value = 0.015. Figure
6.4 right panel). Representative renal histology from animals in the two treatment groups can
be seen in Figure 6.5. The top row shows periodic acid-Schiﬀ staining which allows visualisation
of glomerular crescents and the bottom row shows representative ED-1 immunohistochemistry
sections.
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Figure 6.4: NTN-related phenotypes are improved in DAC (black points) and
Vehicle (red points) treated WKY rats
(Left panel) Percentage of glomerular crescents in DAC and vehicle treated rats. (Cen-
tre panel) 24hr proteinuria measured in DAC and vehicle treated animals. (Right panel)
Macrophage infiltration assessed by quantitative measurement of percentage of ED-1 stained
area per glomerular cross-section. All P-Values from Mann-Whitney U test
The use of DAC in male WKY rats in whom NTN has been induced appears to have a protective
eﬀect on the development of CRGN. This is shown by decreased glomerular crescent formation
(Figure 6.4 left panel) and detectable proteinuria (Figure 6.4 centre panel) in DAC treated
animals. There is also a decreased infiltration of macrophages into glomeruli (Figure 6.4 right
panel). As explained in the introduction (Section 1.4.2) the majority of the genetic susceptibility
of the WKY rat is explained by two quantitative trait loci named Crgn1 and Crgn2 (Aitman
et al., 2006). When NTN is induced in double-congenic rats that have had loci spanning
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Figure 6.5: Renal histology from DAC and Vehicle treated WKY rats
Major glomeruli are indicated by black arrows in all panels. (Upper row) Periodic acid-
Schiﬀ stain indicating severe crescentic change in vehicle treated section (right panel marked
with asterisk). (Bottom row) ED-1 immunohistochemistry shows glomerular monocyte and
macrophage infiltration quantified in Figure 6.4
Crgn1 and 2 from glomerulonephritis-resistant Lewis rats introgressed onto a WKY genetic
background, this results in a 34% reduction in glomerular crescents (Behmoaras et al., 2010)
which is similar to the 39% decrease seem with DAC treatment (Figure 6.4 left panel). In
comparison to previous pharmacological experiments using the NTN model which were designed
to investigate a possible preventative eﬀect on CRGN; the use of an anti-TNF-α monoclonal
antibody was associated with a decrease in ∼27% reduction in crescents (Khan et al., 2005) and
the use of the Syk inhibitor, R788 saw a 100% crescent reduction (Smith et al., 2010).
One question that needs addressing in these experiments is whether the reductions in glomerular
phenotypes achieved by DAC treatment are due to widespread bone marrow or cellular toxicity
and/or an epigenetic eﬀect of the drug. As discussed in Section 6.1.2, uncertainty remains as to
whether treatment eﬀects of DAC observed in haematological and solid organ malignancies are
the direct result of DNA methylation changes or other secondary eﬀects. Although the results in
DAC treated animals exhibit a trend towards generalised bone marrow suppression, only total
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white blood cell count and neutrophils are significantly reduced (Figure 6.3). Furthermore, the
ED-1 immunohistochemistry is reassuring in this regard as macrophage infiltration, although
decreased, is present in the glomeruli of DAC treated animals, suggesting some level of circulat-
ing bone marrow-derived cells capable of tissue diﬀerentiation into macrophages in DAC treated
rats. To address this issue further I carried out in vitro experiments on bone marrow-derived
macrophages from WKY rats.
6.2.2 Eﬀect of 5-aza-2’-deoxycytidine on in vitro bone marrow-derived macrophages
Although DAC appears to exert a treatment eﬀect on CRGN in the NTN model in vivo, it is
important to elucidate whether this is due to an eﬀect on DNA methylation or to cytotoxicity
of eﬀector cells in CRGN.
Recent work using an acute myelogenous leukaemia (AML) cell line has shown that low dose
DAC, in the nanomolar range, has durable eﬀects on inhibiting the clonogenicity of the cell line
without toxic eﬀects on normal bone marrow (Tsai et al., 2012). A 10nM dose of DAC showed
no consequence for the ability of normal bone marrow to generate multiple marrow lineages
(Tsai et al., 2012). This is an important finding for this experimental setup as it suggests that
the DAC treatment of WKY rats in the NTN experiments may not have adversely aﬀected the
ability of their bone marrow to form macrophages and therefore, the observed treatment eﬀect
may be epigenetic. The same investigators also showed that low (10, 50 and 100 nM) doses
of DAC were associated firstly with inhibition of DNA methylation of known epigenetically
silenced gene promoters and a concomitant increase in expression of these genes; and secondly
with decreased CpG methylation linked with both CpG island and non-CpG island containing
genes on a genome-wide scale (Tsai et al., 2012). Therefore, there is evidence to support an eﬀect
of DAC on DNA methylation that is independent of cell toxicity. However, these studies have
used cell lines selected for their clonogenic potential and it is unclear if they will be generalisable
to primary macrophages.
The dose of DAC used in published studies has varied between 10nM/0.01µM and 10,000nM/10µM.
A study of the eﬀects of 15µMDAC on various colorectal cancer cell lines found that the greatest
demethylation eﬀect seen at a specific locus using BS-Sanger sequencing was ∼25% (Mossman
et al., 2010). Another study was able to confirm DAC induced demethylation using Illumina
methylation arrays. The maximum demethylation seen was ∼30% in colorectal cancer cell lines
using 1µM DAC treatment (Hagemann et al., 2011).
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6.2.2.1 Eﬀect of 5-aza-2’-deoxycytidine on cell culture
In order to determine if I could treat cultured BMDMs with DAC to study the impact of the
drug on CpG methylation I cultured macrophages in the presence of DAC and assessed the
eﬀect of the drug on cell toxicity and viability.
To separate any low dose and high dose eﬀects I cultured macrophages at a range of DAC doses;
0.01, 0.1 and 1µM. In vitro, macrophages can be derived from the bone marrow of WKY and
Lew rats following a five day culture period as described in Section 2.1.2. Previous work on
this system has shown that during this culture period, cells have 100% ED-1 staining from day
three onwards (Dr Jacques Behmoaras, Centre for Complement and Inflammation Research,
Imperial College London, unpublished observations). Therefore, I treated the cell preparations
in two ways: throughout the five days of culture and from days three to five. Thus allowing me
to diﬀerentiate any eﬀect on fully diﬀerentiated macrophages (3-5 day culture group) from any
eﬀect on macrophage diﬀerentiation from bone marrow (0-5 day group).
As outlined in Section 6.1.2 DAC is an S-phase dependent reagent. Previous work has shown that
in vitro BMDMs cultured in the presence of colony stimulating factor show active cell cycling
in 93-98% of cells, with 8-9hrs spent in S-phase and a doubling time of 24-28hrs (Tushinski and
Stanley, 1985). So, one should expect DAC to be incorporated into DNA in the experiments
presented here. Experimental procedures for these experiments are in Section 2.1.2.1.
Fewer cells were seen in the culture preparations treated for the full five day period as compared
with those treated from days three to five (Figure 6.6 top row both panels). However, although
the two panels of the top row of Figure 6.6 show a trend towards decreasing number of cells
with increasing DAC dose, the eﬀect was modest (Kruskal-Wallis testing for eﬀect of increasing
DAC dose on cell number; P-Value = 0.11 for 0-5 days treatment & P-Value= 0.83 for 3-5d
treatment).
I used the Trypan Blue exclusion test on samples from these cell preparations to determine the
eﬀect of DAC treatment on cell viability after five days of culture (Louis and Siegel, 2011). As
can be seen from the bottom row of Figure 6.6, there was no demonstrable eﬀect of DAC on
cell viability when compared with mock treated cells (Figure 6.6 bottom row left most columns
in both panels).
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Figure 6.6: Fewer cells are seen in cultures treated from days 0-5 compared to cells
treated from days 3-5, but cell viability is similar in the two treatment regimes
(Left panels) DAC added throughout 5 day culture period. (Right panels) DAC added from
days 3 to 5. Cell viability assayed by trypan blue test. For each point; crossbar = mean &
upper and lower limits = ± standard error. P-Values derived from kruskal-wallis test for eﬀect
of [DAC] on cell number (top row) and viability (bottom row). Mock: no DAC treatment
6.2.2.2 Eﬀect of 5-aza-2’-deoxycytidine on CpG methylation
To investigate the eﬀect of DAC on CpG methylation I used multiplexed Illumina sequencing
of 48 PCR products from bisulfite converted DNA of each DAC dose across the two culture
conditions (0-5d and 3-5d) (Section 2.1.5). Each of the PCR amplicons used was designed to
include at least one dmCpG from the WGBS experiments (see Section 4.2.2) and all amplicons
together assayed 196 CpG dinculeotides in total. The genomic coordinates of these CpGs are
given in additional file DAC.CpGs.xlsx.
As an indicator of the reproducibility of methylation values from distinct macrophage prepara-
tions and using diﬀerent sequencing platforms, I plotted the methylation values of 50 of the CpG
dinucleotides in the PCR amplicons from the mock treated cells against the methylation values
for the same dinucleotides which were derived from the whole genome bisulfite sequencing on
WKY macrophages. These plots produced CpG methylation measurements which were highly
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concordant between the two data sets (Figure 6.7 top row; 0-5d adjusted r2= 0.97 P-value
<2.2× 10−16, 3-5d adjusted r2= 0.95 P-value <2.2× 10−16). In addition, CpG methylation
values in mock treated cells from the two treatment protocols were also consistent (Figure 6.7
bottom row; adjusted r2= 0.95 P-value <2.2× 10−16). I therefore proceeded to evaluate methy-
lation diﬀerences in the DNA samples derived from BMDM culture preparations treated with
escalating DAC concentrations.
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Figure 6.7: Correlation between mock DAC treated amplicon sequencing & WGBS
CpG methylation profiles suggests that distinct in vitro macrophage preparations
and sequencing platforms are comparable
(Top row)WGBS (x) versus Fluidigm (y) methylation percentages for 0-5d of DAC treatment
(left panel); adjusted r2= 0.97 P-value <2.2× 10−16 and 3-5d of DAC treatment (right panel);
adjusted r2= 0.95 P-value <2.2× 10−16. (Bottom row) Fluidigm methylation percentages
for 0-5d treatment (x) and 3-5d treatment (y); adjusted r2=0.95 P-Value <2.2× 10−16
To see if the distribution of CpG methylation varied according to the concentration of DAC with
which cells were treated, I plotted the methylation percentage of all assayed CpG dinucleotides
(n=196) from each DAC concentration. As can be seen in Figure 6.8 there is an apparent
U-shaped relationship between DAC dose and CpG methylation for DNA isolated from both
those cells treated with DAC for five days (Figure 6.8 top row) and those only treated between
days three and five (Figure 6.8 bottom row).
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For cells treated from day 0 to 5, significant demethylation compared to mock treated cells is
seen for a dose of 0.01µM (P-Value = 8.5× 10−19) and 0.1µM (P-Value = 1.8× 10−17), but
not for a dose of 1µM (P-Value = 0.96, all P-Values from Wilcoxon rank sum test) (Figure 6.8
top row). Cells treated from days 3-5 also showed significant demethylation compared to mock
at doses of 0.01µM (P-Value = 3.7× 10−12) and 0.1µM (P-Value = 1.8× 10−15) but not 1µM
(P-Value = 0.64, all P-Values from Wilcoxon rank sum test) (Figure 6.8 bottom row).
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Figure 6.8: Distribution of CpG methylation in mock & DAC treated cell prepa-
rations shows a U-shaped relationship between DAC dose & CpG methylation
(Top row) DAC added throughout 5 day culture period. (Bottom row) DAC added from
days 3 to 5 of culture. Black dots represent median values. *** P-Value <0.05 Wilcoxon rank
sum test compared to mock treated, see text for values
Further analysis of the decreased methylation seen in the box plots in Figure 6.8 shows that
DAC treatment results in demethylation of CpG dinucleotides that are methylated in cells that
are mock treated (i.e. those marked as treated with 0µM concentration of DAC in Figures
6.6 & 6.8). I denoted demethylated CpGs as those showing a decrease in methylation level of
15% or greater after DAC treatment. This value was chosen because although previous studies
performed on methylation array data have used a 20% reduction to identify demethylation
(Hagemann et al., 2011; Klco et al., 2013), a study which exposed cells to up to 10µM DAC
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found a maximum observed demethylation of∼25% (Mossman et al., 2010). >15% demethylated
points are represented in red on individual plots in Figure 6.9. The greatest number of CpGs
showing demethylation was seen in those cell cultures treated with 0.01 and 0.1µM DAC for
the full five day culture period. 63% of sequenced CpGs were demethylated at 0.01µM and 59%
at 0.1µM (Figure 6.9 top row, left and middle panel). When DAC treatment was applied to
fully diﬀerentiated macrophages (from days 3-5 of culture), 35% of CpGs were demethylated
by 0.01µM treatment and 51% by 0.1µM (Figure 6.9 bottom row, left and middle panel).
Comparatively few CpGs were detected as demethylated in cells after 1µM treatment both for
five days (9%; Figure 6.9 top row, right panel) and between days three and five (3%; Figure 6.9
bottom row right panel).
Whilst there is a clear trend towards decreased cell number in the two culture experiments,
there is no clear eﬀect on cell viability (Figure 6.6). A possible explanation for these results
is that live macrophages are adherent cells which require removal from plastic culture vessels
either by scraping or the use of cell dissociation buﬀer. The design of the experiment (Section
2.1.2.1), was such that culture media was changed every 24h to ensure constant exposure of cell
preparations to DAC which is unstable in aqueous solution. Given that higher doses of DAC
are widely reported to be associated with cytotoxicity, it is possible that the daily dosing of cells
with fresh media resulted in removal of dead cells from cultures which was more pronounced at
the 0.1 and 1µM doses.
The methylation distributions (Figure 6.8) and analysis of changes in methylation after treat-
ment (Figure 6.9), show that the highest dose of DAC used; 1µM, produces the smallest mag-
nitude of CpG demethylation. It is feasible that cytotoxicity is the predominant eﬀect in high
dose DAC treatment with any measurable demethylation eﬀects ameliorated by cell death. The
small numbers of cells seen at the end of the five day culture period may be of similar viability
to the other doses because in addition to causing cell toxicity, higher doses of DAC have also
been associated with G2 phase arrest, and a resultant decrease of cells in G1 phase (Hagemann
et al., 2011). As DAC is dependent upon cells entering S phase for action (Figure 6.1), this G2
phase arrest would result in a decreased eﬃcacy of DAC. Alternatively, at lower doses, DAC
cytotoxicity may be small enough that cells survive throughout the culture period and also avoid
entering G2 phase arrest, thus resulting in the measurable eﬀects of DAC on CpG methylation.
A smaller percentage of CpG dinucleotides are demethylated at 0.01µM when DAC treatment
is given between days three and five than when given throughout the culture period (35% versus
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Figure 6.9: Amplicon sequenced CpGs show diverse methylation changes after
DAC treatment depending on length of exposure and dose
(Top row) DAC added throughout 5 day culture period. (Bottom row) DAC added from
days 3 to 5 of culture. Red points represent those with an absolute decrease in CpG methylation
of 15% compared to mock treated cells and the percentage these points represent of the total
dataset is indicated in red. Blue points are those with an absolute increase of 15% and black
points are those ±15%. DAC concentrations used are indicated at the top of the figure
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63%, Figure 6.9 both left panels). A potential explanation for this is that the greatest amount
of cells in S phase are exposed to DAC as macrophages derive from bone marrow in the first
three days of the culture period. Alternatively, the treatment eﬀect of DAC may increase as
cells are exposed to the drug for a greater length of time to sub-cytotoxic doses.
6.2.2.3 5-aza-2’-deoxycytidine-induced demethylation patterns
Previous studies that have examined the eﬀect of DAC on CpG methylation have produced
conflicting results on the genomic localisation of the demethylation eﬀect of DAC. For exam-
ple, Tsai et al. (2012), found that 10nM DAC treatment for 72h of an AML cell line caused
demethylation of promoter regions of genes both containing CpG islands and not containing
CpG islands. Klco et al. (2013) treated primary AML cells with 100nM DAC and found that
DAC-induced changes in methylation were similar for CpGs with similar methylation levels in
untreated cells and that this eﬀect was independent of whether examined CpGs were within
CpG islands or not in CpG islands. The CpGs that had a higher baseline methylation value
were more likely to show a DAC induced demethylation. The study of Hagemann et al. (2011)
which used 24h of 1µM DAC treatment, also found that CpG dinucleotides were more likely
to be demethylated by DAC treatment if they had a higher baseline methylation level in both
a colorectal cancer cell line and a myeloid leukaemia cell line. However, in this study, both
of these cell types showed a preferential demethylation of CpG dinucleotides outside of CpG
islands.
Of the 196 CpGs included in the in vitro dataset, 38 are located within CpG islands and 158
outside of CpG islands. Figure 6.10 shows that both durations of DAC treatment result in
a trend towards a greater magnitude of demethylation seen in CpGs within CpG islands as
opposed to those located outside CpG islands. This only reaches statistical significance in those
cells treated with 1µM DAC.
6.2.3 Eﬀect of 5-aza-2’-deoxycytidine on DNA derived from nephritic glomeruli
In order to extend the observations from both the in vitro bone marrow derived-macrophages
(Section 6.2.2) and the in vivo nephrotoxic nephritis experiments (Section 6.2.1), I examined
the eﬀect of DAC on DNA extracted from ex vivo nephritic glomeruli.
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Figure 6.10: 5-aza-2’-deoxycytidine-induced demethylation patterns in CpG dinu-
cleotides within or not within CpG islands
Proportional change in methylation of 196 CpG dinucleotides from cells treated for five days of
culture period (left three graphs) or from days three to five (right three graphs) at indicated
doses of DAC. P-Values are derived from Wilcoxon rank sum testing of proportional change in
methylation between CpG island and non-CpG island CpG dinucleotides. Dashed horizontal
line represents no diﬀerence in methylation
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WKY rats were inoculated with nephrotoxic serum and treated with either DAC or vehicle
as described in Section 6.2.1. Following sacrifice, kidneys were removed, glomeruli obtained
(method described in Section 2.1.6) and DNA extracted from glomeruli and bisulfite converted.
Six individual control treated glomerular samples and 3 individual DAC treated glomerular
samples were of suﬃicient quality for downstream analysis. I then used mutiplexed Illumina se-
quencing of this DNA to investigate whether the amelioration of NTN seen with DAC treatment
(Section 6.2.1) was associated with decreased methylation in DNA from nephritic glomeruli.
Following multiplexed sequencing, high quality, high sequencing depth data was available for 200
CpG dinucleotides. The distribution of CpG methylation across all of these 200 CpGs showed a
small but significant decrease in methylation in the DAC treated samples (Figure 6.11; P-Value
= 0.049, Wilcoxon rank sum test).
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Figure 6.11: Distribution of CpG methylation in DAC & vehicle treated glomerular
DNA from WKY rats with NTN
Box plots of methylation percentages of 200 CpGs from glomerular samples from 3 WKY rats
treated with DAC and 6 control animals. Methylation percentages for the 200 CpGs were
derived using multiplexed amplicon sequencing. P-Value = 0.049, Wilcoxon rank sum test
Examination of the individual CpG dinucleotides sequenced shows that 150 (95%) had mean
CpG methylation values that were within 15% of each other in the vehicle and treatment sets
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and therefore counted as showing no diﬀerence, 39 (19.5%) showed a >15% demethylation in
the DAC treated glomeruli and 11 (5.5%) showed a >15% increase in methylation in the DAC
treated glomeruli (Figure 6.12).
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Figure 6.12: Methylation diﬀerences in CpGs from nephritic glomeruli from DAC
(n=3) and vehicle (n=6) treated animals
Red points represent those with an absolute decrease of 15% in DAC treated compared to vehicle
treated glomeruli. Blue points are those with an absolute increase of 15% and black points are
those ±15%
Of those 39 CpGs that showed demethylation in DAC treated glomeruli, 19 (49%) were statis-
tically significant with a Mann-Whitney test P-Value of ≤0.05. 14 out of 19 (74%) could be
grouped with at least one additional CpG and 9 out of 19 (47%) occurred within gene bodies.
The demethylated CpGs located within gene bodies are shown in Figure 6.13.
The first row of CpG dinculeotides in Figure 6.13 represents four CpGs which are within the
gene body of Ifitm3. This gene, interferon induced transmembrane protein 3, contains two CpGs
which are diﬀerentially methylated between WKY and Lew macrophages, with greater methy-
lation in WKY. In addition, the gene is diﬀerentially expressed by WKY and Lew macrophages
with increased expression in Lew as compared to WKY. This may suggest that Ifitm3 shows an
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Figure 6.13: Nine CpG dinucleotides within gene bodies are demethylated in
nephritic glomeruli from DAC treated animals
Ensembl gene symbol is given for each gene to the right of plots; the co-ordinate and P-Value
by Mann-Whitney test of each CpG is given on box plots
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inverse relationship between methylation and expression and therefore, makes it an attractive
candidate for further study of the eﬀects of DAC on its expression.
The second row of Figure 6.13, labelled Pxn, represents CpG dinculeotides which are all con-
tained within the gene body of Paxillin, a gene encoding a cytoskeletal protein involved in
actin-membrane attachment at sites of cell adhesion to the extracellular matrix. These CpG
dinucleotides were included in the multiplexed sequencing because the Pxn gene contains four
dmCpGs between WKY and Lew basal macrophages suggesting that this region shows signif-
icant variation in CpG methylation. The exact CpG dinucleotides which are dmCpGs in the
WGBS data are not scored as significant in nephritic glomeruli.
The P2rx7 gene contains five dmCpGs, four of which are hypermethylated in WKY. As a result,
an amplicon to assay this region was included in the multiplexed sequencing. The amplicon
designed to assay these dmCpGs did not capture any of the dmCpGs, but did include a separate
dinucleotide which showed demethylation (Figure 6.13 third row). The nearest dmCpG to that
CpG dinucleotide which was captured in the multiplexed sequencing is hypermethylated in Lew.
The fact that the CpGs in the WGBS data and the multiplexed sequencing are only ∼65 base
pairs apart suggests that either diﬀerential methylation can occur at fine resolution, or that
the value seen in the WGBS dataset may be artifactual. An additional complicating factor is
that the DNA in this experiment is derived from nephritic glomeruli, which are composed of a
number of cell types (See Figure 1.1), thus possibly diminishing the clarity of signal. The protein
of P2RX7, is a ligand-gated ion channel that is up-regulated in human and experimental GN
(Turner et al., 2007), and WKY macrophages and nephritic glomeruli show markedly increased
expression compared to those of the Lew (Deplano et al., 2013).
Figure 6.14 shows five of the ten CpGs which were in intergenic regions. The first row of Figure
6.14 shows CpGs from an amplicon that was initially designed because it contained a CpG
located at 9,627,018-9, that was highly diﬀerentially methylated between WKY and Lew in the
WGBS data with apparent unmethylation (0%) in Lew and ∼94% in WKY, with a P-Value for
diﬀerential methylation of 1.51× 10−32. Although this CpG did not reach statistical significance
for demethylation in DAC treated glomeruli, it did show a 12% decrease in methylation. The
nearest gene to this group of CpGs is Gje1, which is approximately 60kb upstream of the CpGs.
These CpGs are not contained within a syntenic enhancer region as described in Section 5.2.3.1.
The second row of Figure 6.14 assays two proximate CpGs on chromosome 19 which are within
31kb of the Ccl22 gene which is significantly hypermethylated in WKY macrophages compared
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Figure 6.14: Five intergenic CpG dinucleotides demethylated in nephritic glomeruli
from DAC treated animals
Ensembl gene symbol is given for the nearest gene to the CpGs to the right of the plots; the
co-ordinate and P-Value by Mann-Whitney test of each CpG is given on box plots
to Lew. This gene encodes a protein which is a macrophage derived chemokine, C-C motif
chemokine 22. Inhibition of this chemokine has previously been associated with a decrease in
CRGN in WKY rats (Garcia et al., 2003).
The remaining five intergenic CpG dinucleotides were located within amplicons designed to
assay short regions surrounding dmCpGs which were detected in the WGBS analysis. Three of
these remaining five CpG dinucleotides showed relatively low methylation in WKY in the WGBS
dataset which was not reproduced in the WKY nephritic glomeruli samples. This, again, could
be due to the reasons outlined above regarding cell heterogeneity in glomeruli or data artifact.
6.3 Discussion
In this chapter I investigated the eﬀect of the DNA methylation inhibitor 5-aza-2’-deoxycytidine
(DAC) on in vivo and in vitro phenotypes that are relevant to the NTN model of CRGN. In
Chapter 6. 5-aza-2’-deoxycytidine in NTN and Macrophages 152
addition, I used multiplexed PCR sequencing of bisulfite converted DNA from both in vivo and
in vitro samples to detect DNA methylation diﬀerences in DAC treated samples.
These experiments showed that DAC treatment of WKY rats in whom NTN had been induced
had a preventative eﬀect on NTN phenotypes (Figure 6.4) without significant bone marrow
toxicity (Figure 6.3). In vitro treatment of WKY rat bone marrow showed high concordance
between mock DAC treated cells and the WGBS results from independent WKY macrophages
suggesting that CpG methylation levels are reproducible in this cell culture system (Figure
6.7). As a result, I sought to show diﬀerences in CpG methylation in bone marrow derived
macrophages treated either throughout the five day culture period or from days three to five of
the culture period when macrophages are already fully diﬀerentiated from bone marrow.
Treatment with intermediate doses of 0.01 and 0.1µM DAC produced the largest eﬀects on
CpG methylation (Figure 6.8). However, the smaller number of CpG dinculeotides detected
as demethylated at the highest dose of 1µM may have been because the major eﬀect of DAC
at higher doses is either direct cell death or cell cycle arrest. Cell cycle arrest prevents cells
entering S-phase and therefore impedes the downstream eﬀects of DAC (Shen and Laird, 2012).
Once DAC treatment had been commenced in vitro, I used a continuous exposure to DAC to
minimise re-methylation of CpG dinucleotides, which has been observed upon removal of the
drug in colorectal cancer cells (Mossman et al., 2010). The two diﬀerent periods of DAC treat-
ment were used to delineate any diﬀerence in demethylation seen in cells treated throughout
their culture period (0-5d) with cells treated after full diﬀerentiation into macrophages (treat-
ment form 3-5d). Fewer CpG dinucleotides showed demethylation in the 3-5d treatment protocol
than in the 0-5d treatment protocol indicating that length of exposure to DAC may increase its
eﬀect. However, a basic dose-response relationship is not shown as fewer CpG dinucleotides are
demethylated by 0.1µM treatment than 0.01µM treatment in the 0-5d culture period.
One limitation of this experiment was the lack of phenotyping of the treated cells, especially
in the 0-5d group. Multiple haematopoiesis-specific genes have been shown to have densely
methylated promoters and low gene expression in haematopoietic stem and progenitor cells
followed by promoter demethylation and increased expression in fully diﬀerentiated cell types
(Calvanese et al., 2012). As a result, DAC treatment throughout the cell culture period could
have had significant eﬀects on macrophage diﬀerentiation.
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I was able to link DNA methylation in macrophages in NTN pathogenesis by bisulfite sequenc-
ing of nephritic glomeruli extracted from both DAC and vehicle-control treated WKY rats with
NTN. The in vivo experiments showed that DAC treatment ameliorated relevant disease pheno-
types (Figure 6.4 left and centre panels) whilst still exhibiting glomerular macrophages (Figure
6.4 right panel and Figure 6.5 bottom row). I went on to show a generalised decrease in CpG
methylation in DNA extracted from glomeruli (Figure 6.11) and found that 39 out of 200 (19.5%)
CpG dinucleotides assayed in nephritic glomeruli showed demethylation compared to glomeruli
from vehicle control WKY rats (Figure 6.12). 19 out of the 39 demethylated CpGs reached sta-
tistical significance. Combined, these results suggest that intermittent in vivo DAC treatment
has significant eﬀects on NTN with accompanying eﬀects on CpG methylation. Whilst Figures
6.8, 6.9 & 6.11 - 6.14 report statistically significant diﬀerences in CpG methylation between
DAC and vehicle treated samples, these results could be strengthened by knowledge of the over-
all level of 5mC in DAC treated and untreated samples. This could be achieved either by use of
a relevant HPLC assay or 5mC DNA ELISA. A result showing a reduction in total 5mC in DAC
treated samples would suggest that any locus-specific diﬀerences were part of a DAC eﬀect on
overall CpG methylation. The data shown in Figure 6.11, for example, would be particularly
strengthened by an overall measure of 5mC as they show only a small demethylation eﬀect of
DAC at the CpGs included.
Another consideration for the in vivo experiments is whether macrophages cycle through S
phase, and therefore allow incorporation of DAC into DNA and downstream demethylation (see
Section 6.1.2 for the importance of S phase to the mechanism of action of DAC). Studies in adult
male Lewis rats have shown that approximately 15% of cells in bone marrow, blood and spleen
are ED-1 positive (Westermann et al., 1989). Of these ED-1 positive cells; 20% can be shown to
be actively synthesising DNA at any time and up to 6% in bone marrow and 2% in whole blood
are actively proliferating (Westermann et al., 1989). Therefore, one can reasonably assume that
DAC was incorporated into eﬀector macrophages in the in vivo experiments presented in this
chapter.
The CpGs showing statistically significant demethylation in DAC treated nephritic glomeruli
include dinucleotides whose nearest genes are P2rx7 (Deplano et al., 2013) and Ccl22 (Garcia
et al., 2003), both of which have been previously implicated in the pathogenesis of NTN. How-
ever, previous studies looking at the eﬀect of DAC induced demethylation on resultant changes
in transcription have shown a variable relationship between drug induced demethylation and
the extent to which gene expression is increased. For example, Klco et al. (2013) showed little
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influence of demethylation on transcriptional activity in acute myeloid leukaemia cells, whilst
others (e.g. Tsai et al. (2012)) have been able to show sustained increases in gene expression
associated with DNA demethylation following DAC treatment. As a result, any conclusions to
be drawn regarding the role of DNA methylation in the pathogenesis of NTN would need careful
experimental validation. However, these studies and results have generated testable hypothe-
ses concerning the mechanisms by which DAC may ameliorate disease phenotype in NTN by
aﬀecting CpG methylation.
Chapter 7
General Discussion
The overall aim of this PhD project was to investigate the hypothesis that epigenetic variation,
specifically in DNA methylation, contributes to disease susceptibility in an animal model of
CRGN. The NTN model used as the basis for this study relies on the diﬀerential susceptibility
of two rat strains, the susceptible WKY and the resistant Lew, to CRGN following the injection
of a single dose of nephrotoxic serum. The WKY and Lew strains have an identical MHC
haplotype and the model has proved to be a tractable substrate for investigations of both the
genetic basis of CRGN susceptibility (Aitman et al., 2006; Behmoaras et al., 2008) and the
biology of macrophages, which are the main eﬀector cells underlying the model (Hull et al.,
2013; Tam et al., 1999).
Although epigenomic changes have been widely studied in cancer biology (Baylin and Jones,
2011; Irizarry et al., 2009), relatively little is known about the distribution of epigenetic modifi-
cations in other important diseases. Epigenetic studies have been largely restricted to cultured
cell lines (Consortium, 2012; Lister et al., 2009) or representative cell types such as whole blood
(Javierre et al., 2010) or circulating monocytes (Li et al., 2010). However, epigenetic modifica-
tions show wide variation according to cell type (Lister et al., 2009; Stadler et al., 2011; Ziller
et al., 2013). As a result, the use of bone marrow-derived macrophages, the key eﬀector cells
in CRGN, in this study can be seen as a key strength. The experimental focus of this project
was the single epigenetic modification of DNA methylation. DNA methylation is a defining
feature of cellular identity (Ziller et al., 2013) and most mature cell types show a stable DNA
methylation pattern (Bird, 2002) with a bimodal distribution of 70-80% of CpG dinucleotides
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showing high methylation and 0-30% of CpGs displaying only 0-10% methylation (Akalin et al.,
2012; Stadler et al., 2011).
The first main objective of the project was to use a preliminary study to investigate if genes dif-
ferentially expressed between WKY and Lew macrophages showed diﬀerences in DNA cytosine
methylation in putative promoter regions, and if these promoter regions showed methylation
changes in response to the environmental stimulus of LPS (Chapter 3). This objective was inves-
tigated by first identifying genes as diﬀerentially expressed between WKY and Lew macrophages
using a novel analysis of previously published microarray data from Hull et al. (2013). This
analysis (method in Section 2.2.1) identified 1037 transcripts representing 1025 unique genes
as diﬀerentially expressed (Table 3.1). Notably, comparison with the dataset of Maratou et al.
(2011) revealed a relatively modest overlap between genes labelled as diﬀerentially expressed in
the two datasets (Table 3.3 & Figure 3.1), highlighting the importance of identical experimental
conditions and analysis platforms (in this case, the type of microarray used) in high throughput
experiments.
In-depth analyses of diﬀerentially expressed genes in BMDMs between WKY and Lew in the
basal state and following LPS stimulation have been published elsewhere (Hull et al., 2013;
Maratou et al., 2011). In this study, I found enrichment for a number of relevant Gene Ontol-
ogy (GO) terms in diﬀerentially expressed genes between the macrophages of the two strains
(Table 3.2). Functional annotation clustering also showed that relevant individual GO terms
could be clustered to identify groups of similarly annotated genes (Supplementary Figure 1 in
the Appendix to Chapter 3), thus suggesting that genes involved in specific processes may be
diﬀerentially expressed in macrophages from the two rat strains.
A previous study by Ji et al. (2010) defined diﬀerences in the DNA methylation profiles of
4.6 million CpG sites at diﬀerent stages of haematopoiesis in mouse cells; thus both delineat-
ing diﬀerences in CpG methylation at diﬀerent stages of haematopoietic development down the
myeloid lineage, and allowing comparison between cytosine methylation in advanced progenitors
of the myeloid (granulocyte/macrophage progenitor cells) and lymphoid lineages (DN3 thymo-
cyte progenitors). Many of the regions showing dynamic methylation during haematopoiesis also
showed associated changes in transcription suggesting that methylation and expression may be
correlated in myeloid cells such as the BMDMs used in this project (Ji et al., 2010).
Examination of the 1037 diﬀerentially expressed transcripts in the basal macrophage data used
in this project (Table 3.1), shows that mouse homologs of 89 out of 1037 (8.6%) are diﬀerentially
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methylated through the diﬀerent stages of myeloid development in mouse. Furthermore, mouse
homologs of 49 of the 1037 (4.7%) transcripts show diﬀerential methylation in myeloid compared
to lymphoid cells (Ji et al., 2010). Therefore, because the work of Ji et al. (2010) linked
diﬀerences in methylation to changes in expression, it is possible that the diﬀerential expression
of some of the genes between WKY and Lew macrophages may be mediated by underlying
strain diﬀerences in methylation.
Whilst I found six CpG dinucleotides associated with genes known to be diﬀerentially expressed
between WKY and Lew that showed diﬀerential CpG methylation according to strain of origin
(Figure 3.6), none of 51 BS-Sanger sequenced CpG dinucleotides showed a significant diﬀerence
in CpG methylation after LPS stimulation. The lack of detection of LPS mediated changes in
CpG methylation may be limited in this project by the small number of assayed sites. However,
the recent work of Stadler et al. (2011) suggests that CpG sites which show dynamic methylation
require transcription factor (TF) binding and are more likely to occur in CpG poor regions of
the genome. As outlined in Section 3.2.2, loci for the sequencing in Chapter 3 were selected for
the presence of CpG rich CpG islands and therefore may be unlikely to demonstrate dynamic
CpG methylation in response to LPS. A number of TFs are implicated in diﬀerent stages of the
LPS dependent transcriptional response including NF-κB, the IFN-regulatory factors (IRFs),
CCAAT/enhancer-binding protein-δ (C/EBPδ) and PU.1 (Medzhitov and Horng, 2009). As
a result, a possible area of future study in this model could be to concentrate on measuring
plasticity of DNA methylation in genes known to be under the control of these relevant TFs.
The second main objective of the project was to assess DNA methylation on the whole-genome
scale using whole genome shotgun bisulfite sequencing (WGBS; Chapter 4). The aim of this was
to find diﬀerentially methylated CpG dinculeotides between WKY and Lew rats in macrophages
and thus associate these CpGs with diﬀerential susceptibility to CRGN. These CpGs could then
be analysed for biological relevance to macrophage function and glomerulonephritis. Although
changes in DNA methylation have been implicated in the diﬀerentiation of stem cells into
myeloid cells, including macrophages (Ji et al., 2010), little is known about the potential role of
methylation in the behaviour of fully diﬀerentiated macrophages.
One of the strengths of the WGBS dataset is that recent work has shown that biologically
relevant cytosine methylation diﬀerences may be in genomic regions of low CpG density (Ernst
et al., 2011; Stadler et al., 2011). These regions are best assayed by WGBS because other
genome-wide methylation techniques use enrichment methodologies or restriction enzymes that
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are necessarily biased towards regions of high CpG density (Laird, 2010). WGBS presented in
Chapter 4 achieved 13.5x coverage of the Lew strain and 17.6x coverage of the WKY strain (Ta-
ble 4.1). These coverages allowed post alignment analysis to call 13,553 diﬀerentially methylated
CpGs (dmCpGs) between the WKY and Lew strains (0.09% of analysed CpGs).
The reported depth of sequence was achieved through the use of a single lane on the HiSeq 2000
per sample. Increasing the depth of sequence to 30x through the use of two lanes per biological
replicate may have improved the pick up of dmCpGs (Hansen et al., 2012; Lister et al., 2009),
whilst also doubling the cost of the project. In the absence of greater sequencing depth, a future
re-analysis of the data using a modern statistical technique such as local likelihood smoothing
(Hansen et al., 2012) could be used to improve dmCpG detection. The technique of smoothing
is used to create functions which capture important patterns in a data set whilst dispensing
with data noise (Davison and Ramesh, 2000). Smoothing of methylation data with sequencing
depth of as low as 4x is suﬃcient to achieve a correlation of 0.90 with data sequenced to
30x coverage, thus demonstrating that this analysis technique produces valid results from less
densely sequenced data (Hansen et al., 2012).
The data from this project showed that bone marrow-derived macrophages from the WKY and
Lew rat strains have diﬀerent baseline distributions of cytosine methylation in CpG dinucleotides
(Figures 4.3 & 4.6). With fewer CpG dinucleotides in the WKY strain showing full methylation
(>50%) (Figure 4.3). This finding may mirror the observation that T cells from SLE patients
show a generalised hypomethylation compared to controls (Richardson et al., 1990; Richardson
and Patel, 2014). This result could be confirmed through the use of an HPLC assay (such as
that used in Mossman et al. (2010)) on BMDM preparations from WKY and Lew results.
6.2% of analysed WKY CpG dinucleotides had between 10 and 50% methylation, compared
to 6.0% in the Lew strain. Recent work by Stadler et al. (2011) has defined that CpGs with
10-50% methylation form clusters which are termed low methylated regions or LMRs in mice.
LMRs occur within CpG poor regions so would be well detected by the sequencing technique
and analysis used in this project. LMRs represent excellent candidates for regulatory regions in
that they are labelled by DNAse I hypersensitivity and enhancer marks as well as demonstrating
enhancer activity in functional assays (Stadler et al., 2011). Importantly, LMRs are formed by
the binding of transcription factors (TFs) to highly methylated regions, with this TF binding
initiating local demethylation (Stadler et al., 2011). In addition, cell specific LMRs co-localise
with cell-specific TFs adding further weight to the idea that it is TF binding that shapes the
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methylome (Stadler et al., 2011). Finally, formation of an LMR is significantly correlated with
expression changes, where LMR formation associates with increased expression and remethy-
lation of LMRs associates with decreased expression. A very recent paper (Gutierrez-Arcelus
et al., 2013) has expanded this work to three diﬀerent human cell types; fibroblasts, lymphoblas-
toid cells and T cells. This paper found that between 9 and 25% of TF binding sites across
111 diﬀerent TFs show an association between TF binding and methylation suggesting that the
association of TF binding with methylation is robust across species and TF type.
The work of Stadler et al. (2011) and Gutierrez-Arcelus et al. (2013) suggests that transcrip-
tionally important regions related to methylation are dynamic and shaped by transcription
factor binding. Previous work in the NTN model has shown that one specific transcription fac-
tor, Jund, is diﬀerentially expressed between the WKY and Lew rat strains (Behmoaras et al.,
2008) and that the increased expression of Jund in WKY rats is associated with an increased
number of binding events of Jund in WKY macrophages compared to a congenic animal with
lower Jund expression (Hull et al., 2013). As a result, in the NTN experimental model where
inbred rats with defined diﬀerences in gene expression (see Chapter 3, Hull et al. (2013); Mara-
tou et al. (2011)) and defined diﬀerences in TF binding of at least one TF (Hull et al., 2013)
are used, one could integrate ChIP-Seq mapping of TF binding with methylation data and gene
expression measurements. Stadler et al. (2011) suggest that cell type specific TF binding should
cause local demethylation to form LMRs and be associated with an increase in gene expression.
The results of TFBS analysis reported in Section 5.2.4 indicate that the proposed model of TF
binding influencing CpG methylation (Stadler et al., 2011) may also be true in BMDMs. This is
because using dmCpGs in which one of the WKY or Lew strain shows LMR-value methylation
(10-50%), the genomic sequence surrounding the dmCpG (120bp) is enriched for TFBS relevant
to macrophage function (Figure 5.10). As a result, integration of methylation, TF binding and
expression datasets in the NTN model, could define regions in which diﬀerential methylation in
one of the rat strains away from LMR-value methylation may aﬀect TF binding and subsequent
gene expression
The relationship between CpG methylation and expression of associated genes is an area of
intense study. The idea that methylation of CpGs occurring in the context of CpG islands is
associated with transcriptional silencing (Jones, 2012) has recently been challenged by studies
suggesting that this relationship may be more complex (Jones, 2012; Muers, 2013). In this
project, microarray datasets of genome-wide gene expression in WKY and Lew macrophages
allowed study of a key objective: appraisal of the relationship between DNA methylation and
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gene expression in rat macrophages (Chapter 5). Integration of microarray expression data and
WGBS data showed that highly expressed genes in both WKY and Lew macrophages showed a
relative decrease in CpG methylation around the gene start (Figure 5.1). Given that the WGBS
data also showed that CpG islands (CGIs) in the WKY and Lew rat genomes exhibit a lower
level of methylation (Figure 4.4), this data may suggest that highly expressed genes in the two
rat strains have CGI-containing promoters or CGI-containing regions near to what was defined
as the gene start in this project. Such a result would be in keeping with work in other mammals
(Jones, 2012).
The association between DNA methylation and gene expression is dependent on where CpG
methylation is examined in relation to the TSS. Previous work has suggested that genes whose
gene bodies are highly methylated are more actively transcribed than genes without gene body
methylation (Cokus et al., 2008; Kulis et al., 2012). Integrative analysis from this project showed
that this is true in rat macrophages (Figure 5.2 & Table 5.1). This finding is in keeping with
numerous other studies (reviewed in Jones (2012)). Interestingly, recent work has demonstrated
that intragenic CpG methylation may show significant tissue- and cell type-specific variation
and that these variations may play a role in regulating cell type-specific alternative promoters
in gene bodies (Maunakea et al., 2010). Because this project considered a single cell type
showing diﬀerent phenotypic behaviour between two rat strains, it is attractive to postulate
that diﬀerential methylation in intragenic CpGs between the strains could underlie diﬀerent
gene expression via alternative promoters. 3,045 of the dmCpGs were >5kb from the gene
start and within gene bodies, and the WKY strain showed departure from the expected pattern
of high intragenic methylation being associated with lower expression (Figure 5.5 & Section
5.2.2.1). Although the absolute diﬀerences in expression seen were small, an investigation of
possible alternative promoter activity and its contribution to phenotypic diﬀerences between
WKY and Lew macrophages could therefore, be an attractive area of further study.
In addition to a relationship between DNA methylation and gene expression, recent studies
have shown that certain histone modifications can be predictive of gene expression (Cheng and
Gerstein, 2012; Karlic´ et al., 2010; Pekowska et al., 2010). For example, genes in human CD4+ T
cells can be classified according to whether they have either high CpG content promoters (HCPs)
or low CpG content promoters (LCPs) (Karlic´ et al., 2010). Derivation of models that relate
gene expression in T cells to histone modifications shows that H3K4me3 and H3K79me1 are the
most predictive of gene expression in LCP genes, whereas HCP associated genes require a model
based on H3K27ac and H4K20me1 to predict their expression (Karlic´ et al., 2010). Similar to
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the work described above showing that variation in DNA methylation may be secondary to TF
binding, recent studies examining histone modifications have also suggested that TF binding
may be responsible for recruiting histone modifying enzymes, that sequence polymorphisms in
TFBS are correlated with diﬀerences in histone modifications (McVicker et al., 2013) and that
these changes in either TFBS and histone tails may have transcriptional consequences (Kasowski
et al., 2013; Kilpinen et al., 2013; McVicker et al., 2013). As a result, TFs may regulate gene
expression both by aﬀecting DNA methylation (Stadler et al., 2011) and histone modifications
(Kasowski et al., 2013; Kilpinen et al., 2013; McVicker et al., 2013). Thus, it is possible that
the key to modifying the epigenetic layer of gene regulation is regulation of TFs.
Given the apparent association between histone modifications, DNA methylation, TFs and gene
expression described above I used publicly available ChIP-seq data to investigate the relationship
between a set of histone modifications and DNA methylation in rat BMDMs (Section 5.2.3.1).
Diﬀerentially methylated CpGs were enriched in macrophage gene enhancer regions derived
from syntenic regions of the mouse genome (Figure 5.9 left panel). Although this exploratory
analysis would require validation with ChIP-seq datasets specific to the rat, a recent study
has shown that disease-associated SNPs in GWAS catalogues are more likely to occur within
enhancers and that this enrichment shows cell type specificity (Ernst et al., 2011). For example,
Ernst et al. (2011) found that SNPs associated with SLE were found in enhancers specific to
lymphoblastoid cells. I used histone data that labelled enhancer regions in both mouse bone
marrow and mouse macrophages (Figure 5.8) suggesting that these associations with dmCpGs
may be interesting for ongoing investigation to further define the role of enhancers in myeloid
cells in CRGN.
Furthermore, dmCpGs located within enhancer regions were more frequently hypermethylated
in the resistant Lew strain compared to the susceptible WKY strain (Figure 5.9 right panel).
This is in keeping with a growing body of data, using distinct techniques, that has demonstrated
DNA hypomethylation in patients with SLE (see Absher et al. (2013); Richardson et al. (1990);
Zhang et al. (2013) and Section 1.9.1.1). Although the majority of this evidence has used T
cells, recent work has showed hypomethylation of genes regulated by type I interferon in B
cells and monocytes from patients with SLE (Absher et al., 2013), suggesting that immune
cell types distinct from T cells may play a role in the pathogenesis of SLE. Therefore, if the
results in Figure 5.9 are considered in concert with the fact that the overall distribution of DNA
methylation is less in the WKY than the Lew (Figure 4.3), this thesis could be used as evidence
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implicating DNA hypomethylation of a novel cell type; the bone marrow-derived macrophage
in immunological disease.
As noted above, the work of Ernst et al. (2011) has demonstrated the importance of cell type
in exploring the role of enhancers in disease-susceptibility. Novel work has showed that the
relationship between DNA methylation and gene expression may be dependent on cell type or
tissue of origin. Gutierrez-Arcelus et al. (2013) analysed DNA methylation, single-nucleotide
polymorphism (SNP) genetic variation and gene expression at the genome wide scale in three
distinct cell types. This paper identified eQTLs (defined in Section 1.4.2) aﬀecting gene expres-
sion; loci aﬀecting DNA methylation, denoted mQTLs; and methylated sites associated with
gene expression, named eQTMs (Gutierrez-Arcelus et al., 2013). Using these data, the group
could examine the relationship between sequence variation, DNA methylation and expression.
They found that in T cells, DNA methylation played an active role in regulating gene expression
above that of sequence variation (i.e. DNA methylation was the main factor aﬀecting gene ex-
pression) (Gutierrez-Arcelus et al., 2013). Alternatively, in fibroblasts and lymphoblastoid cells,
Gutierrez-Arcelus et al. (2013) found that SNP sequence variability independently aﬀects gene
expression and DNA methylation, suggesting that methylation has a passive role in modulating
gene expression in this context (i.e. the role of methylation in gene expression is a consequence
of sequence variation in these cell types).
These results indicate that an active or passive role for DNA methylation in aﬀecting gene
expression may depend on cell type and that in a mature immune cell such as the T cell, DNA
methylation may be a frequent cause of gene expression variation. As mentioned in Section
4.2.1.1, my study removed SNPs between the WKY and Lew strains. However, it may be that
a re-analysis of the expression and methylation data taking into account WKY and Lew SNP
data and using the Bayesian network analysis (Schadt et al., 2005) used by Gutierrez-Arcelus
et al. (2013) may be of general importance in showing if the aﬀect of DNA methylation on gene
expression in macrophages is active or passive.
The final objective of this project was to assess whether a DNA methylation inhibitor, decitabine
(DAC), was able to improve phenotypes associated with CRGN and whether these could be
linked to a reduction in DNA methylation in biologically relevant genes or genomic regions
(Chapter 6). DAC has previously been associated with significant cytotoxicity (Shen and Laird,
2012) and therefore in vitro methodologies and assays of bone marrow function were also nec-
essary to assess whether any treatment eﬀect of DAC was likely a result of inhibition of DNA
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methylation or generalised cytotoxicity.
I investigated this question both in vitro and in vivo and found that whilst there were apparent
cytotoxic eﬀects (Figure 6.3 and Figure 6.6), these were small. However, given that the in vivo
work used animals with NTN, it is important to bear in mind that observed diﬀerences in blood
counts may also reflect the underlying NTN disease process as well as just the aﬀects of DAC.
It would, therefore, be important to examine the bone marrow eﬀects of DAC in rats without
NTN to better analyse the cytotoxic eﬀects of the drug.
Moreover, I was able to show generalised reductions in DNA methylation in selected CpGs
both in in vitro macrophages treated with DAC (Figure 6.8) and in glomeruli isolated from
animals treated with DAC following NTN induction (Figure 6.11). This reduction in methy-
lation is partly caused by significant reductions in specific dinucleotides previously associated
with macrophages and CRGN (Figure 6.13). This may suggest a possible therapeutic role for
inhibition of DNA methylation in CRGN but it would be important to further investigate the
eﬀect of DAC in macrophages and nephritic glomeruli using an assay of total cellular DNA
methylation as mentioned in Section 6.3.
Although these results are of interest, clinical use of DAC in diseases associated with CRGN is
unlikely to be a successful strategy. This is because clinical studies using DAC in the haema-
tological malignancy AML have shown that an eﬃcacious dosing regime requires infusions of
the drug for up to five days every four weeks (Kantarjian et al., 2012). Such dosing regimes
would likely be of limited acceptability to patients over the course of a chronic disease such
as those associated with CRGN. Furthermore, the high drug exposure associated with such
regimes could be associated with downstream side eﬀects such as myelosuppresion and malig-
nancy (Chapman-Rothe and Brown, 2011).
As mentioned in a recent review (Chapman-Rothe and Brown, 2011), modification of DNMT
enzymes may not be the only avenue by which therapeutic modification of DNA methylation
is possible. Transcriptional silencing via DNA methylation is mediated by MBD proteins (in-
troduced in Sections 1.7 & 5.1.1), and release of MBD proteins following CGI demethylation
in cancer cells is associated with expression of previously silenced genes (Esteller, 2007). As
there are a family of MBD proteins with at least five well characterised members, targeting
specific members of the family may lead to more specific eﬀects than those shown by DNMT
inhibitors such as DAC. Also, eﬀects on gene expression using drugs targeted at MBDs would
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be independent of DNA replication (see Figure 6.1 for obligate involvement of DNA replication
in the mechanism of action of DAC).
The above discussion relates either to decreasing DNA methylation or its transcriptional partner
of increasing expression. However, DNA hypomethylation is a feature of autoimmune diseases
(Section 1.9.1.1) and is demonstrated in BMDMs from the CRGN susceptible WKY strain in
this project (Figure 4.3). Therefore, increasing cellular CpG methylation levels might be a
useful treatment strategy in CRGN. Design of pharmacological agents able to increase DNA
methylation through the inhibition of DNA demethylating pathways has been hampered due
to controversies in the understanding of active demethylation (Kohli and Zhang, 2013). How-
ever, recent progress in the understanding of how the enzymes TET and TDG and the BER
pathway (see Section 1.6.1 and He et al. (2011); Kohli and Zhang (2013)) mediate active DNA
demethylation may lead to progress in this area. Although much of the laboratory work into
the BER pathway has focused on stem cells and primordial germ cells, the occurrence of TDG
at loci showing rapid cycling of cytosine methylation in response to hormonal (Kangaspeska
et al., 2008; Me´tivier et al., 2008) and cytokine stimulation (Thillainadesan et al., 2012) may
imply that TDG may modify transcription in the absence of DNA replication making this an
attractive drug target.
The results of this and other studies have shown the key role of cell-specific TFs in mediating
DNA methylation plasticity (Figure 5.10 & Gutierrez-Arcelus et al. (2013); Stadler et al. (2011)).
In addition, the Jund TF has been implicated in the predisposition of the WKY strain to CRGN
(Behmoaras et al., 2008; Hull et al., 2013). As a result, targeting of TFs may be a future avenue
for treatment of diseases showing aberrant DNA methylation. However, whilst the potential
of TF drug targets has long been acknowledged, a number of distinct factors including the
usual nuclear localisation of TFs and the fact that TFs often show poor aﬃnity for small
molecules, have traditionally made these poor targets for drug design (Konstantinopoulos and
Papavassiliou, 2011). These impediments are beginning to be addressed by the application of
novel approaches using artificial transcription factor mimics designed to specific TFs (Leong
et al., 2003). This method could be explored in the future in diseases relevant to CRGN.
In addition to identifying potential drug targets, DNA methylation could also be used clinically
either as a marker of disease activity or prognosis. Patients with AAV, one of the archetypal
diseases responsible for CRGN (see Section 1.1), have high titers of detectable antibodies to
two antigens: PR3 and MPO. A study has demonstrated that patients in disease remission
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have high levels of the histone modification H3K27me3 at the PR3 and MPO loci. These levels
were similar to healthy controls, and significantly diﬀerent from patients with active disease
(Ciavatta et al., 2010). With regards to DNA methylation; the same study, showed that CpG
islands associated with the MPO and PR3 genes diﬀered in that an MPO gene-associated
CpG island was unmethylated, whilst a PR3 gene-associated CGI showed full methylation
(Ciavatta et al., 2010). A study in na¨ıve CD4+ T cells derived from patients with SLE has
shown that whilst two interferon-regulated genes that have been confirmed as hypomethylated
in patients by multiple studies, BST2 and IFI44L, show robust hypomethylation in patients,
this does not correlate with disease activity (Coit et al., 2013). These data suggest that the
relationship between disease activity and epigenetic modifications is complex but that this may
be a worthwhile area of study.
DNA methylation patterns have been evaluated as potential markers of survival in patients
with both solid tumours (Dai et al., 2011) and AML (Bartholdy et al., 2014). One of the
challenges in the management of diseases associated with CRGN is their high relapse rate
and diﬃculty in prediction of such relapses (Walsh et al., 2012). As a result, use of DNA
methylation patterns as a biomarker for relapse prediction or survival would be of clinical utility
and could be achieved through building multivariate Cox models incorporating methylation
data. A previous study incorporating methylation data in multivariate Cox models identified
an epigenetic signature enriched for binding sites of known hematopoietic transcription factors
that was highly prognostic for patient survival in AML (Bartholdy et al., 2014). Similarly,
the data in my study suggests that methylation of regions enriched for TF binding may be of
importance in CRGN susceptibility (Figure 5.10), suggesting that an analogous study to that
of Bartholdy et al. (2014) may be of interest in CRGN.
7.1 Concluding Remarks
The work presented in this thesis used bisulfite sequencing methodologies to investigate DNA
methylation in bone marrow-derived macrophages from WKY and Lew rat strains in order to
explore if this epigenetic modification might influence gene expression and CRGN susceptibility.
This approach confirmed that the strains show significant diﬀerences in DNA methylation and
that these diﬀerences are associated with genes relevant to macrophage activation and CRGN.
Integration of this data with genome wide expression data from WKY and Lew BMDMs showed
that this cell type appears to obey previously demonstrated associations with regards to how
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DNA methylation influences transcription of associated genes, and therefore may allow modifica-
tion of macrophage gene expression through the targeting of DNA methylation. The interaction
of DNA methylation with other constituents of the transcriptional machinery is incompletely but
increasingly understood. Work in this thesis showed that strain diﬀerences in DNA methylation
are enriched in both enhancer elements and binding sites for macrophage-relevant transcription
factors. At least one transcription factor is known to play a key role in macrophage activation
and CRGN susceptibility in the NTN model used in this thesis. Additionally, TF binding of
DNA is known to influence DNA methylation levels. Finally, perturbation of DNA methyla-
tion using the DNA methylation inhibitor DAC reduced CRGN independently of bone marrow
toxicity, suggesting that epigenetic therapy may be of use in this broad class of disease. Taken
together, these results suggest that one can associate DNA methylation diﬀerences with suscep-
tibility to glomerulonephritis and that perturbation of DNA methylation may be useful in the
treatment of CRGN.
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Annotation Cluster 1 Enrichment Score: 3.19
Category Term P-Value Fold Enrichment FDR
GOTERM_MF_FAT GO:0008047~enzyme activator activity 4.4E-05 4.7 0.1
GOTERM_MF_FAT GO:0030695~GTPase regulator activity 6.2E-05 3.9 0.1
GOTERM_MF_FAT GO:0060589~nucleoside-triphosphatase regulator activity 7.8E-05 3.8 0.1
GOTERM_MF_FAT GO:0005083~small GTPase regulator activity 7.2E-04 4.1 1.0
GOTERM_BP_FAT GO:0051056~regulation of small GTPase mediated signal transduction 8.2E-04 4.0 1.4
GOTERM_MF_FAT GO:0005096~GTPase activator activity 1.1E-03 5.0 1.5
GOTERM_BP_FAT GO:0046578~regulation of Ras protein signal transduction 3.3E-03 4.1 5.4
GOTERM_MF_FAT GO:0005085~guanyl-nucleotide exchange factor activity 7.1E-02 3.2 64.5
Annotation Cluster 2 Enrichment Score: 2.69
Category Term P-Value Fold Enrichment FDR
KEGG_PATHWAY rno00600:Sphingolipid metabolism 5.4E-04 8.7 0.6
GOTERM_BP_FAT GO:0006665~sphingolipid metabolic process 6.2E-04 8.6 1.0
GOTERM_BP_FAT GO:0006643~membrane lipid metabolic process 7.3E-04 8.3 1.2
GOTERM_BP_FAT GO:0030148~sphingolipid biosynthetic process 8.4E-04 20.7 1.4
GOTERM_BP_FAT GO:0046467~membrane lipid biosynthetic process 1.0E-03 19.4 1.7
GOTERM_BP_FAT GO:0008610~lipid biosynthetic process 3.3E-03 3.0 5.5
GOTERM_BP_FAT GO:0006672~ceramide metabolic process 5.3E-03 11.1 8.6
GOTERM_BP_FAT GO:0046519~sphingoid metabolic process 6.5E-03 10.3 10.4
GOTERM_BP_FAT GO:0046513~ceramide biosynthetic process 6.9E-03 23.3 10.9
GOTERM_BP_FAT GO:0046520~sphingoid biosynthetic process 6.9E-03 23.3 10.9
Annotation Cluster 3 Enrichment Score: 2.30
Category Term P-Value Fold Enrichment FDR
GOTERM_BP_FAT GO:0051056~regulation of small GTPase mediated signal transduction 8.2E-04 4.0 1.4
GOTERM_BP_FAT GO:0046578~regulation of Ras protein signal transduction 3.3E-03 4.1 5.4
GOTERM_BP_FAT GO:0051336~regulation of hydrolase activity 6.8E-03 2.9 10.8
GOTERM_BP_FAT GO:0032318~regulation of Ras GTPase activity 9.1E-03 6.1 14.2
GOTERM_BP_FAT GO:0043087~regulation of GTPase activity 1.9E-02 4.8 28.0
Annotation Cluster 4 Enrichment Score: 1.61
Category Term P-Value Fold Enrichment FDR
SP_PIR_KEYWORDS membrane 1.4E-03 1.4 1.8
UP_SEQ_FEATURE topological domain:Cytoplasmic 1.5E-03 1.6 2.1
UP_SEQ_FEATURE transmembrane region 1.6E-03 1.5 2.3
SP_PIR_KEYWORDS transmembrane 2.1E-03 1.4 2.6
UP_SEQ_FEATURE glycosylation site:N-linked (GlcNAc...) 1.2E-01 1.2 82.2
UP_SEQ_FEATURE topological domain:Extracellular 1.3E-01 1.3 85.3
SP_PIR_KEYWORDS glycoprotein 1.5E-01 1.2 87.2
GOTERM_CC_FAT GO:0031224~intrinsic to membrane 3.7E-01 1.0 99.8
GOTERM_CC_FAT GO:0016021~integral to membrane 5.0E-01 1.0 100.0
Annotation Cluster 5 Enrichment Score: 1.58
Category Term P-Value Fold Enrichment FDR
GOTERM_MF_FAT GO:0005539~glycosaminoglycan binding 1.2E-02 4.3 15.7
UP_SEQ_FEATURE region of interest:Heparin-binding 1.6E-02 14.9 20.5
SP_PIR_KEYWORDS heparin-binding 1.7E-02 7.3 19.1
GOTERM_MF_FAT GO:0001871~pattern binding 2.0E-02 3.8 24.8
GOTERM_MF_FAT GO:0030247~polysaccharide binding 2.0E-02 3.8 24.8
GOTERM_MF_FAT GO:0008201~heparin binding 7.3E-02 4.1 65.3
GOTERM_MF_FAT GO:0030246~carbohydrate binding 8.5E-02 2.0 71.2
Annotation Cluster 6 Enrichment Score: 1.51
Category Term P-Value Fold Enrichment FDR
GOTERM_BP_FAT GO:0046504~glycerol ether biosynthetic process 1.5E-02 15.5 22.9
GOTERM_BP_FAT GO:0046486~glycerolipid metabolic process 1.6E-02 3.5 23.3
GOTERM_BP_FAT GO:0006662~glycerol ether metabolic process 4.0E-02 5.3 49.5
GOTERM_BP_FAT GO:0018904~organic ether metabolic process 4.3E-02 5.1 52.5
GOTERM_BP_FAT GO:0045017~glycerolipid biosynthetic process 6.5E-02 4.3 67.6
Annotation Cluster 7 Enrichment Score: 1.44
Category Term P-Value Fold Enrichment FDR
SP_PIR_KEYWORDS glycosyltransferase 3.9E-04 5.0 0.5
SP_PIR_KEYWORDS Signal-anchor 2.4E-02 2.8 26.4
GOTERM_BP_FAT GO:0043413~biopolymer glycosylation 6.9E-02 4.2 70.1
GOTERM_BP_FAT GO:0006486~protein amino acid glycosylation 6.9E-02 4.2 70.1
GOTERM_BP_FAT GO:0070085~glycosylation 6.9E-02 4.2 70.1
SP_PIR_KEYWORDS golgi apparatus 8.3E-02 2.0 66.1
GOTERM_BP_FAT GO:0009100~glycoprotein metabolic process 9.0E-02 2.9 79.4
GOTERM_BP_FAT GO:0009101~glycoprotein biosynthetic process 1.3E-01 3.2 90.6
Annotation Cluster 8 Enrichment Score: 1.39
Category Term P-Value Fold Enrichment FDR
GOTERM_CC_FAT GO:0005925~focal adhesion 6.8E-04 6.5 0.9
GOTERM_CC_FAT GO:0005924~cell-substrate adherens junction 9.1E-04 6.2 1.2
GOTERM_CC_FAT GO:0030055~cell-substrate junction 1.3E-03 5.8 1.6
GOTERM_CC_FAT GO:0005912~adherens junction 2.1E-03 4.4 2.7
GOTERM_CC_FAT GO:0070161~anchoring junction 2.9E-03 4.2 3.6
GOTERM_CC_FAT GO:0016323~basolateral plasma membrane 1.9E-02 2.9 22.1
GOTERM_CC_FAT GO:0030054~cell junction 2.7E-02 2.0 30.3
GOTERM_CC_FAT GO:0015629~actin cytoskeleton 2.0E-01 1.9 94.2
SP_PIR_KEYWORDS cell junction 2.3E-01 1.7 96.2
GOTERM_CC_FAT GO:0005856~cytoskeleton 6.3E-01 1.0 100.0
UP_SEQ_FEATURE compositionally biased region:Pro-rich 6.4E-01 1.2 100.0
GOTERM_CC_FAT GO:0044430~cytoskeletal part 8.9E-01 0.8 100.0
GOTERM_CC_FAT GO:0043232~intracellular non-membrane-bounded organelle 9.8E-01 0.7 100.0
GOTERM_CC_FAT GO:0043228~non-membrane-bounded organelle 9.8E-01 0.7 100.0
Annotation Cluster 9 Enrichment Score: 1.34
Category Term P-Value Fold Enrichment FDR
GOTERM_BP_FAT GO:0030030~cell projection organization 1.8E-02 2.4 26.1
GOTERM_BP_FAT GO:0030031~cell projection assembly 5.1E-02 4.8 58.3
GOTERM_BP_FAT GO:0008283~cell proliferation 1.1E-01 2.1 85.0
Annotation Cluster 10 Enrichment Score: 1.32
Category Term P-Value Fold Enrichment FDR
GOTERM_BP_FAT GO:0016192~vesicle-mediated transport 4.2E-03 2.5 6.8
GOTERM_BP_FAT GO:0010324~membrane invagination 1.4E-02 3.5 21.5
GOTERM_BP_FAT GO:0006897~endocytosis 1.4E-02 3.5 21.5
GOTERM_BP_FAT GO:0016044~membrane organization 3.3E-02 2.4 43.3
GOTERM_BP_FAT GO:0006909~phagocytosis 8.1E-02 6.3 75.9
GOTERM_BP_FAT GO:0009968~negative regulation of signal transduction 4.7E-01 1.6 100.0
GOTERM_BP_FAT GO:0010648~negative regulation of cell communication 5.7E-01 1.3 100.0
Figure 1: Most enriched functionally annotated clusters amongst diﬀerentially ex-
pressed genes in WKY and Lew BMDMs
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chrom start end strand
1 9627018 9627019 -
1 37944129 37944130 -
1 201199603 201199604 -
10 45328842 45328843 -
10 45899618 45899619 -
10 102709515 102709516 -
12 2519477 2519478 -
12 10262178 10262179 -
12 35112464 35112465 -
12 42324942 42324943 -
12 42361846 42361847 -
12 42363060 42363061 -
12 42366755 42366756 -
13 102790100 102790101 -
13 102790398 102790399 -
14 14040058 14040059 -
14 99807063 99807064 -
15 9324177 9324178 -
15 9324293 9324294 -
17 33460790 33460791 -
19 10735089 10735090 -
2 77092111 77092112 -
2 244388288 244388289 -
20 10945389 10945390 -
20 14074863 14074864 -
3 121874967 121874968 -
4 61786818 61786819 -
4 61786849 61786850 -
4 61786860 61786861 -
4 61786918 61786919 -
4 61786977 61786978 -
4 125728659 125728660 -
4 135227006 135227007 -
4 135227014 135227015 -
4 135227034 135227035 -
4 135227049 135227050 -
4 135227077 135227078 -
6 137911448 137911449 -
7 13476210 13476211 -
7 55779473 55779474 -
7 118248278 118248279 -
8 46828059 46828060 -
8 93638247 93638248 -
9 8113731 8113732 -
9 8113786 8113787 -
9 8113789 8113790 -
9 8113800 8113801 -
9 8113842 8113843 -
9 8113845 8113846 -
9 68538125 68538126 -
CpG location
Figure 2: Genomic location of CpG dinucleotides validated by Fluidigm experi-
ments
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chrom start end strand Amplicon length CpGs in amplicon Left Primer Right Primer 
20 14050424 14050725 - 208 7 GAGGTAGAAATAGATTGAATATTTGTG AAAAAAACCCTATTTTAATACCCCC
10 102709365 102709666 - 210 4 TTGTGGGTTTAAGTAGGGTATTTTT AAACACATAACTATCCACAAACAATTT
7 69965890 69966191 + 210 4 TTGGTTTGGTGAGAAAGGGATA AAATAACAACCTATCTAAAACAACAAA
1 9626868 9627169 - 157 4 TGAGTTAATTATGAATTAGTTGGGGA AACATAACACAAAACAAAAAATAACAC
14 99806913 99807214 - 197 8 TAGGTAATAGGAAGAAGAGTGGTTT AACCCCATAAAAACAAAAATAACCC
14 99806913 99807214 - 197 8 TAGGTAATAGGAAGAAGAGTGGTTT AACCCCATAAAAACAAAAATAACCC
10 45328692 45328993 - 178 5 TTTGAAGGATTTATTTTTGGATAAGG AACCTTAATAAACACCACACACTCC
13 103116388 103116689 - 183 5 TTGTGTATTGTAATAGTGAGTTAATAGGA AACTTCAAAACCTACCCAAAAAAAC
2 244388138 244388439 - 208 4 AAAAGGTGGAATTGATTAATAATGATG AATACCCTCACCTAAAAATAACCTAA
2 244388138 244388439 - 208 4 AAAAGGTGGAATTGATTAATAATGATG AATACCCTCACCTAAAAATAACCTAA
4 6033775 6034076 + 175 4 GGAATTTAGTTTGTTTTGAGTTGTG AATCCAAAAAACAACCCACCTTAT
12 10262028 10262329 - 210 4 GGAGGTTAAGTAGATATGGGATTTA ACAAAACTCCACACTCCTATCCC
12 10262028 10262329 - 210 4 GGAGGTTAAGTAGATATGGGATTTA ACAAAACTCCACACTCCTATCCC
7 13476060 13476361 - 174 4 AAGGATTAATGAGATTGGTTAAATG ACAAAATACCCTCTCCTCACTCATA
14 17265888 17266206 - 165 5 AAATGGTTTTGGTGGTTTTTATTTT ACTACATTCCAATCCCAACTACATC
14 14039908 14040209 - 189 6 AGGAAGGGAGGGAAAGGAGAG ATAATTTTTCCAACTTTCCAACTCC
14 14039908 14040209 - 189 6 AGGAAGGGAGGGAAAGGAGAG ATAATTTTTCCAACTTTCCAACTCC
19 11073040 11073379 - 210 4 TATGGGGTTAGATTTTGAATTTTGA ATACAACATCCCACAATACCAACTA
6 137911298 137911599 - 202 5 GTGGTATGAAAGATAGAGTTGGGTG ATTTCAAAATTCCAAAACATCCTCT
3 74824666 74825135 + 195 8 TTTTTGGATAGTTAAGTTTTTATGGG ATTTTTAAAACAAAACCCTAACCAA
8 46827909 46828210 - 207 7 TTGTTATTATGATTTTTTTTGTGGGA CAACCCCTTCTTAAAAAACTACTCC
8 46827909 46828210 - 207 7 TTGTTATTATGATTTTTTTTGTGGGA CAACCCCTTCTTAAAAAACTACTCC
19 52777913 52778214 - 149 5 AGAATAGTTGGTTTTTGGTGAGTTG CACACCTACCATCTCATTCTCTAAA
19 52777913 52778214 - 149 5 AGAATAGTTGGTTTTTGGTGAGTTG CACACCTACCATCTCATTCTCTAAA
4 125728509 125728810 - 209 7 AGTTGATAGATTAAGAAATGGTTGGA CATACCACCAAAACTTTTCCCTAAC
3 121874817 121875118 - 209 4 GGTGGAGAAAAGTTATGAGAAAGGT CCAAAACATCTTTTCCAACAATAAC
20 14074713 14075014 - 209 5 GGTTTATGTTTTGGGTTTGATTAGA CCACTCCATCATATAAATATCTCTTCC
14 81918676 81919055 - 201 4 GGGAGTATTTGTATTATTAGGAGGA CCTAAAAATTTCTAACAAACATATCCAA
5 140720799 140721168 + 196 4 GGTTGGTGGAGTAAGAGAGGTTT CCTCCTAACTTCCCCACTCACTAC
10 45899468 45899769 - 210 4 TGATTGGAAATTTGAGTAGTTTTGT CCTTTCTATCCTACCTTCACATTAAA
10 45899468 45899769 - 210 4 TGATTGGAAATTTGAGTAGTTTTGT CCTTTCTATCCTACCTTCACATTAAA
5 139756241 139756542 - 190 5 TGTTTATTTTAGAGTTAGTGAGTGAGTGG CTTTCATAAAATTAAAACTACCCACC
1 37943979 37944280 - 210 4 TGAGTGGTTGGTTATAGAATAGAAGAA TAAAAAACTCAAAAAACCAACTCCC
9 85934039 85934501 + 210 4 GTTTGGGAGTTATAATTTATGGAGT TAAAACAAACCACAACACCCTTC
17 33460640 33460941 - 198 4 TTATTGTTTGTAGAGGGAGAGAAGG TAAAATCAAAACCTATTCCACCAAA
17 33460640 33460941 - 198 4 TTATTGTTTGTAGAGGGAGAGAAGG TAAAATCAAAACCTATTCCACCAAA
1 122572071 122572372 - 205 6 TTTTTTAAATAGGGTGGGAGATGAT TAACCACAACACACACAATAAAAAT
3 116948361 116948662 + 159 4 GGGTGTTGTTTATATTTGTTTTGGT TAACCTCTATCTAAAACACCCACTC
8 116821065 116821374 + 207 9 GTGTGTGTGTTGTGAGTGTATGAGT TATCTCCCATTCCTTCTCCTTCAT
8 93638097 93638398 - 207 6 TTGTGAGTTATTATATGAGTGTTGGAA TCAAAAAAACTAAAAAATCAACCAA
2 116712816 116713461 - 159 4 GGTTGTATATATGTATTTTTGATAGTTGTT TCAACATAACCAAACTCCCCAA
2 77091961 77092262 - 209 4 AGTAGGAGTTGAGTGGGTAAAATGA TCCACACAAATTAATTACATTCCAA
2 176357302 176357603 - 198 4 TTTTATAGGGAGGATAGAAATGGGT TCCATCAAATCAAACAAATAAAAAC
14 16669206 16669550 - 210 4 GGGTTTAAAGTTTTATAGAGTATTTTTAGA TTACAACTTCCATCAACTTCTACCC
7 55779323 55779624 - 210 7 TGGTAGTTTTGGGGTTAGAGTTTTA TTTCACTCACCCTCTATTCAACACT
1 22532631 22532932 - 194 4 TTGGGTAATTAATTGTAAAGTTTGTTTG TTTCTTCACTAACAACTCTAATACACAA
11 32954471 32954772 - 178 5 TTGTTGTGAGTTTGTTTTATGTTGG TTTTCTTTAAAAACACACAATTCAAC
13 102789950 102790549 - 202 4 AATAGATTGAATGGAGGAAATTTAAG TTAACCAAAAATTAAATCCCTTTCT
9 68537975 68538276 - 196 5 AAAGTTGATATTTAAATGTAAGGAAAATG TCTTTCAAAACAAAATACTCACAATA
19 10734939 10735240 - 180 5 GGGAGATGTGTTTTTGTTTTATTTT TACACACTTACTCCCATCAATCAAA
9 8113581 8113993 - 167 6 GGTAGATTTTGATTAGTAAGTTTTGTTTTT CACTTCTTCCTCTTAACTTTACACCA
9 8113581 8113993 - 200 9 GAAGGGGAGATTTTGTTTGTGTAGT TCCTAAACTCTAAAAACCTCCATAA
9 8113581 8113993 - 196 9 TTTTGGTGTAAAGTTAAGAGGAAGAA AACCCACCAAAAAATAAAAATTACC
13 102789950 102790549 - 176 4 GTTGGGGTATAAAGGAGTAGAGAGAA ACAAATACAAACACACAAACCCTTT
12 2519327 2519628 - 204 6 AAAGTGGAAAGGAGTAAGGAGTTGT CCAAAAAAAACACCTAAAAAAAACA
4 135226856 135227228 - 172 6 AGGAGGAAATGTTTTAATTTTGAGG AACAAACTAACTCCCAACAACCATA
4 135226856 135227228 - 186 6 TTTTTTTGTTTTTAAGGAGGAAATG AACAAACTAACTCCCAACAACCATA
12 42324792 42325093 - 202 4 AGAGTTTGGGAGTAGGTAGTGGG TCATTTAAATATCACAACTCTATCCA
12 42362910 42363211 - 179 11 GGATTTATATTTGAATGGATGTGGA AAACTCTTATTCAACACCTACCATC
12 42366605 42366906 - 205 6 GAGGGTGATAGTTTTTTGAGGGAT CCTTAAAACAAAATAAAAACCACAA
12 42361696 42361997 - 199 5 GGGGTTAGGGAGTTTTATTTAGGT ACATCCTCCTTCACAACCTACTTC
1 201199453 201199754 - 172 4 GAAAGAATTAAGGAAGAATATGAGGTG AAACAATAAAACCCAAACAACAAAA
15 9324003 9324444 - 189 4 GAGAAAAGTTGAAAGTTTGGTTTTT AACTTTTCAATACCCTCTCTCCC
12 35112314 35112615 - 175 6 GGAGGATTAGAAAAGGTTTATTTGG TACCCTAACTCCTATTCCTCCCTAA
20 10945239 10945540 - 208 4 ATTTGATTTGTGGTGGATATAAAAGT CTATATTTCCAAACAACCAACTTTAC
4 61786421 61787128 - 203 4 GTGATTGTTTTTGTTAGGTAATGTG TTTTTAATCCTAAACACATAACATCCT
4 61786421 61787128 - 185 5 AAGTAAAATTGAAGGTATTTGTTGAA TCCTTAAACCTTCATTAATCACAA
20 10945239 10945540 - 209 4 AATTTGATTTGTGGTGGATATAAAAGT CTATATTTCCAAACAACCAACTTTAC
7 118248128 118248429 - 210 4 AGGTTAGGTTAGTTAGGTTGAAGGG AACAACACTCCCCTATAAAAACCA
10 97575388 97575689 - 147 4 GTAGTGTGGTTTGTAGGTTATTTTTT ATCTTCCATCTAACCATCTTTCTCC
10 97407031 97407332 - 210 5 GATGTTTTTTAATGTGGGAAGTTGA TACCTATAATAATTCCCAACCCCAT
6 123501082 123501438 - 207 4 TTAGTGGAGTGAGTATTAGGAAGGG AAACAACTAAACACTAAATTAACACTACCA
6 123674869 123675170 - 200 5 GTAGTTTGAAGTGTATTTAAAATTTTTTTG CCCCCACTACTAAATATACTCTATCTTTTC
13 44914530 44914841 + 207 4 TGTATAGGTGTGTTATAGTGTATGTATGG TAAACCATCTCTCCAACCCAAATA
20 11965186 11965487 + 208 5 AGTAGGTGGAGTTGTTTTTATAGGA AACCACAAACTCAACAAAACTAACC
5 156767532 156767833 + 200 6 TTTGTGATTGTTAGGATTATTTTTAGTTT ATTCACCCACATCTACCCCTACT
13 44943575 44943876 + 190 4 TTTTGATGTTAAGGAGGGTAGAGATT CCTCTCCACTCACATTTACAACTCC
13 44920592 44921285 + 144 5 TAAATTTGGTGGTTTTTTTGTTGTT TCCCTATTAACACTTCACCAAAACT
13 44920592 44921285 + 208 5 TTAGAAGGGTAAGTAAATTTGGTGG ATAAAAAACAAACAAACTTTTCCCC
13 44920592 44921285 + 187 4 TTTTGGTTTTTTGTGTTAGTTTGGT AAACCACCAAATTTACTTACCCTTC
13 44914530 44914841 + 208 4 TGTATAGGTGTGTTATAGTGTATGTATGG TTAAACCATCTCTCCAACCCAAATA
20 11965186 11965487 + 168 4 GGATTTGTATGTAATAGGATTGGAGA AACCACAAACTCAACAAAACTAACC
11 44235364 44235720 + 209 6 TTTGGGGTTGATGTTTTTTGAG AACAACTCCACATATACATCCCATC
1 196783453 196783754 + 210 4 GGATTAGATTTGAGAAGAGGAAATG CCTCCACAAAACAAATAAAATACCT
11 63811673 63811974 + 210 5 TTTTGAGATGGGGGAGATTTT CCTAATAAAACACAAACAAAAAACTCTAT
11 63810496 63810797 + 195 5 TATTTGGTTTTTTTGGTTTTTTGAA AAAAAAACATTACAACATCTAACCCA
6 7949853 7950154 + 142 5 TTTTTTTTGGTTGTTTTTTTAGGTT TATCATACAAACTCTTCCCAATTCC
12 8000648 8000949 + 201 6 GGGTTGGGTTAAGTTTAGAGTGAAT ACCTTCCTTAAACATCCCACTCTTT
17 91581853 91582223 + 182 5 ATTTTTGTGATAGAGATTGAGGTAAA CCTCTCACTAACAACATTTCTTTTCA
20 11965186 11965487 + 208 5 AGTAGGTGGAGTTGTTTTTATAGGA AACCACAAACTCAACAAAACTAACC
4 9869445 9869746 + 159 6 TTTTGAGATGTTTATTGTGTGGTGT AAAAATAATCATCCCCCATCAAC
2 199106664 199106965 + 196 5 AGTAAAGAAGTTTGAGAGGTGAAAGA AAACATCCATCAACATACACCACTA
19 32339216 32339517 + 210 4 GGTGATGATGTAAGTTTTGTTTAGGTT TCCTACACAATCATCTTCAACTACTAAA
20 49118441 49118742 + 210 6 AAATAGATGTTATTTTGGGTGAGG CACAAAATACTACTATATCCCAAACAT
20 49189165 49189466 + 190 7 GAGTTTTTAGAATAAGTGAGGAGTTGG AAAATTATTCACAAAAAAATCCTTTCTC
1 21012596 21012897 + 152 4 AAGATAGATAGATATGGTAGATGAGGATG TCACTAAAAACCCTAAATTTTCTCC
Target Sequence Amplicon Information Primers
Figure 3: Amplicons and primer sequences used for Fluidigm experiments
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ID Count Fold Enrichment PValue FDR Term
GO:0030054 86 2.3 2.74E-13 4.0E-10 cell junction
GO:0030030 71 2.3 2.36E-11 4.4E-08 cell projection organization
GO:0043005 78 2.1 4.51E-10 6.6E-07 neuron projection
GO:0045202 70 2.2 1.00E-09 1.5E-06 synapse
GO:0005856 131 1.6 1.11E-08 1.6E-05 cytoskeleton
GO:0019899 80 1.9 1.95E-08 3.1E-05 enzyme binding
GO:0060589 53 2.3 1.97E-08 3.2E-05 nucleoside-triphosphatase regulator activity
GO:0030695 52 2.3 2.44E-08 3.9E-05 GTPase regulator activity
GO:0000902 61 2.1 2.68E-08 4.9E-05 cell morphogenesis
GO:0006811 98 1.7 5.57E-08 1.0E-04 ion transport
GO:0048666 61 2.1 5.79E-08 1.1E-04 neuron development
GO:0033674 42 2.5 6.07E-08 1.1E-04 positive regulation of kinase activity
GO:0000267 131 1.6 6.32E-08 9.2E-05 cell fraction
GO:0006812 78 1.9 6.51E-08 1.2E-04 cation transport
GO:0032989 64 2.0 8.81E-08 1.6E-04 cellular component morphogenesis
GO:0000904 47 2.3 1.24E-07 2.3E-04 cell morphogenesis involved in differentiation
GO:0046872 313 1.3 1.35E-07 2.2E-04 metal ion binding
GO:0006796 116 1.6 1.46E-07 2.7E-04 phosphate metabolic process
GO:0045860 40 2.5 1.63E-07 3.0E-04 positive regulation of protein kinase activity
GO:0006793 116 1.6 1.64E-07 3.0E-04 phosphorus metabolic process
GO:0043169 316 1.3 1.71E-07 2.8E-04 cation binding
GO:0043549 52 2.2 1.91E-07 3.5E-04 regulation of kinase activity
GO:0051347 42 2.4 2.17E-07 4.0E-04 positive regulation of transferase activity
GO:0043167 320 1.3 2.18E-07 3.5E-04 ion binding
GO:0045859 50 2.2 2.40E-07 4.4E-04 regulation of protein kinase activity
GO:0022803 61 2.0 2.54E-07 4.1E-04 passive transmembrane transporter activity
GO:0015267 61 2.0 2.54E-07 4.1E-04 channel activity
GO:0046578 34 2.7 2.82E-07 5.2E-04 regulation of Ras protein signal transduction
GO:0006468 90 1.7 2.97E-07 5.5E-04 protein amino acid phosphorylation
GO:0005083 38 2.5 3.43E-07 5.5E-04 small GTPase regulator activity
GO:0003779 45 2.3 3.49E-07 5.6E-04 actin binding
GO:0022610 72 1.8 4.79E-07 8.8E-04 biological adhesion
GO:0007155 72 1.8 4.79E-07 8.8E-04 cell adhesion
GO:0007010 55 2.0 4.83E-07 8.9E-04 cytoskeleton organization
GO:0030001 65 1.9 5.14E-07 9.5E-04 metal ion transport
GO:0030182 71 1.8 6.08E-07 1.1E-03 neuron differentiation
GO:0051174 66 1.9 6.92E-07 1.3E-03 regulation of phosphorus metabolic process
GO:0019220 66 1.9 6.92E-07 1.3E-03 regulation of phosphate metabolic process
GO:0005216 57 2.0 7.16E-07 1.2E-03 ion channel activity
GO:0022838 58 2.0 8.50E-07 1.4E-03 substrate specific channel activity
GO:0051338 52 2.1 8.78E-07 1.6E-03 regulation of transferase activity
GO:0044093 76 1.8 9.51E-07 1.8E-03 positive regulation of molecular function
GO:0014069 23 3.2 1.13E-06 1.7E-03 postsynaptic density
ionic channel 50 2.1 1.28E-06 1.8E-03
GO:0044456 47 2.1 1.36E-06 2.0E-03 synapse part
GO:0005626 103 1.6 1.53E-06 2.2E-03 insoluble fraction
domain:EGF-like 3 14 4.7 2.03E-06 3.5E-03
GO:0044430 96 1.6 2.22E-06 3.2E-03 cytoskeletal part
GO:0005261 45 2.1 2.30E-06 3.7E-03 cation channel activity
GO:0019900 36 2.3 2.74E-06 4.4E-03 kinase binding
GO:0043406 22 3.2 2.91E-06 5.4E-03 positive regulation of MAP kinase activity
GO:0032559 154 1.4 3.15E-06 5.1E-03 adenyl ribonucleotide binding
GO:0032559 154 1.4 3.15E-06 5.1E-03 adenyl ribonucleotide binding
cell junction 52 2.0 3.18E-06 4.5E-03
ion transport 72 1.7 3.22E-06 4.5E-03
GO:0048858 43 2.1 3.31E-06 6.1E-03 cell projection morphogenesis
GO:0042325 62 1.8 3.45E-06 6.4E-03 regulation of phosphorylation
GO:0048667 39 2.2 3.68E-06 6.8E-03 cell morphogenesis involved in neuron differentiation
GO:0043085 67 1.8 3.69E-06 6.8E-03 positive regulation of catalytic activity
GO:0051056 37 2.3 4.00E-06 7.4E-03 regulation of small GTPase mediated signal transduction
GO:0035023 19 3.4 7.13E-06 1.3E-02 regulation of Rho protein signal transduction
GO:0030425 42 2.1 7.17E-06 1.0E-02 dendrite
IPR005821:Ion transport 24 2.8 7.55E-06 1.3E-02
GO:0001882 163 1.4 7.71E-06 1.2E-02 nucleoside binding
GO:0022836 46 2.0 7.93E-06 1.3E-02 gated channel activity
GO:0015629 39 2.2 8.00E-06 1.2E-02 actin cytoskeleton
GO:0005624 96 1.6 8.04E-06 1.2E-02 membrane fraction
IPR006209:EGF 22 3.0 8.25E-06 1.4E-02
GO:0032553 180 1.4 8.33E-06 1.3E-02 ribonucleotide binding
GO:0043025 44 2.0 9.56E-06 1.4E-02 cell soma
GO:0030554 159 1.4 9.57E-06 1.5E-02 adenyl nucleotide binding
GO:0032990 43 2.1 9.62E-06 1.8E-02 cell part morphogenesis
GO:0031175 46 2.0 9.64E-06 1.8E-02 neuron projection development
IPR001849:Pleckstrin homology 30 2.4 9.69E-06 1.6E-02
GO:0032555 179 1.3 1.16E-05 1.9E-02 purine ribonucleotide binding
GO:0016310 94 1.6 1.35E-05 2.5E-02 phosphorylation
GO:0001883 160 1.4 1.73E-05 2.8E-02 purine nucleoside binding
GO:0046873 48 1.9 1.89E-05 3.0E-02 metal ion transmembrane transporter activity
GO:0019901 31 2.3 1.98E-05 3.2E-02 protein kinase binding
IPR001791:Laminin G 12 4.6 2.02E-05 3.4E-02
GO:0048812 38 2.1 2.24E-05 4.1E-02 neuron projection morphogenesis
GO:0005524 147 1.4 2.29E-05 3.7E-02 ATP binding
membrane 346 1.2 2.33E-05 3.3E-02
synapse 37 2.1 2.34E-05 3.3E-02
GO:0000187 17 3.4 2.53E-05 4.7E-02 activation of MAPK activity
GO:0043405 25 2.6 2.62E-05 4.8E-02 regulation of MAP kinase activity
GO:0017076 184 1.3 2.95E-05 4.7E-02 purine nucleotide binding
GO:0005912 26 2.5 3.13E-05 4.6E-02 adherens junction
Figure 4: All GO terms enriched within gene bodies associated with dmCpGs. See
Section 4.2.3.1
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Figure 5: Relationship between sequencing depth and dmCpG detection across all
chromosomes
